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In humans, most of the higher neuronal functions, like behaviour, learning, 
memory and emotions are driven by or are dependent on vision. In fact, 
vision is the most developed sense in human beings and almost 30% of the 
brain’s input information is originated in the retina1. 
The retina is the part of the eye responsible for capturing light stimuli from 
our surroundings. It is a neuronal tissue located at the posterior part of the 
eye, which captures light photons, converts the luminic energy into 
electrochemical stimuli, and finally sends visual information to the brain 
where it is integrated. Vertebrate retina is formed by seven neuronal cell 
types organized in six precise functional and structural layers (Figure 1). The 
main function of the retina, the phototransduction, is mainly carried out by 
two types of photoreceptor cells (PhR), cones and rods (see below). The 
retinal pigmented epithelium (RPE) is found in the most posterior part of 
the eye, and it is formed by a monolayer of pigmented cells that are 
responsible for: 1) phagocyting the old and unstructured distal discs of the 
photoreceptors, and 2) protecting and nursing photoreceptor cells.  
The rest of the retina is composed of different finely interconnected 
neuronal types. Below the RPE the retina is structured in three nuclear layers 
(NL) with two intercalated plexiform layers (PL). The nuclear layers are: the 
outer nuclear layer (ONL), formed by the photoreceptor nuclei; the inner 
nuclear layer (INL), where nuclei of bipolar, horizontal, amacrine, Müller 
glial and interplexiform cells are located; and the ganglion cell layer (GCL), 
with the ganglion cell nuclei and somas. The two plexiform layers are the 
16 
outer plexiform layer (OPL) (between the ONL and the INL), which is the 
layer where photoreceptors synapse with horizontal and bipolar cells; and the 
inner plexiform layer (IPL) (between INL and GCL), where ganglion cells 
synapse with bipolar and amacrine cells. Phototransduction takes place right 
below the RPE, within the membranous discoid outer segments (OS) of 
photoreceptors. 
 
 
 
The vision process starts with light entering the eye and passing through all 
the retinal layers, from the GCL to eventually find the outer segments of 
photoreceptors. The photosensitive pigment (opsin) of these segments is the 
responsible for the phototransduction process, thereby converting light 
stimuli into electrochemical stimuli. This electric pulse will then be sent from 
the PhR to the bipolar cells and finally, to the ganglion cells. The axons of 
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these ganglion cells converge to form the optic nerve, which will directly 
send the electrical information to the visual cortex, thus allowing the brain to 
create and perceive an image.  
In this visual process, horizontal cells synapse to photoreceptors and bipolar 
cells to increase the image quality; while amacrine cells interconnect bipolar 
cells to control the information flow. In addition, there is another 
information flow that travels backwards, from the ganglion cells to the 
photoreceptors, which is carried out by the interplexiform cells. 
The development of the vertebrate retina is initiated from an outgrowth of 
the neural tube that generates two symmetric protrusions called optic 
vesicles. The furthest end of these vesicles invaginates and generates a 
double layered cup-shaped structure, serving as the basic structure from 
which the different layers of the retina are built up. The outer wall, closer to 
the ventricular surface (named external laminar membrane, ELM), becomes 
the retinal pigmented epithelium (RPE); while the inner wall, closer to the 
vitreal surface, is formed transiently by a pseudoestratified epithelium (the 
internal limiting membrane, ILM) that thickens and differentiates into the 
neural retina2 (Figure 2). 
18 
 
 
 
Once the optical vesicle has been generated, two major steps must occur in 
order to build up the final stratification of the retina: 1) the generation and 
establishment of cohorts of retinal progenitors; and 2) the fate determination 
and migration of these progenitors to their final destiny2,3 (Figure 3). 
Therefore, after the generation of the optic vesicle, several cell divisions 
occur, leading to the generation of cohorts of retinal precursors. During this 
process, precursor cells generate cytoplasmic processes that connect with 
both the external and internal limiting membranes (ELM and ILM). These 
cells undertake several displacements until they settle in the ELM, generating 
non-replicative cohorts of post-mitotic retinal progenitors2. 
Subsequently, post-mitotic retinal progenitors differentiate into the seven 
retinal cell types and migrate to form a stratified and functional neural retina. 
The migration progression has not been precisely defined, but the most 
accepted scenario is what is called the perikaryal translocation. In this process, 
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post-mitotic cells settled close to the RPE (or ELM) extend a cytoplasmic 
process and translocate their nuclei towards the IML. During translocation 
of the nuclei, cells maintain cytoplasmic contact with the two limiting layers 
of the optic vesicle and they lose contact with the external laminar 
membrane only when they arrive at their final position in the retina, where 
post-mitotic progenitors readily differentiate into a particular cell type2,3 
(Figure 3).  
The first cells to become post-mitotic and establish a differentiated layer are 
the ganglion cells, which form the ganglion cell layer (GCL). Subsequently, 
horizontal and amacrine cells differentiate; and synapses between amacrine 
and ganglion cells are formed, generating the inner plexiform layer (IPL). 
Later on, photoreceptors differentiate as well as bipolar and Müller cells, 
creating the inner nuclear layer (INL) and starting to form the first synapses 
of the outer plexiform layer (OPL). At the final stages of retinal 
development, rods are differentiated and the functional outer segments of 
PhR are formed2,3.  
Therefore, retinal layers are created through a strictly ordered process, 
starting from the differentiation of the basal GCL upon which the rest of the 
layers are built. The differentiation of each cell type occurs sequentially; 
hence, the signals emitted by each differentiating cell type promote the 
differentiation of the following cell type while self-inhibiting further 
differentiation of their own layer. Eventually, retinal cell layers are 
established that allow the capture, Figure 7 integration and transmission of 
light stimuli from the retina to the brain. 
20 
 
 
Photoreceptors are the cells responsible for capturing light stimuli and 
transducing it into an electrochemical signal. They are extremely specialized 
cells with a distinctive morphology and can be subdivided into two types: 
cones and rods. Cones are responsible for visual acuity and colour 
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perception in photopic conditions; while rods are sensitive in dim light 
conditions and are responsible for scotopic vision (Figure 4). 
 
 
Both cell types show a polarized morphology, and display outer (OS) and 
inner segments (IS) and a synaptic region, besides the nucleus, which is 
surrounded by a reduced cytoplasm region. The axon projects and synapses 
with the bipolar and horizontal cells. The inner segment is highly enriched in 
mitochondria and other organelles, and it is where cellular metabolic 
processes take place. On the other hand, the outer segment, which intimately 
contacts the RPE, is formed by a series of stacked membranous discs that 
contain the photopigments or opsins. In cones, these discs are attached to 
the inner part of the plasma membrane, contrary to what occurs in rods, 
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where discs are unattached. The discs are generated from the lower part of 
OS and grow up to the apical part, where will be recycled and phagocyted by 
the RPE. 
The main morphological and functional differences between PhR cells reside 
in the OS. Morphologically, cones owe its name to the cone-like morphology 
of their OS; whereas rods, to their straight rod-like shape. Physiologically, the 
difference between cones and rods resides in their different photopigments 
or opsins. Rods express rhodopsin as the only photopigment: it is the most 
abundant protein in rods, accounting for the 95 % of the total proteins in the 
OS; and it is capable of capturing even single light quanta. However, opsin 
diversity in cones is wider, both within an individual and among different 
species. In humans, there are three types of cones, containing one of three 
possible types of opsins: S, M and L opsin – sensitive to short (blue), 
medium (green) and long (red) light wavelengths, respectively. They are 
distributed in a mosaic-like pattern throughout the retina. In mice, the only 
opsins present are the S and M opsins. These two opsins are expressed 
within the same cell although their amount is distributed in opposing 
gradients throughout the retina4. In diurnal primates, the L opsin gene 
generated from the duplication of the ancestral M opsin gene located at the 
X chromosome.  
Concerning the vision process, both rods and cones synapse in the OPL with 
bipolar cells, which transfer their impulses to the ganglion cells. If the image 
thus generated were to be sent to the brain, the visual perception would be 
rather fuzzy and imprecise; to produce a neater and accurate image, 
horizontal cells capture stimuli from several cones at a time and send the 
information to the ganglion cells.  
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Around 70% of retinal cells are photoreceptors, but both in human and in 
mouse, rods outnumber cones in 18-20:1 and 30:1 proportions5,6, 
respectively. The difference between species is due to the fact that mice are 
nocturnal animals, which require a larger number of rods since they provide 
night-vision. Humans, as diurnal primates, not only have more cones 
throughout the retina but they also show a unique rich-cone region called 
fovea, which is located in the centre of the retina and provides higher visual 
acuity.  
The development of photoreceptor cells follows a tightly controlled genetic 
program in which a multipotent retinal progenitor cell (RPC) undergoes first 
a process of fate determination and later on commits into differentiation of a 
specific photoreceptor type. The very same RPC can become either a rod or 
a cone, and this fate decision is regulated through an intricate genetic 
network. The timeframe for this fate determination varies among species: for 
instance, in humans the S opsin mRNA is detected at foetal week 12 (Fwk 
12), while expression of rhodopsin, M and L opsins appear by Fwk 157. On 
the other hand, murine cones start to differentiate by embryonic day 11 
(E11), and the S opsin is expressed at later embryonic stages whereas M 
opsin expression is not detected until postnatal day 6 (P6). The genesis of 
rods peaks at P2, close to the time of rhodopsin transcription8,9. Several 
developmental traits are shared between both species: opsin expression 
increases with time; the outer segments grow towards the RPE and axons 
grow towards bipolar and horizontal neurons for synapsing. 
During development, RPC multipotency and proliferation is maintained by 
the expression of several transcription factors (TF), such as paired box 
24 
protein PAX6, retinal homeobox RX1, SIX3, SIX6, LIM-homeobox protein 
LHX2, visual system homeobox 2 (VSX2), HES1 and Notch1. RPCs will 
divide and produce either more multipotent progenitors, or progenitors that 
will be restricted in competence. These cells can then become lineage 
specific, e.g. photoreceptor precursors. The transcription factor OTX2 
together with undetermined signals controls the formation of early 
photoreceptors. At the same time, the cone-rod homeobox protein CRX and 
the nuclear receptor RORβ are also expressed and elicit the cell default 
pathway, which is to become an early S cone. Thyroid hormone receptor β2 
(TRβ2) expression will decide between M opsin or S opsin identity. 
However, the determination of a rod fate from the early S cone requires the 
action and fine regulation of additional factors. In particular, NRL binds 
several promoters, including that of the photoreceptor specific nuclear 
receptor gene (NR2E3), which also induces and consolidates the rod cell 
state by both, activating rod-specific genes, such as rhodopsin (RHO) and 
GNAT, and suppressing cone specific genes1 (Figure 5). 
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Other transcription factors participating in cone development and 
maintenance are the retinoid X receptor-γ (RXRγ), COUP transcription 
factor 1 (COUP-TF1 or NR2F1) and neurodiferentiation factor 1 
(NEUROD1). While achaete-scute homologue 1 (ASCL1 or MASH1) and 
PIAS3 also participate in the rod state acquisition1. 
In mouse, CRX knockouts (KO) fail to produce cells expressing opsins, 
which eventually leads to retinal degeneration. Concerning NRL, mutations 
in this gene have been reported to cause rod absence and S-cone syndrome, 
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characterized by an excess of cones in the retina. Finally, NR2E3 mutant 
mice show rod-like photoreceptors that express cone-specific genes.  
In humans, mutations in Crx have been described as causative of several 
retinopathies, including, cone-rod dystrophy10, Leber congenital amaurosis 
(LCA)11 and retinitis pigmentosa12. Moreover, Nrl and Nr2e3 has also been 
related to human enhanced S-cone syndrome13,14 and retinitis pigmentosa15,16. 
All these diseases cause a degeneration in cones and rods, which at first lead 
to tunnel-like vision and finally to a complete blindness.  
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Ubiquitin (Ub) is a 76 amino acid (8kDa) peptide extremely conserved 
among eukaryotic cells: only three amino acids differ between the yeast to 
the human proteins. The three dimensional structure shows an α-helix 
surrounded by five β-sheets (Figure 6)17. Ubiquitination is the reversible 
post-translational conjugation of a ubiquitin peptide to the lysine (Lys, K) 
residues of target substrate proteins through an isopeptidic bond. The 
number of conjugated Ubs and the lysines within the Ub molecules used to 
build chains will determine the fate and function of the modified protein. In 
fact, this post-translational modification changes the interaction interfaces 
between proteins, thus providing changes in protein recognition and binding 
affinities18. 
Protein post-translational modifications are regulatory mechanisms that cells 
use in response to intra- and extracellular signals. These signals modulate a 
panoply of conjugating enzymes that modify proteins post-translationally by 
the conjugation of a small functional group or peptide. The consequences of 
these modifications are very diverse, but they all present a common feature: 
they shift protein fate, localization or function. Besides, in the case of 
covalent protein modifications, such as ubiquitination, these regulatory 
mechanisms are reversible and dynamic. 
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Ubiquitination relies on the formation of an isopeptidic bond between the C-
terminal glycin (Gly, G) of the ubiquitin molecule and the ε-amino group of 
a lysine in the substrate protein. This substrate can be any protein in the cell, 
including other ubiquitin molecules, which will thereby generate ubiquitin 
polymers (also called ubiquitin chains). Furthermore, other type of unions 
have been observed, such as the attachment of a Ub moiety to the N-
terminal part of the protein instead to a inner Lys, known as the “N-end 
rule”19, or to a cysteine (Cys, C) via a thioester bond20. Ubiquitination always 
necessarily initiates through the activation of the ubiquitin molecule by an 
activator enzyme E1, which will then transfer the active ubiquitin to the 
conjugating enzyme E2. This E2-ubiquitin complex is able to interact with 
an E3 ligase, responsible for the eventual conjugation of the Ub molecule to 
the substrate protein.  
In mammals, only two E1 and around thirty E2 ligases have been described, 
in contrast to the approximately 600 E3 ligases identified. This remarkably 
large number of E3 ligases can be explained by their high substrate 
 29 
specificity: E3 Ub ligases are the enzymes responsible for substrate 
recognition. Finally, as aforementioned, this is a highly dynamic process and 
thus, cells also deploy a group of deubiquitinating enzymes (DUBs), 
responsible for detaching ubiquitin from its substrates (Figure 7). 
 
 
Concerning evolution, ubiquitination is a well established and conserved 
cellular process common to all eukaryotes; it is even present in archaeal 
groups although not in eubacteria. In silico research has revealed that the 
ubiquitin system has greatly expanded and diversified through evolution, in 
terms of gene innovation and domain architecture22, thus supporting the 
concept that higher organism complexity comes along with a higher need of 
a more tight and fine regulation of ubiquitination. 
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Conjugation of ubiquitin onto a substrate protein can be performed as a 
modification with either single Ub moieties (mono- and multi-
monoubiquitination), or with Ub polymers (polyubiquitination). In any case, 
this process is never performed randomly by E3 ligases, but rather it is a 
tightly regulated mechanism that will alter protein fate and function. 
Generally, monoubiquitination is involved in signalling, endocytosis and 
DNA repair, while multiple monoubiquitination is implicated in signalling 
and endocytosis, and polyubiquitination is involved in a variety of cell 
processes, as described below (Figure 8). 
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Ubiquitin chains can be assembled by the conjugation of two or more 
ubiquitin molecules through one of their lysine residues: K6, K11, K27, K29, 
K33, K48 and K63; or to the N-terminal methionine residue (M1). These Ub 
polymers can contain bonds to either a single type of lysine–homotypic 
chains, or to different lysines –heterotypic chains23. Furthermore, the same 
ubiquitin can be ubiquitinated at two different sites, creating branches24, or 
be posttranslationally modified by acetylation or phosphorylation23. 
The Ub chains build upon K48 and K63 have been extensively shown to be 
the main proteasomal degradation signal25. Thus, proteins post-translationally 
modified with these ubiquitin chains will be targeted to the proteasome, 
where they will be degraded, constituting the proteolytic ubiquitin pathway. 
It is well known that tetra-ubiquitin K48 chains increase the affinity for 
proteasome up to a 100x fold, in comparison to di-ubiquitin chains25.  
The non-proteolytic ubiquitin pathway involves monoubiquitination or the 
rest of polyubiquitin chains, and the effect they have on their substrates is 
very diverse. Heterotypic K11 polymers widely increase when the metazoan 
anaphase-promoting complex (APC/C) is expressed, which ubiquitinates 
substrates to activate proteasomal degradation and mitotic exit, thus strongly 
indicating these types of chains are involved in cell cycle control23. On the 
other hand, K27 chains have been linked to DNA damage response, as they 
are the most abundant type of ubiquitin polymers on chromatin and histones 
H2. These ubiquitination events at the damage site is one of the signals that 
activate the DNA Damage Response (DDR)23,26. They have also been 
involved in interferon/NFκB innate immune response23. Also, K33 chains 
are implicated in protein trafficking through microtubules; while K6 
polymers might be involved in mitochondrial quality control and UV DNA 
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damage, but their specific function remains to be elucidated23. Finally, M1 
ubiquitination has been related to NFκB signalling23 
Ubiquitination is a reversible cell process and thus, besides the large number 
of Ub ligases, cells also deploy a significant number of Ub deconjugating 
enzymes, named deubiquitinating enzymes (DUBs). DUBs are responsible 
for hydrolizing and editing ubiquitin bonds and thus, recovering Ub moieties 
to maintain the intracellular pool; but most importantly, for making 
ubiquitination a dynamic and reversible regulatory mechanism. DUBs: 1) 
process the ubiquitin precursor that has been transcribed from several genes 
as fusion proteins; 2) deubiquitinate substrate and rescue them from protein 
degradation; and finally 3) recycle Ub molecules from proteins targeted to 
proteasomal degradation27. DUBs play important roles in cellular processes 
and disease; however and despite its evident importance in the organism, 
data on their mode of regulation and substrate specificity is still scarce28. 
 
28
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There are 95 putative deubiquitinating enzymes described in the human 
genome, but only around 80 have been demonstrated to display 
deubiquitinating activity, similarly to what has been observed in the mouse 
genome. The large number of DUB genes might well be explained by their 
high substrate specificity, since so far no overlapping functions have been 
described, at least in humans. DUBs can be divided into 5 major families 
depending on their catalytic domain architecture: i) ubiquitin specific 
proteases (USP), ii) ubiquitin COOH-terminal hydrolases (UCH), iii) ovarian 
tumour proteases (OTU), iv) Machado-Joseph Disease proteases (MJD) and 
v) JAB1/MPN/MOV34 (JAMM) proteases. Most families are cysteine 
proteases, whose enzymatic activity resides on the thiol group of a central 
cysteine, Cys, C, and two adjacent residues (a histidine, His, H; and an 
aspartate, Asp, A, or an asparagine, Asn, N) in their catalytic site28,29. Only 
the JAMM family are Zn2+ metalloproteases, in which a triad of His, Asp and 
Ser residues coordinate the catalytic Zn2+29 (Figure 9 and Table 1). 
 
 
 
 
 
 
 
34 
USP 
 
JAMM 
USP 1 USP 2 USP  3 USP 4 AMSH 
AMSH-
LIKE 
BRCC36 CSN5 
USP 5 USP 6 USP 7 USP 8  EIF3H JAMM2 JAMM3 MYSM1 
USP 9X USP 9Y USP 10 USP 11  POH1 PRPF8 PSMD7 
 
USP 12 USP 13 USP 14 USP 16  
 
MJD 
 
USP 17 USP 18 USP 19 USP 20  ATX JOSD1 JOSD2 JOSD3 
USP 21 USP 22 USP 24 USP 25 
 OTU 
 
OTU B1 OTU B2 OTU D1 OTU D3 
USP 26 USP 27 USP 28 USP 29  
USP 30 USP 31 USP 32 USP 33  OTU D4 OTU D5 
OTU 
D6a 
OTU 
D6b 
USP 34 USP 35 USP 36 USP 37  OTU D7a 
OTU 
D7b 
PARPF11 TNFAIP3 
USP 38 USP 39 USP 40 USP 42  VCPIP1 YOD1 ZRANB1 
 
USP 43 USP 44 USP 45 USP 46  UCH 
USP 47 USP 48 USP 49 USP 50  BAP1 UCH-L1 UCH-L3 UCH-L5 
USP 51 USP 52 USP 53 USP 54  
    
CYLD 
   
 
    
 
The first DUB family to be structurally characterized was the UCHs. This 
family is formed by four proteins that contain a 230 amino acid catalytic core 
that share close homology and usually deubiquitinate small proteins (20-40 
amino acids)30. The substrate specificity is limited by the three dimensional 
structure of the catalytic core: ubiquitinated peptides cannot be larger than 
20-40 amino acids, as they have to pass through a confined loop that sits 
directly over the active site29. Furthermore, neither UCH-L1, nor UCH-L3 
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can cleave K48 or K63 Ub polymers, and therefore their function is highly 
specific27. They play an important role in the processing of new Ub free 
monomers from ubiquitin precursors and in the recycling of Ub moieties 
from already lysed or wrongly modified substrates. 
UCH-L1 is one of the most abundant proteins in the brain, making up to 1-
2% of the total protein. Not surprisingly, mutations in UCH-L1, both gain or 
loss of function,  are directly related with neurodegenerative disorders, such 
as Parkinson’s (PD) and Alzheimer’s (AD) diseases29. Moreover, aberrant 
expression of this gene has been observed in several types of cancer and 
associated with cell invasion and chemotherapy resistance29. 
Another member of this family is BAP1, a protein that is basically confined 
in the nucleus. It has been related to several types of cancer and it described 
to participate in the regulation of several transcription factors29.  
Makarova et al. (2000)31 identified amino acid sequence similitude and 
evolutionarily conservation between the gene responsible for ovarian 
development in Drosophila melanogaster, otu, and a cysteine protease present in 
some viruses and in Chlamydea pneumoniae, thus proposing OTU as a new 
deubiquitinating enzyme family. Despite basal structural conservation, 
phylogenetically, the 15 OTU members can be divided into three subgroups: 
the Otubains, OTUB1 and OTUB2; the A20-like OTUs, including A20 (also 
known as TNFAIP3), VCPIP1, OTUD7B and ZRANB1; and the classical 
OTUs27. Besides, OTU members show different Ub chain specificity29. 
Concerning the structure of the catalytic site, it is worth mentioning that it 
differs from the rest of the cysteine proteases, as the canonical catalytic triad 
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of the DUBs is incomplete in OTUs, creating a hole in the catalytic core that 
is stabilized by hydrogen bonds28. 
So far, research on OTU proteins has mainly been focused on A20 
(TNFAIP3). Previous studies have demonstrated that this protein regulates 
the duration and intensity of NFκB (Nuclear Factor Kappa B Subunit 1) 
signalling during proinflammatory processes. Not surprisingly, germ-line 
single-nucleotide polymorphisms (SNPs) in humans have been linked to 
inflammatory conditions such as lupus erythematosus, rheumatoid arthritis 
and Chron’s disease29. On the other hand, OTUB1, involved in DNA double 
strand break repair and one of the most highly expressed DUBs in cells29 has 
also attracted some attention. OTUB1 has been shown to regulate the 
activity and stability of p53, increasing apoptosis and inhibiting 
proliferation32. However, both the ubiquitous expression and the functional 
role on double strand breaks, suggest an alternative function independent of 
the deubiquitinating activity. Finally, ZRANB1 (also known as TRABID) is 
involved in the regulation of the Wnt canonical pathway during development 
by promoting WNT33-dependent transcription. 
Machado-Josephine Disease (MJD) is the most common type of 
spinocerebellar ataxia worldwide. It is caused by CAG (triplet encoding 
Glutamine, Gln, Q) expansion in the ataxin 3 gene, ATXN3, which causes 
the formation of protein aggregates once a threshold in the number of polyQ 
repeats has been reached29. Some experimental evidence indicates that 
ATXN3 plays a role in transcription regulation or even in DNA repair34, but 
it is not clear whether it is related to its deubiquitinating activity28.  
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In vitro experiments confirm the deubiquitinating activity of ATXN3, but 
protease activity for the other three family members has not been described 
so far28. 
The JAMM family in the human genome is constituted by 12 Zn2+ 
metalloproteases containing a JAB1/MPN/MOV34 motif. Generally, they 
participate of larger protein complexes such as the proteasome (POH1), 
COP9 signalosome (CSN5) or the endocytic ESCRT (endosomal sorting 
complex required for transport) machinery (AMSH). However, they are 
involved in other cellular processes such as DNA repair (BRCC36) and the 
epigenetic switch in B-cell development (MYSM1). Most of them, e.g. 
AMSH, AMSH-L, BRCC36 or POH1, show strong preference for K63 
polyubiquitin chains. Nonetheless, there are some functional differences 
worth noting: POH1, a constitutive proteasomal component, cleaves in 
block whole Ub polymers from the proximal end to the substrate, whereas 
MYSM1 cleaves off monoubiquitin29.  
Concerning the catalytic site, the JAMM motif is a highly conserved domain 
throughout evolution, including prokaryotes. However, proteins of this 
family in bacteria do not display Ub or Ub-like cleavage activity, which 
suggests that JAMM proteases might have evolved to process different types 
of protein conjugation28. 
 
USPs constitute the largest DUB family, with more than 50 DUB encoding 
genes in the human genome. The number of USP members has greatly 
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expanded during evolution, conferring the family specialization and de novo 
functions. The USP catalytic core contains two short motifs, the cysteine 
(Cys, C) and histidine (His, H) boxes, that combined span 300 to 800 amino 
acids28. Note that some members of the USP family lack part of the catalytic 
triad, as observed in the OTUs: for instance, the stabilizing Asp of the 
catalytic triad is missing in USP30 and USP16. There is a special case, 
USP39, which lacks the Cys or the His residues in the catalytic core, which 
strongly indicates that USP39 is no longer a deubiquitinase. However, this 
DUB plays a role in spliceosomal maturation, as well as other DUBs, which 
led researchers to speculate whether these members display ubiquitin binding 
but no protease capacity28.  
The functional roles of USPs are as wide as the family itself, ranging from 
histone deubiquitination (USP16) to the control of tumour suppression gene 
levels (p53, FOXO4 or PTEN among others), as is the case of USP7. 
Knockout USP7 -/- mice suffer embryonic lethality, in part due to 
permanent p53 activation29. Other USPs have been linked to the regulation 
of DNA metabolism pathways: e.g. USP1 regulates the DNA cross-link 
repair genes complementation group D2 (FANCD2) and proliferating cell 
nuclear antigen (PCNA) in Fanconi anemia. Besides, it has also been related 
with osteosarcoma cancer when depleted in mouse and human29. In the case 
of USP14, together with UCHL5 (not present in yeast), they are reversibly 
associated to the proteasomal machinery and deubiquitinate proteins that are 
committed to degradation. 
Several USPs influence otherwise cell physiology through the control of 
receptors and channels and their regulatory cascade. In fact, the closely 
related USP4, USP11, USP15 and USP19 have been linked to the regulation 
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of the signalling events triggered by TGFβ (Transforming Growth Factor 
Beta) and NFκB, an been involved in the MAP kinase pathway and β-catenin 
stability. 
The above related structural and functional differences within the whole set 
of deubiquitinating enzymes highlight that, despite the large number of 
DUBs present in the human genome and their a priori similar function, high 
substrate and functional specificity must prevail within these gene families. 
This novel family was reported for the first time in July 2016. Motif 
Interacting with Ub containing Novel DUB family (MINDY)35 is an 
evolutionary conserved cysteine (thiol proteases) DUB family which 
selectively cleaves K48 polyubiquitin chains, that is, the poly Ub tag that 
targets substrates to proteasomal degradation. Rehman et al. described the 
catalytic activity to be encoded by a previously unnanotated domain which 
displays a distinct crystal structure (Figure 10). Nonetheless, a single unique 
protein has been described in the family. MINDY-1 is a DUB enzyme whose 
catalytic active site shows a preference for hydrolizing long ubiquitin chains 
from the distal end. 
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Note that almost all the experiments in this Thesis were performed prior to 
the description of this very novel family and thus, the unique member of the 
MINDY family does not appear in any of them (neither in most of the most 
acclaimed reviews of the field). 
As previously seen, the whole panoply of DUBs presents a high level of 
substrate specificity, which implies their involvement in a great variety of 
cellular processes. Thus, their dysfunction can vastly affect cell physiology 
and metabolism. In fact, several mutations in DUBs have been described as 
the genetic cause of human diseases ranging from cancer and neuropathies to 
autoimmunity.  
One of these cases is BAP1 (breast cancer early-onset 1-associated protein 
1), which associates with the potent tumour suppressor BRCA1, and 
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interacts with transcriptional machinery proteins. Mutations in this gene have 
been strongly correlated with predisposition to several types of cancer. BAP1 
recruits polycomb proteins to control the expression of selected target genes, 
generating a self-regulating complex controlled by deubiquitination36. Thus, 
when mutated, it produces the misregulation of the target genes leading to a 
potential cancer. Other DUBs instead, stabilize oncogenes or tumour 
suppressors, e.g. USP7, ATX3, JOSD1 (PTEN); USP7, USP10, OTUB1 
(p53); USP7, USP2a (MDM2); USP28 (MYC); or USP9X (MCL1)36; making 
them potential cancer-causing genes. 
Concerning neuropathies, the aforementioned member of the MJD family, 
ATXN3, has been described as the causative gene of the most common type 
of autosomal dominant inherited ataxia. Polyglutamine repeats expansion on 
the gene leads to ATXN3 aggregation, as well as to dysfunctional association 
to other proteins and DNA. Despite the exact molecular contribution to 
disease is still unclear, it has been argued36 that these clumps might produce: 
1) functional depletion of ATXN3, 2) retention of target proteins and 
consequent functional incapacity, and 3) toxic accumulation of 
polyubiquitinated proteins within the cell.  
Mutations in AMSH have also been related to another neuropathy, 
microcephaly-capillary malformation syndrome (MIC-CAP); in this case, 
however, the disease is due to the incapacity of AMSH to deubiquitinate, and 
thus regulate, RAS-MAPK and PI3K pathway36. 
It is worth mentioning that both A20 (also known as TNFAIP3) and CYLD, 
when mutated, cause a down regulation of NFκB singling pathway. 
Nevertheless, the first causes autoimmunity and lymphomas; while the 
second has been described as the driving cause of several types of cancer, 
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including melanoma, breast and prostate cancer. This striking differences 
might be partly due to the chain specificity of each of the enzymes36: in vitro 
studies have shown that A20 prefers K48 and K11 chains over K63 chains; 
while CYLD prefers K63 polyubiquitin chains.  
Overall, DUB protein specificity is vast enough as to participate in a wide 
range of human diseases and syndromes. And despite they have a common 
deubiquinating activity, the molecular bases for each of these diseases are 
also very diverse and might imply: 1) non-processing of ubiquitin precursors, 
which leads to a lack of free ubiquitin molecules and a disruption of the 
whole ubiquitin cycle; 2) rescue of a protein that should be degraded, thus 
increasing its nocive effects; 3) hyper-degradation of proteins; 4) mis-
functioning of the proteasomal machinery and a consequent accumulation of 
malfunctioning proteins; or 5) disruption of the regulation of DNA binding 
complexes regulation and a further disruption in transcriptional regulation. 
Ubiquitin is merely the best well-known representative member of a much 
larger group of other small peptides (from 40 to 100 amino acids) that can be 
also post-translationally conjugated to substrate proteins. All the members in 
this group, called Ubiquitin-Like proteins (UbL), maintain an evolutionarily 
preserved structural folding, named the Ub folding, and an extremely similar 
hierarchical conjugation system based on E1-E2-E3 enzymes37 (Table 2, 
adapted from38). 
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Modifier 
Amino acid 
identity with Ub 
(%) 
E1 E2 Comments 
Ubiquitin 
(Ub) 
100 Uba1 & Uba6 many 
Multiple genes encode 
ubiquitin precursors 
Rub1/NEDD8 55 Uba3-Ula1 Ubc12 Substrates: cullins, p53 
Smt3/SUMO1–
3 
18 Uba2-Aos1 Ubc9 
Vertebrates have 3–4 
SUMO genes 
Atg12 NDc Atg7 Atg10 ~20% identical to Atg8 
Atg8 ND Atg7 Atg3 
3 known human isoforms; β-
grasp fold 
Urm1 ND Uba4 – 
Related to MoaD, ThiS; β-
grasp fold 
ISG15 32/37b Ube1L UbcH8 Induced by type I interferons 
UFM1 ND Uba5 Ufc1 β-grasp fold 
FUBI/MNSFβ 38 – – 
Derived from ribosomal 
protein precursor 
FAT10 32/40b Uba6 – 
Substrates unknown; β-grasp 
fold 
 
One of the most studied UbLs is the Small Ubiquitin-like Modifier (SUMO). 
SUMO proteins can be found in all evolutionary eukaryotic clades, from 
protozoans to metazoans. Considering mammals, four SUMO paralogs have 
been described: SUMO 1, SUMO 2, SUMO 3 and SUMO 4. SUMO 1 is a 
small 11kDa protein that only shares 47% identity with SUMO 2 and 3, 
which between them only differ by three N-terminal residues. The high 
similarity peptide sequence between SUMO 2 and 3 explains why they are 
often referred as a single group, SUMO2/3. Concerning SUMO 4, it was 
first annotated in silico from human genome DNA sequences, as it shares 
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87% amino acid similarity with SUMO2. However, no evidences have been 
reported so far to support actual functionality39,40. 
SUMO conjugation is, similarly to ubiquitination, a dynamic and reversible 
ATP-dependent process, in which E1, E2 and E3 ligases coordinate to bind 
a SUMO moiety to its substrate protein (Figure 11, Table 3). There are only 
two activating E1 enzymes, SAE1 (SUMO-activating enzyme E1) and SAE2 
(only present in mammals), that act as a dimer and will transfer the activated 
SUMO molecule to the only known E2 conjugating enzyme, UBC9 
(ubiquitin-conjugating 9). UBC9 recognizes in the protein substrate the 
consensus ψKxD/E (where ψ is a large hydrophobic residue) sequence, 
which is considered a SUMOylation motif. Despite UBC9 can recognize the 
protein on its own, there are a set of E3 ligases, such as PIAS 1-4 (Protein 
inhibitor of activated STAT; Signal Transducer and Activator of 
Transcription), which will serve as scaffold for the UBC9-SUMO and the 
final substrate41. In addition, other proteins have been reported to work as 
SUMO E3 ligases: MUL1 (mitochondrial E3 ubiquitin ligase 1), MMS21 and 
TOPORS (topoisomerase I-binding, arginine/serine-rich), the latter being 
the first dual ubiquitin and SUMO ligase ever reported. On the other hand, 
HDAC4 (histone deacetylase 4), HDAC7, TLS (translocated in liposarcoma) 
and TRAF7 (tumour-necrosis-factor-associated protein 7) also serve as 
scaffold for SUMOylation. None of the aforementioned ligases display any 
active E3 ligase activity per se41. 
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SUMOylation is reversible thanks to the presence of deSUMOylating 
enzymes, SENP (sentrin/SUMO-specific protease) proteases. In contrast 
with the large amount of deubiquitinating enzymes, there are only six 
different SENPs in mammals, SENP 1-3 and SENP 5-7, which differ by 
their specificity and subcellular localization: SENP 1/2 are responsible for 
SUMO maturation as well as the deconjugation of SUMO 1, 2 and 3. All 
SENPs are preferentially located within the nucleus, but while SENP 1, 6 
and 7 are mainly found in the nucleoplasm, SENP 2 is located in the nuclear 
pore, and SENP 3 and 5 are enriched in the nucleoli42.  
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SUBSTRATES  E3 LIGASES 
 
PROTEASES 
SUMO1 
 
PIAS1 HDAC7 
 
DESI1 
SUMO2 
 
PIAS2 MUL1 
 
DESI2 
SUMO3 
 
PIAS3 RASD2 
 
SENP1 
E1 LIGASES 
 
PIAS4 TOPORS 
 
SENP2 
SAE1 
 
RANBP2 TLS 
 
SENP3 
SAE2 
 
CBX4 TRAF-7 
 
SENP5 
E2 LIGASE 
 
MMS21 EGR2 
 
SENP6 
UBC9 
 
HDAC4 
  
SENP7 
 
Similarly to Ub, the SUMO pathway genes are involved in cell cycle 
progression, DNA damage repair, cellular transport and transcription factor 
regulation43. Furthermore, it has been observed that SUMO can synergize, 
antagonize or cooperate with ubiquitin and other posttranslational 
modifications to more precisely regulate cellular processes42,43.  
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Photoreceptors are highly specialized cellular types, which differ both 
structurally and functionally, but that develop from the same photoreceptor 
progenitor precursor. Therefore, there must be a fine and tight genetic 
control to successfully achieve a properly structured and functional retina.  
Gene expression regulation by photoreceptor-specific transcription factors 
has been amply described1,44,45; however, it is not their bare action that 
determines photoreceptor fate, since SUMO conjugation –and possibly other 
post-translational modifications– of TFs play a key role in this process46. As 
mentioned, during photoreceptor commitment NR2E3 activates rod specific 
genes; however, when this TF is post-translationally modified by SUMO, 
NR2E3 recruits an alternative protein complex that will instead silence cone-
specific genes. In fact, mutations in the human gene that interfere with this 
process cause S-cone syndrome, a retinal dystrophy with an excess of cone-
like photoreceptor cells. Similarly the rod specific TF, NRL, is also 
SUMOylated, leading to a finer regulation of rod specific genes 47 (Figure 12, 
adapted from 46). 
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Other examples illustrate Ub cycle genes participating in retinal development 
and retinal disease: mutations in ubiquitin pathway genes, such as the E3 
ligases TOPORS48–50 and KLHL751,52 are causative of the most prevalent 
retinal hereditary dystrophy, retinitis pigmentosa (RP)48–50. Moreover, protein 
homeostasis via the ubiquitin-proteasome system is also relevant to other 
retinal diseases, as altered protein degradation has been associated to 
Stargardt's disease, age-related macular degeneration, glaucoma, diabetic 
retinopathy and retinal inflammation (reviewed in53). Thus, given the clear 
implication of ubiquitin and SUMO pathway genes in retinal processes, it 
might well be that deubiquitinating enzyme genes are also involved in retinal 
development. 
In mammals, several comprehensive surveys of DUBs have been reported 
resulting in: in silico inventories of the DUBs in the human genome27,28; 
identification of protein interactors by cell-based proteomics analysis54; 
S N
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studies of subcellular localization55; functional involvement in maintaining 
genome integrity56. A recent review reported the expression levels of DUBs 
in human organs and the disease phenotypes associated to DUB mutations 
in humans and animal models29. Despite their importance, detailed 
expression and functional analysis for most DUBs on particular tissues or 
organs, such as the retina, is still missing. For these reasons, this work is 
intended as a study of deubiquitinating enzymes in the retina and their 
possible role in photoreceptor development and homeostasis. 
 
  
  
  
 
 
 
 
 
 
 
Objectives 
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1. Analysis of the involvement of deubiquitinating enzymes (DUBs) in 
the mouse retina: 
 Description of the expression pattern of all DUBs in the mouse 
retina, analyzing mRNA expression and pattern of expression via 
real time RT-qPCR and in situ hybridization. 
 Determination of the protein localization of a set of DUB enzymes 
in the adult mouse retina via fluorescent immunohistochemistry. 
 Sequence and functional conservation analysis of DUBs through 
phylogenetic and phenotypic studies. 
 Transcriptomic analysis of DUBs’ mRNA expression in the retina 
during development, considering wild type mouse retinas; CRX and 
NRL knockout mouse retinas; flow sorted rods and cones; and 
human retina. 
 Preliminary analysis of the functional role of selected DUBs in 
mouse retinal development via in vivo gene knockdown. 
2. Devising an in-vivo cell system to study the role of DUB enzymes on 
the regulation of retinal promoters: 
 Establishing a cell culture system to study the behaviour of DUBs 
upon retinal promoters. 
 Knockdown of DUB genes in the established cell culture 
system via shRNA and siRNA silencing techniques. 
3. Identification of CRX post-translational modifications, particularly 
ubiquitination. 
  
  
 
  
 
 
 
 
 
 
Materials and methods 
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For bacterial transformation, competent DH5α Escherichia coli strain were 
heat shocked at 42°C for 90 seconds, kept in ice for 2 min, grown at 37°C 
for 1h in LB medium and plated in LB-agar plates with either ampicillin or 
kanamycin (according to the resistance provided by the transformed 
plasmid). LB plates were with transformed bacteria were incubated overnight 
(O/N) at 37°C. 
For constructs made in pGEM-T vector, colony colour selection was 
performed adding to LB-agar plates with transformed bacteria 1:1 IPTG:X-
Gal reagents. White colonies contained pGEM-T with a DNA inserted, 
while blue colonies contained religated pGEM-T. 
The promoters of the retinal specific genes: S opsin, M opsin, Rhodopsin 
and GNAT were cloned upstream the luciferase gene in the pGL3-Promoter 
Vector. Thus, if a transcription factor bound the promoter, the changes in the 
luciferase gene expression could be easily quantified by the changes in 
luciferase activity as measured in a luminometre. The human CRX, NRL, 
NR1D1 and NR2E3 transcription factors were cloned in the pcDNA3 
vector containing Xpress epitope. The DNA fragments containing the 
human Rhodopsin, human M opsin and mouse GNAT promoters, as well as 
the transcription factor (TF) constructs were provided by Dr. Pomares (a 
former member of our group). 
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For in situ hybridization, 400-700 bp cDNA sequences of each analyzed 
DUB were cloned into a pGEM-T Easy Vector (Promega) to obtain the 
riboprobes.  
The mouse cell line 661W (precursor of cones) was cultured in DMEM 4.5 
g/L glucose, 1.1 g/L sodium pyruvate (Invitrogen) medium, supplemented 
with 0.3 g/L glutamine, β-mercaptoethanol (40 µL/L) (Invitrogen). RGC5 
cells (rat transformed ganglion cell line) were cultured in 4.5 g/L glucose, 1.1 
g/L sodium pyruvate (Invitrogen) DMEM medium, supplemented with 0.3 
g/L glutamine, 1 g/L D-glucose. Human retinoblastoma Y-79 was cultured 
in DMEM with 25mM HEPES (Invitrogen). HEK293 (Human Embryonic 
Kidney), HEK293T (Human Embryonic Kidney transformed with SV40 
virus T antigen) and Mio-M1 (human Müller cells) were cultured in DMEM 
with L-glucose (ATCC). All culture media were further supplemented with 
10% Foetal Bovine Serum (FBS; Invitrogen) and 1% Penicillin-Streptomycin 
(PenStrep, Invitrogen). Cells were kept at 37°C and 5% CO2.  
HEK293T, 661W, RGC5 and Y-79 cells were transfected with Lipofectamine 
2000 (Invitrogen) following the manufacturer’s instructions. HEK 293 cells 
were transfected with Lipotransfectine (Niborlab) following the manufacturer’s 
instructions, using a ratio of DNA:Lipotransfectine of 1:3. The efficiency of 
different liposomal systems was tested on HEK293T cells by transfecting a 
control GFP construct, and checking GFP expression at 28 h, 50 h and 72 h 
post-transfection. TransIT-Neural (Mirus), TransIT-293 Transfection Reagent 
(Mirus), FuGENE HD Transfection Reagent (Roche), TransFast Transfection 
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Reagent (Promega) and Metafectene Pro (Biontex) were used following the 
manufacturer’s instructions. The appropriate amount of CRX and S opsin 
promoter was tested using different relative amounts, as referred in Table 4. 
µg of S opsin 
promoter 
µg of 
CRX 
0,05 0,2 
0,2 0,2 
0,3 0,1 
0,4 0,4 
0,4 0,1 
0,6 0,1 
0,6 0,075 
0,8 0,05 
0,8 0,1 
1 0,1 
2 0,1 
3 0,1 
 
HEK293 cells were transfected with 145 ng of S opsin-Luciferase construct 
(reporter gene), 25 ng of β-galactosidase construct (for transfection 
normalization), 240 ng of CRX construct (transcription factor) and a total of 
750 ng of shRNA (for assaying the effects of the each analyzed DUB 
knockdown) per condition in 48 well plates. Three different constructs of 
shRNA were used per each silenced gene. Lipotransfectine (Niborlab) was used 
in a 1:3 ratio of DNA:Lipotransfectin according to the manufacturer’s 
instructions, and cell lysates were collected 72h post-transfection. The list of 
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genes silenced with shRNA is shown in Table 5. Deconvolution of the three 
shRNA from selected genes was performed under the same conditions, using 
750 ng of each shRNA construct. 
 
shRNA 
SUMO DUBs 
SUMO-1 Rasd2 JOSD2 
SUMO-2 TOPORS ATXN3 
SUMO-3 TLS BAP1 
SAE1 TRAF-7 STAMPB 
SAE2 DESI1 USP9X 
Ubc9 DESI2 USP25 
PIAS1 SENP1 USP45 
PIAS3 SENP2 USP54 
PIAS2 SENP3 UCHL1 
PIAS4 SENP5 UCHL3 
RANBP2 SENP6 USP12 
CBX4 SENP7 USP11 
Mms21 SENP8 TNFAIP3 
HDAC4 USPL1 USP47 
HDAC7A 
 
PRPF8 
Mul1 
 
OtuD7b 
HEK293 cells were transfected with 150 ng of S opsin-Luciferase construct 
(reporter gene), 25 ng of β-galactosidase construct (for transfection 
normalization), 250 ng of CRX construct (transcription factor) and a total of 
5 µM of siRNA (for assaying the effects of the each analyzed DUB 
knockdown) per condition in 48 well plates. Two different constructs of 
siRNA were used per each silenced gene. Lipotransfectine (Niborlab) was used 
in a 1:3 ratio of DNA:Lipotransfectin according to the manufacturer’s 
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instructions, and cell lysates were collected 48h post-transfection. The list of 
genes silenced with siRNA is shown in Table 6. Deconvolution of the three 
siRNA from selected genes was performed under the same conditions, using 
750 ng of each siRNA. 
 
siRNA 
DUB genes 
USP 1 USP 13 USP 31 
USP 2 USP 14 USP 32 
USP 3 USP 15 USP 33 
USP 4 USP 16 USP 34 
USP 5 USP 18 USP 36 
USP 6 USP 19 USP 37 
USP 7 USP 20 USP 42 
USP 8 USP 22 USP 44 
USP 9 USP 24 USP 46 
USP 10 USP 25 USP 47 
USP 11 USP 29 CYLD 
USP 12 USP 30 
 
To assess the activity of the S opsin-Luciferase promoter, a luciferase assay 
was performed to measure luciferase activity. Cells were lysed using the 
Reporter Lysis Buffer (Promega), frozen at -80°C and centrifuged to discard 
cellular debris for 2 min at 12000 g. Luciferase activity was measured after 5 
min of reaction with ONE-Glo Luciferase Assay System (Promega). Reads 
were performed in the Modulus Microplate Multimode Reader (Turner 
Biosystems) luminometer. Results were normalized with values obtained 
from β-galactosidase reaction, expressed from the cotransfected pCMV- β-
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gal vector, measured with Beta-Glo Assay System (Promega), following the 
manufacturer’s instructions. 
All procedures in mice were performed according to the ARVO statement 
for the use of animals in ophthalmic and vision research, as well as the 
regulations of the Animal Care facilities at the Universitat de Barcelona. The 
protocols and detailed procedures were evaluated and approved by the 
Animal Research Ethics Committee (CEEA) of the Universitat de Barcelona 
(our institution), and were submitted and also approved by the Generalitat de 
Catalunya (local Government), with the official permit numbers DAAM 
6562 and 7185.  
Murine retina samples and eye slides were obtained from 2 month-old 
C57BL/6J (wild-type) and CD-1 (albino) animals. Animals were euthanized 
by cervical dislocation. Some retinas were dissected and immediately frozen 
in liquid nitrogen, while the rest were fixed in 4% paraformaldehyde (PFA) 
for 2 h at room temperature (RT), washed, cryoprotected overnight in 
acrylamide at 4°C, embedded in O.C.T. (Tissue-Tek, Sakura Finetech, 
Torrance, CA), frozen in liquid nitrogen and sectioned at -20°C.  
For each sample, retinas from three different animals were pooled. 
Therefore, up to 9 animals in three independent replicates were analysed. 
Retinas were homogenized using a Polytron PT 1200 E homogenizer 
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(Kinematica, AG, Lucerne, Switzerland). Total RNA was extracted using the 
High Pure RNA Tissue Kit (Roche Diagnostics, Indianapolis, IN) following 
the manufacturer’s instructions with minor modifications (increasing the 
incubation time with DNase I). Reverse transcription reactions were carried 
out using the qScript cDNA Synthesis Kit (Quanta Biosciences) following 
the manufacturer’s protocol. 
Quantitative reverse transcription PCR was performed using the 
LightCycler® 480 SYBR Green I Master Mix (Roche Applied Science) and a 
LightCycler® 480 Multiwell Plate 384. The final reaction volume was 10 μl. 
Raw data was analysed with the LightCycler® 480 software using the 
Advanced Relative Quantification method. Gapdh expression was used to 
normalize the levels of expression. Rho and Cerkl were considered as 
reference genes with high and low levels of expression, respectively, in the 
mouse retina. Three independent sample replicates were analysed for each 
gene. Primers used for the Real Time qPCR are listed in Table 7 and in Table 
8. 
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Human Mouse 
GAPDH Fw ctcaagggcatcctggctac GAPDH Fw agactgaacggaagctcac 
Rv agcgtcaaaggtggaggagtg Rv tactccttggaggccatgtagg 
RHO Fw tcgactactacacgctcaagc Rho Fw gcccttctccaacgtcacag 
Rv gaagacgagctgcccatagg Rv gcagcttcttgtgctgtacgg 
M opsin Fw catagccatggcccagcagt M opsin Fw tcttgtggtcgttgcatctgtc 
Rv agttgctgttggtgtaggtga Rv agtggatggcgcagcttctt 
S opsin Fw gtgggcctcagtaccacat S opsin Fw gcgggagatgtcaggagagg 
Rv cagtgtggccaccagcac Rv caggagcaaggtggtactgagg 
GNAT Fw gacctggagcgcctggtaac Gnat Fw tgcctaccctgtccctttgc 
Rv cgatgatgccagtggtcttga Rv tccagctctctggagtgcttct 
CRX Fw caactggaggagctggagg Crx Fw ccaccgtgtccatttggagt 
Rv tgaaccctggactcaggcag Rv agagggcccagaagccacta 
NRL Fw ccgttcagagcaccttgtgg Nrl Fw ggtgcctccttcacccacct 
Rv cgatgcagagaaccgtgcag Rv gggtggccagccaatatagc 
NR1D1 Fw agacttcacccacccagcac Nr1d1 Fw actccacatccacctctgg 
Rv aggcgtcagctgttgtggaa Rv ggaactgagagaagcccacca 
NR2E3 Fw ccagcaatgaccctgagttcc Nr2e3 Fw gccttggccagtgcagagac 
Rv ccgaggtctcatggatgctg Rv Gccttcaggcaggcaaactc 
 
For in situ hybridization (ISH), 16-18μm sections were recovered on 
commercial Superfrost Plus glass slides (Electron Microscopy Sciences, 
Hatfield, PA), dried 1 h at RT, rinsed three times for 10 min with phosphate-
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buffered saline (PBS), treated with 2 μg/ml proteinase K for 15 min at 37°C, 
washed twice for 5 min with PBS, and fixed with 4% PFA. Acetylation with 
0.1 M triethanolamine-HCl (pH 8.0) containing first 0.25%, and then 0.5% 
acetic anhydride, was performed for 5 min each. Hybridization was carried 
out overnight at 55°C with digoxigenin-labelled riboprobes (2 μg/ml) in 50% 
formamide, 1 x Denhardt’s solution, 10% dextran-sulfate, 0.9 M NaCl, 100 
mMTris-HCl (pH 8.0), 5 mM EDTA (pH 8.0), 10 mM NaH2PO4, and 1 
mg/ml yeast tRNA. For each gene, cDNA fragments generated by RT-PCR 
of approximately 400-700bp were subcloned into the pGEM-T® Easy Vector 
(Promega) and sense and antisense riboprobes were generated from the 
flanking T7 RNApol promoter. The name and sequence of all the primers 
used for RT qPCR and in situ hybridization are listed in Table 8. 
After hybridization, slides were washed in 2x SSC for 20 min at 55°C, 
equilibrated in NTE (0.5 M NaCl, 10 mM Tris-HCl pH 8.0, 5 mM EDTA) at 
37°C, and then treated with 10 μg/ml RNase A in NTE at 37°C for 30 min. 
Subsequently, the sections were washed at 37°C in NTE for 15 min, twice in 
2x SSC and 0.2x SSC for 15 min each, equilibrated in Buffer 1 (100 mM Tris-
HCl pH 7.5, 150 mM NaCl), and blocked in Blocking Buffer (1% BSA and 
0.1% Triton X-100 in buffer 1) for 1 h at RT. An anti-digoxigenin-AP 
conjugate antibody (1:1000; Roche Diagnostics, Indianapolis, IN) in 
Blocking Buffer was incubated overnight at 4°C. Sections were then washed 
twice in Buffer 1 for 15 min, once in Buffer 2 (100 mM Tris-HCl pH 9.5, 
150 mM NaCl), and once in Buffer 2 supplemented with 50 mM MgCl2 (5 
min each) prior to adding the BM Purple AP Substrate (Roche Diagnostics, 
Indianapolis, IN). For each gene, antisense and sense ISH staining reactions 
were processed in parallel. The reaction was stopped in 1x PBS. Sections 
were cover-slipped with Fluoprep (Biomérieux, France) and photographed 
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using a Leica DFC Camera connected to a Leica DM IL optic microscope 
(Leica Microsystems, Germany). 
 Real Time qPCR In Situ Hybridization 
Family Gene Orientation Sequence (5’-3’) Gene Orientation Sequence (5’-3’) 
 
Gapdh* 
Fw tgacaatgaatacggctacagcaa 
  
 Rv tactccttggaggccatgtagg 
 
Rho 
Fw gcccttctccaacgtcacag 
Rho* 
Fw gcccttctccaacgtcacag 
 Rv gcagcttcttgtgctgtacgg Rv gcagcttcttgtgctgtacgg 
JAMM Amsh Fw attgttcaagagttcgggaagg Amsh Fw caccgagactacaaatcagctatc 
  Rv gggggccacatctacacaagg  Rv gggggccacatctacacaagg 
 Amsh-L Fw gctgctatgcctgaccatacaga Amsh-L Fw gagaacccagaggcccggacta 
  Rv gacctgaagtaacggcgtggggtg  Rv gacctgaagtaacggcgtggggtg 
 Brcc36 Fw gcggcgttctgacaagagaaagg Brcc36 Fw aacacaaagactggccgggta 
  Rv ataccagccaacaactctcatggg  Rv cgatgcaggaaccaaagcag 
 Csn5 Fw ttccgggagtggtatggcccag Csn5 Fw ttccgggagtggtatggcccag 
  Rv cgccgccaggatttctttcttgttg  Rv gtgtactaacatcaatcccggag 
 Eif3h Fw catgtttgaagaagtgccgattg Eif3h Fw NP 
  Rv gtgcttatccgccacagctgac  Rv NP 
 Jamm2 Fw cctgcctgaatgctgtaaagattg Jamm2 Fw cctgcctgaatgctgtaaagattg 
  Rv agtaagatggctgccagaattctgt  Rv tcctctcttacttctcctctgtg 
 Jamm3 Fw cctgttcctcgaggcctgt Jamm3 Fw tccatggcagctcccgagtct 
  Rv tcaatgtcctgcaagcaaggagggta  Rv ctcctccaacagcagttcttcc 
 Mysm1 Fw tgtctctgctctgtgccaactg Mysm1 Fw NP 
  Rv cacctctcctgctgagaaacca  Rv NP 
 Poh1 Fw acatgtggatgtcttatgacttca Poh1 Fw caatgctaatatgatggtcttgg 
  Rv gcgccactgacagctctctacgt  Rv gccactgacagctctctacg 
 Prpf8 Fw gcgtggaattacccctctgc Prpf8 Fw NP 
  Rv cacccgctgcttcgttactg  Rv NP 
 Psmd7 Fw  Psmd7 Fw NP 
  Rv  Amsh Rv NP 
MJD Atxn Fw gccctgtggagctatcctcaat Atxn Fw gccctgtggagctatcctcaat 
  Rv actcccccttctgccattctc  Rv gagggcactctgctctttcaga 
 Josd1 Fw ccatggtctctgcaggtctga Josd1 Fw ccatagtttgggacagagttggg 
  Rv tgctcaggattaacatgcaagc  Rv tgctcaggattaacatgcaagc 
 Josd2 Fw gtgcgaggtgctattggtggt Josd2 Fw gccgacgaaatctgcaagag 
  Rv gcagcagatcagcttgtgttca  Rv gcagcagatcagcttgtgttca 
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 Josd3 Fw gaacaccaccttaaggaatgcttg Josd3 Fw ggcatcggatagagctggagat 
  Rv gtatttgtgcctccgactgtca  Rv gtatttgtgcctccgactgtca 
OTU 
Otub1 
Fw agcaggtggacaagcagacctc 
Otub1 
Fw agcaggtggacaagcagacctc 
 Rv cagtcgcaggtagaccacaagg Rv cctctgtacatgtctagcgcc 
 
Otub2 
Fw gccacttaccttgccttgctgc 
Otub2 
Fw acattctatccattcttcgggatca 
 Rv acagggtggtcccatggttatc Rv agaagtcagctcggttcctgatg 
 
Otud1 
Fw catggggcagatgctgaatgtg 
Otud1 
Fw agaagctagccctgtacctgg 
 Rv ggcccagatagtggatcatgg Rv ggcccagatagtggatcatgg 
 Otud3 Fw gatgcggaggagaaccatga Otud3 Fw tccacatcgcctaccgctac 
  Rv tgccttcatttctgccctga  Rv tgccttcatttctgccctga 
 
Otud4 
Fw cctgttcccgtgtatcctcaga 
Otud4 
Fw cctgttcccgtgtatcctcaga 
 Rv catcggtgcaaggacagtcac Rv tccaaaggcaaatccaattctcc 
 
Otud5 
Fw ctgagcaccctgaactgcat 
Otud5 
Fw gcctaccgtcatttaagccagg 
 Rv tgaaggaggtttggcaagagcta Rv tgaaggaggtttggcaagagcta 
 
Otud6a 
Fw cgagatggagcagaggcacaa 
Otud6a 
Fw NP 
 Rv gctgtaaccgaatccacactgc Rv NP 
 
Otud6b 
Fw ccgggaagaaaggatagcagagg 
Otud6b 
Fw NP 
 Rv ggctgccaatatttgagcaagtt Rv NP 
 
Otud7a 
Fw tctgacggattcggaacacaag 
Otud7a 
Fw cttgcacagccagagtctcc 
 Rv tggctaaccgggcattgtcg Rv ggcgacgctcccgacgc 
 
Otud7b 
Fw atgatccagcgttaccttgcag 
Otud7b 
Fw gggcctgatgcacagcaagg 
 Rv ccctccattcatgatcttcctc Rv ccctccattcatgatcttcctc 
 
Parp11 
Fw tgctatccccatccagctttg 
Parp11 
Fw NP 
 Rv tgcttcccaatttgagtgactg Rv NP 
 
Tnfaip3 
Fw ataatggattctgtgagcgttgc 
Tnfaip3 
Fw tttgagcttgttcagcacgaatac 
 Rv gaaggcaggcttggcactttc Rv gaaggcaggcttggcactttc 
 
Vcpip1 
Fw atggggtgtgcctcaggaccttatt 
Vcip1 
Fw gaaacgaagggaccgaagaatc 
 Rv ctgcaaacttctgtctcctccaa Rv tgctgctgaaagtgctgctta 
 
Yod1 
Fw cagcgtaacttccctgatccaga 
Yod1 
Fw gaaggaccgaggccgagtc 
 Rv cttcatcagctaattccagtgcttg Rv cgggtagccaacgaggattc 
 
Zranb1 
Fw tcccagacctaataacattgaagca 
Zranb1 
Fw ggtggaagtagtcctttgatatg 
 Rv ctccatcgagctctgtcttgctc Rv ctccatcgagctctgtcttgctc 
UCH Bap1 Fw tcctgggagtgggagtgacat Bap1 Fw ctgcttcctgagcattgaggag 
  Rv ctgcttcctgagcattgaggag  Rv gctgtgactcttgagatttgtg 
 Uch-l1 Fw gattaaccccgagatgctgaac Uch-l1 Fw cgcttcgccgacgtgctagg 
  Rv ggatggcactgagcccagag  Rv gcccatcgagctcgtacaga 
 Uch-l3 Fw tatgcgcgcagtgttactcctctt Uch-l3 Fw tatgcgcgcagtgttactcctctt 
  Rv tcgttccacaggcattgctgat  Rv ggcatcctctaacaacgtctcatc 
 Uch-l5 Fw agatgtgattcgacaagtgcacaa Uch-l5 Fw ggggtcttcaccgagctcat 
  Rv agatgtgattcgacaagtgcacaa  Rv agatgtgattcgacaagtgcacaa 
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USP Usp1 Fw ggacaccattcaccgacaatag Usp1 Fw NP 
  Rv aacgcctgtttggtcactggat  Rv NP 
 Usp2 Fw acctgaagcgattctcagaatc Usp2 Fw gatggtctccacaatgaggtg 
  Rv ctctcaagtccaggtctctta  Rv ctctcaagtccaggtctctta 
 Usp3 Fw ccgctggttccatttcaatgac Usp3 Fw NP 
  Rv ctggcctgacgctccacataa  Rv NP 
 Usp4 Fw tggtgaggacgatcagggaga Usp4 Fw NP 
  Rv aggagttcacgaggctgaagg  Rv NP 
 Usp5 Fw cacccatgctggacgaatccg Usp5 Fw cggatgagcccaaaggtagcct 
  Rv gccccgctgtttcccgtatag  Rv gccccgctgtttcccgtatag 
 Usp6 Fw cggaagtatctggagctgagc Usp6 Fw NP 
  Rv cagtccatctttcggcccttc  Rv NP 
 Usp7 Fw gatgatgacgtggtatccaggtg Usp7 Fw NP 
  Rv catataggcatttgtgcagtgtc  Rv NP 
 Usp8 Fw caacgagcacctggatgacc Usp8 Fw tatttggaggatcaggaccagc 
  Rv acgatgatggactcgttgagc  Rv acgatgatggactcgttgagc 
 Usp9X Fw ttaaaaggaaatggacctgggc Usp9X Fw tcaagaatgcagtcttcgatca 
  Rv gctttgcactggaggagacc  Rv gctttgcactggaggagacc 
 Usp9Y Fw gtggacttgggctatggaatgg Usp9Y Fw NP 
  Rv gtactggaggagaccagttgc  Rv NP 
 Usp10 Fw atgcccaggacttgtgacagc Usp10 Fw NP 
  Rv cctggcatcgcctcctagtg  Rv NP 
 Usp11 Fw gcctggcagaaccataaacgac Usp11 Fw NP 
  Rv cattgccacaatcagggcacac  Rv NP 
 Usp12 Fw accagcttcaccggtacacga Usp12 Fw NP 
  Rv ctgtcagggttggtcgcatct  Rv NP 
 Usp13 Fw cactggactggatcttcagcc Usp13 Fw tgatgaaccagttgatagaccc 
  Rv gcctcagacacgatgttggca  Rv gcctcagacacgatgttggca 
 Usp14 Fw atggaattgccatgtggattgac Usp14 Fw NP 
  Rv gggcatctttgagttcaggcac  Rv NP 
 Usp15 Fw cgcgcagtcacttaaggagca Usp15 Fw NP 
  Rv ccatcagtgtgtaccagctgac  Rv NP 
 Usp16 Fw agcacttgcgggagaagtgga Usp16 Fw NP 
  Rv ggccatccaaatccttctggtta  Rv NP 
 Usp17L8 Fw ctgccaatgacaagcccagtc Usp17L8 Fw NP 
  Rv cagggctgcattcaggtagca  Rv NP 
 Usp18 Fw acgcaggagtccctgatttgc Usp18 Fw NP 
  Rv cagaggctttgcgtccttatcaa  Rv NP 
 Usp19 Fw cctggctctggtgtggcgga Usp19 Fw NP 
  Rv cagcagagcctggatcttcagc  Rv NP 
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 Usp20 Fw cggcatgaggtgatgtactcct Usp20 Fw tggctggccttcatcgtgg 
  Rv cagggacgtgcactccttgg  Rv cagggacgtgcactccttgg 
 Usp21 Fw ccgagtgggagccaagatacc Usp21 Fw NP 
  Rv cctgggaggcaaaggtcgtaa  Rv NP 
 Usp22 Fw tctaccccattctggcccttg Usp22 Fw NP 
  Rv ttcgcaggcagtctgtgagag  Rv NP 
 Usp24 Fw gtgtgcccagacaggatgctc Usp24 Fw NP 
  Rv ggttctcctcccactcctgg  Rv NP 
 Usp25 Fw agagcagccatcaagaagtgac Usp25 Fw ccaccgggagagccggtggat 
  Rv atcttcaagatcatgtgacgcct  Rv atcttcaagatcatgtgacgcct 
 Usp26 Fw cgcaaggtggatccaacaaagt Usp26 Fw NP 
  Rv tagtggcctccattgggactg  Rv NP 
 Usp27X Fw tctggacttgcctggctcttg Usp27X Fw NP 
  Rv agtggtgatgcctgggatgtg  Rv NP 
 Usp28 Fw catgaggagtactccaggctct Usp28 Fw catgaggagtactccaggctct 
  Rv catgctgaaggcgagggtcac  Rv acaccaggtaggacaatgcttc 
 Usp29 Fw ccagcgcagaagtgaacaagg Usp29 Fw NP 
  Rv ttctctgctttgccgcctctg  Rv NP 
 Usp30 Fw ctgccacagtgcctctgcat Usp30 Fw actggaagtctcagcaccct 
  Rv aactgcacgtgctcgtgcc  Rv aactgcacgtgctcgtgcc 
 Usp31 Fw ctgacagagccagcgtcacct Usp31 Fw NP 
  Rv acgtgcttgccatccactctg  Rv NP 
 Usp32 Fw caccgactctgcctacattctt Usp32 Fw NP 
  Rv ctcgtgtccgccatcttcttg  Rv NP 
 Usp33 Fw tcctccgacctccagttgttc Usp33 Fw NP 
  Rv gtgtcctcagaactacaaagagc  Rv NP 
 Usp34 Fw atggcaggtttgacgactgt Usp34 Fw tgacgaaggagcaactcctgt 
  Rv tcggattcatcttcagctagtg  Rv tcggattcatcttcagctagtg 
 Usp35 Fw catggtggcctctctggtcaa Usp35 Fw NP 
  Rv agcccgggaaccgaaacacc  Rv NP 
 Usp36 Fw gcatcgacacgctcctccca Usp36 Fw gcatcgacacgctcctccca 
  Rv gcaccctcaccctccgagc  Rv ctcttcatcctgctgtggctc 
 Usp37 Fw agaggtgctggcagctgtgtt Usp37 Fw NP 
  Rv gtgtccggactgctggttgg  Rv NP 
 Usp38 Fw cagcttcgttacccagtgctca Usp38 Fw NP 
  Rv gacaaaggcagctgttgctgga  Rv NP 
 Usp39 Fw caagccgtccacaagaacacc Usp39 Fw NP 
  Rv tgatgaagcacgtggatcctg  Rv NP 
 Usp40 Fw ctgaggacacagctacgcatc Usp40 Fw NP 
  Rv tcaaggagccagcagtccatc  Rv NP 
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 Usp41 Fw  Usp41 Fw NP 
  Rv   Rv NP 
 Usp42 Fw acaacgtcgacttcccccagt Usp42 Fw NP 
  Rv tctgaggactcggccccatag  Rv NP 
 Usp43 Fw gactcgggagcctcaacaaca Usp43 Fw NP 
  Rv tggtgaagacaggagagtcgg  Rv NP 
 Usp44 Fw gagcccagttccccgtacag Usp44 Fw NP 
  Rv agcatggcaaacggtgagacc  Rv NP 
 Usp45 Fw agcctcactgacggcagcg Usp45 Fw agcctcactgacggcagcg 
  Rv aggctgcttggaagcgatc  Rv gacaggactggactgagcat 
 Usp46 Fw accgggtggtcttccctctg Usp46 Fw NP 
  Rv aacgaccacagcaaccaggtc  Rv NP 
 Usp47 Fw gtccatgtcacagcttgccatc Usp47 Fw gagagtacagagttaaagtgtgcc 
  Rv gctttccaacacaagctcctgg  Rv gctttccaacacaagctcctgg 
 Usp48 Fw gcagcagcaggatgcacaaga Usp48 Fw NP 
  Rv ctgctgcacaacattccgaaca  Rv NP 
 Usp49 Fw caggagcctggagctcattca Usp49 Fw NP 
  Rv cccacttcccagaccacatga  Rv NP 
 Usp50 Fw actttggagatctggatggtgg Usp50 Fw NP 
  Rv tcactgactcgggtgtcatcaa  Rv NP 
 Usp51 Fw gacctgggtagcagtgccaaa Usp51 Fw NP 
  Rv gaaagcaggccacaatcggtaa  Rv NP 
 Usp52 Fw cggaagtatctggagctgagc Usp52 Fw NP 
  Rv cagtccatctttcggcccttc  Rv NP 
 Usp53 Fw ggagtccatgcatgacccagg Usp53 Fw tgaacaactggacgggtagctg 
  Rv tgaacaactggacgggtagctg  Rv catctgtgagaactgctgggct 
 Usp54 Fw cacgtgcaacctgcctagaa Usp54 Fw gaagagagcactgtcgctgg 
  Rv tccagttcagaggtctcctgc  Rv tccagttcagaggtctcctgc 
 Cyld Fw tcccaggcagtgccgcatc Cyld Fw tcccaggcagtgccgcatc 
  Rv tgcttgatcttcccagctgag  Rv gaatgttgaagccattctgacc 
 
For retina immunofluorescence, 16 μm sections were recovered on 
commercial Superfrost Plus glass slides (Electron Microscopy Sciences, 
Hatfield, PA), dried 30-45 min at RT, washed 10 min with PBS and blocked 
for 1 h with Blocking Buffer (2% Sheep Serum and 0.3% Triton X-100, in 
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PBS 1x). Primary antibodies were incubated overnight at 4°C with Blocking 
Buffer. After incubation, slides were washed with PBS (3 x 10 min) and 
treated with DAPI (Roche Diagnostics, Indianapolis, IN) (1:300) and with 
secondary antibodies conjugated to either Alexa Fluor 488 or 561 (Life 
Technologies, Grand Island, NY) (1:300) in a 1x PBS solution. After 
secondary antibody incubation slides were washed again in PBS (3 x 10 min). 
Sections were mounted in Fluoprep and analyzed by confocal microscope 
(SP2, Leica Microsystems). Primary antibodies and dilutions used were:  
Dilution Host Protein  Manufacturer 
1:50 Rabbit  ATXN3  in house, kind gift from Dr. S. Todi 
1:20 Rabbit  BAP1  Biorbyt (orb33784) 
1:300 - DAPI Roche (70237122) 
01:50 Rabbit  JOSD2  Aviva Systems Biology (OAAB00616) 
1:50  Rabbit  JOSD2  Origene (TA337367) 
1:50 Rabbit  JOSD3  
 
1:100 Rabbit  OTUD4  Abcam (ab106368) 
1:50 Rabbit  OTUD7B  ProteinTech (16605-1-AP) 
1:50 - PNA Life Technologies (L32460) 
1:100 Rabbit  PRPF8  Abcam (ab79237) 
1:500  Mouse  Rhodopsin  Abcam (ab5417) 
1:100 Rabbit  TNFAIP3  Abcam (ab74037) 
1:100 Rabbit  UCHL3  Abcam (ab126703) 
1:100 Rabbit  USP13  Abcam (ab109264) 
1:100 Rabbit  USP16  Abcam (ab135509) 
1:100 Rabbit  USP22  Abcam (ab4812) 
1:300 Rabbit  USP25  in house 
1:250 Rabbit  USP28  ABGEN (AP2152b) 
1:50  Rabbit  USP46  ProteinTech (13502-1-AP) 
1:20  Rabbit  USP48 Abcam (ab72226) 
1:100 Rabbit  USP9X  Abcam (ab19879) 
1:3000 Mouse  β3-Tubulin Sigma Aldrich  
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PNA (Life Technologies, L32460) was used to label cone photoreceptors; 
and DAPI to counter-stain DNA. Antibodies against: AMSH (Biorbyt 
orb101007), JAB1 (Abcam ab12323), OTUB1 (Abcam ab76648), OTUD1 
(Abcam ab122481), POH1 (Abcam ab8040), USP5 (Abcam ab154170) and 
USP45 (Novusbio H00085015) did not produce reproducible and consistent 
results and are thus not included. 
Retinas were homogenized in RIPA buffer, containing deoxycolate 0.25% 
w/v, NP40 1% v/v, Tris pH 7.5 1 M, EDTA 500 mM, NaCl 5 M with 
addition of a cocktail of protease inhibitors (Complete Mini, Roche). Though 
occasionally cultured cells were also recovered with RIPA, generally they 
were directly lysed with 1x Protein Loading Buffer (120 mM Tris-HCl pH 
6.8, 4% SDS, 20% Glycerol, 0,2% Bromophenol Blue in MiliQ Water). 
Protein lysates were boiled 5 min at 95°C and loaded on 10% or 12.5% SDS-
PAGE gels, transferred onto PVDF (polyvinylidene fluoride) membranes 
and blocked with 10% skimmed milk in PBST for 1 h. Only when using the 
GAPDH antibody the blocking solution was 5% BSA (Bovine Serum 
Albumin). Membranes were incubated overnight 4°C, washed three times 10 
min in PBST, incubated 1h at RT with the corresponding secondary 
antibodies and washed again three times 10 min in PBST. Chemiluminiscene 
signal was revealed using a LAS-4000 mini (Fujifilm). Primary antibodies and 
dilutions were as follows: 1:500 Mouse CRX (Abnova H00001406-M02), 
1:1000 Mouse GAPDH (Abcam ab9484), 1:1000 Rabbit GFP (SantaCruz), 
1:1000 Mouse HA (Covance), 1:1000 Mouse Nr2e3 (Abcam ab41922), 
1:1000 Rabbit PIAS3 (Abcam ab58406), 1:2000 Mouse Tubulin (Sigma 
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Aldrich T5168), 1:1000 Mouse Xpress (ThermoFisher R910-25). The ImageJ 
software (http://imagej.nih.gov/ij/) was used for quantification.  
Both cells and retinas were lysed with RIPA Buffer (for composition, see 
above), sonicated and centrifuged for 10 min at 13000 rpm at 4°C. Fifty 
microliters of protein lysate was kept as the input protein control (INPUT 
from now on), and the rest of supernatant was separated from the debris and 
incubated with 4 µg of antibody, end-over-end overnight at 4°C. Protein-
antibody complexes were captured using Sepharose-Potein G (Invitrogen) 
and incubated for 4 h at RT. The mix was centrifuged 30 seconds at 3000 
rpm at 4°C, and the supernatant was kept as the bead efficiency control. The 
pellet containing the beads attached to the antibody was washed three times 
with PBS and centrifuged 30 seconds at 3000 rpm at 4°C between each 
washing step. The elution from the bead-antibody complex to recover the 
immunoprecipitated proteins was performed by adding 2x Protein Loading 
Buffer and boiling the samples for 5 min at 95°C. The protein lysate was 
then loaded into a SDS-Page gel to perform immunoblotting. 
In protein samples that were further processed for Mass Spectrometry, 
precipitation with urea was used for protein elution: bead-antibody 
complexes were washed with pre-urea buffer (50 mM Tris HCl pH 8.5, 1 
mM EGTA, 75 mM KCl), centrifuged 30 min at 3000 rpm. After discarding 
the supernatant, samples were incubated 30 min end-over-end in urea elution 
buffer (7 M urea, 20 mM Tris-HCl pH 7.5 and 100 mM NaCl), centrifuged 
30 seconds  at 3000 rpm, and the supernatant containing eluted proteins was 
electrophoresed in a 12,5% Tris-HCl SDS-page gel. 
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Mass spectrometry was performed at the CCiT UB Proteomic Platform 
(Barcelona Science Park). The sample was digested in-gel with trypsin as 
follows: The gel band was washed with ammonium bicarbonate (25mM 
NH4HCO3) and acetonitrile (ACN). The sample was reduced (DTT 10mM; 
30 min, 56o and alkylated (iodoacetamide 55mM; 21oC, 30 min, in the dark). 
Subsequently, the sample was digested with trypsin (Sequence grade 
modified Trypsin, Promega; 37o peptide mixture was extracted from the gel 
matrix with 10% formic acid (FA) and ACN, and dried on a SpeedVac 
vacuum system. The dried-down peptide mixture was analyzed in a 
nanoAcquity liquid chromatographer (Waters) coupled to a LTQ-Orbitrap 
Velos (Thermo Scientific) mass spectrometer. Tryptic peptides were 
resuspended in 1% FA solution and an aliquot was injected for 
chromatographic separation. Peptides were trapped on a Symmetry C18TM 
trap column (5 μm 180 μm x 20 mm; Waters), and were separated using a 
C18 reverse phase capillary column (75 μm Øi, 25 cm, nanoAcquity, 1.7 μm 
BEH column; Waters). The gradient used for the elution of the peptides was 
1% to 40% B in 25 min, followed by gradient from 40% to 60% in 5 min (A: 
0.1% FA; B: 100% ACN, 0.1% FA), with a 250 nL/min flow rate.  
Eluted peptides were subjected to electrospray ionization in an emitter 
needle (PicoTipTM, New Objective) with an applied voltage of 2000 V. 
Peptide masses (m/z 300-1700) were analyzed in data dependent mode 
where a full Scan MS was acquired in the Orbitrap with a resolution of 
60,000 FWHM at 400m/z. Up to the 10 most abundant peptides (minimum 
intensity of 500 counts) were selected from each MS scan and then 
fragmented in the linear ion trap using CID (38% normalized collision 
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energy) with helium as the collision gas. Multistage activation was enabled in 
order to favour the detection of phosphopeptides. The scan time settings 
were: Full MS: 250 ms (1 microscan) and MSn: 120 ms. Generated .raw data 
files were collected with Thermo Xcalibur (v.2.2). Searches were performed 
by Sequest HT search engine against the Uniprot Swissprot Human database 
(v. March 2015) using Thermo Proteome Discover (v.1.4.1.14.) To improve 
the sensitivity of the database search, Percolator (semi-supervised learning 
machine) was used in order to discriminate correct from incorrect peptide 
spectrum matches. The PhosphoRS node was used to provide a confidence 
measure for the localization of phosphorylation in the peptide sequences 
identified with this modification. 
Phylogenetic analyses were performed in collaboration with Xavier Bové-
Grau and Dr. Iñaki Ruiz-Trillo at Institut de Biologia Evolutiva (CSIC- 
Universitat Pompeu Fabra). Protein sequences from each enzyme group 
were queried against complete genome sequences of 14 animal taxa (Homo 
sapiens, Mus musculus, Danio rerio, Petromyzon marinus, Branchiostoma floridae, 
Saccoglossus kowalevskii, Strongylocentrotus purpuratus, Drosophila melanogaster, 
Daphnia pulex, Caenorhabditis elegans, Lottia gigantea, Capitella teleta, Nematostella 
vectensis and Acropora digitifera) using the HMMER 3.1 algorithm. For each 
analyzed enzyme family (USP, UCH, OTU, MJD and JAMM) we searched 
all proteins containing the Hidden Markov motifs of their catalytic region as 
defined in Pfam (UCH/UCH_1, Peptidase_C12, OTU/Peptidase_C65, 
Josephin and JAB domains, respectively). Protein domain architectures of 
each retrieved protein were then computed using Pfamscan 1.5 and Pfam 27 
database57 of protein domains. 
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We aligned the catalytic region of each enzyme family using Mafft 7 L-INS-i 
58(optimized for local sequence homology), and inspected each alignment 
matrix manually. The most suitable evolutionary model for the analyses, 
selected with ProtTest 3.459, was LG+ Γ. We used RaxML 8.1.1 60 to infer 
Maximum Likelihood trees of each family, with 100 bootstrap replicates as 
statistical supports. Complete sequences, alignments and phylogenies are 
provided in the Annex I, Supporting Information (S1-S3 Files). Manual 
inspection of the trees allowed us to identify subfamilies, named after their 
human orthologs, based on their bootstrap support and conservation of 
protein domain architectures. 
For direct comparison of disparate RNA-sequencing (RNA-seq) datasets 
used for expression analysis of DUB genes all data was analyzed with a single 
analysis pipeline1. Datasets included in the analysis were mouse retinal 
development (Brooks, et. al, Manuscript in Preparation), Nrl and Crx KO 
mouse retina61, flow sorted rod and S-like cone photoreceptors8, extra-ocular 
mouse tissue62, and human foetal retina (Hoshino, et. al, Manuscript in 
Preparation). Transcript level FPKM values were averaged and log 2 
transformed prior to hierarchical clustering using Euclidean distance and 
Ward’s method. Heatmaps of clustered data were generated using the 
heatmap.2 function in the gplots package in the R environment [www.r-
project.org]. 
In vivo DNA electroporation in the mouse retina (technique developed by C. 
Cepko´s laboratory)63 was performed following Dr. Ana Méndez and Dr. 
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Santiago López-Begines instructions and small modifications. This technique 
allows transient expression or silencing of a gene of interest into retinal cells.   
Either siRNA (small interfering RNA) against USP48, or shRNAs (short 
hairpin RNA) against JOSD1 and USP46 were separately used to perform 
specific DUB silencing in mice retinas. A DNA solution (6 µg/µl) in PBS 
and fast green 0,1% dye was prepared by mixing the siRNA or shRNA of 
interest at a molar ratio of 2:1. The plasmid encoding EGFP was added to 
easily identify the injection area for analysis 10 or 21 days later. For in vivo 
DNA electroporation, new born mouse pups at postnatal day 1 are 
anesthetized by immersion in ice for 4 min, an opening is performed with a 
scalpel following the natural line of the eyelid, after cleaning the zone with 
povidone-iodine solution. A small incision is then performed on the sclera, 
with a 30-gauge needle. For DNA injection, customized capillary glass 
pipettes were used [(#300048. Harvard Apparatus), pulled in a Puller P-97 
from Sutter Instruments according to the following parameters: heat=650, 
Pull=60, Velocity=60, Time=200)]. The capillary glass pipettes were attached 
to a nanoinjector (Drummond Nanoject) and were managed by a 
micromanipulator. After inserting the glass pipette in the eye, and carefully 
micromanipulating it to reach the subretinal space (reached when the pipette 
meets the resistance of the back of the eye upon touching the choroid), 
approximately 0,5-1 µl of circular naked DNA were delivered. After DNA 
injection, tweezer-type electrodes briefly soaked in PBS were placed to softly 
hold the heads of the pups placing the positive electrode of the tweezer over 
the injected eye, and five square pulses of 80 V of 50-ms duration with 950-
ms intervals were applied by using a pulse generator (CUY21, Nepagene). 
Pups were left to recover over a thermal blanket until the end of procedure, 
returned to their cage and raised in normal conditions. Mice were processed 
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at postnatal day 10 or 21, retinas were dissected and processed for IHC and 
western blotting. 
  
  
 
 
 
 
 
 
Results 
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NOTE: Most of the data presented in Section 1 and 2 of the present 
chapter have been published in the referred PloS One article below 
(see Annex I). 
“Expression atlas of the deubiquitinating enzymes in the adult mouse retina, their 
evolutionary diversification and phenotypic roles.” 
Mariona Esquerdo, Xavier Grau-Bové, Alejandro Garanto, Vasileios Toulis, 
Sílvia Garcia-Monclús, Erica Millo, Mª José López-Iniesta, Víctor Abad-
Morales, Iñaki Ruiz-Trillo, Gemma Marfany 
PLoS One. 2016 Mar 2;11(3):e0150364. doi: 10.1371/journal.pone.0150364. 
eCollection 2016. 
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Ubiquitin has been amply shown to play a major role in regulating several 
cellular processes23,26,64, including cell differentiation37. Moreover, many 
studies on the function of ubiquitin E3 ligases in a wide variety of research 
fields have been reported. Nonetheless, their counter-partners in the 
ubiquitination cycle, the Deubiquitinating enzymes (DUBs), have been the 
focus of attention in research only in the last few years. 
Concerning the retina, several studies pointed to the importance of ubiquitin 
and ubiquitin-like cycle enzymes in retinal development46,47,50,65, but little is 
known about the roles DUBs might play in this intricate regulatory network. 
For this reason, the first aim of the present work was to define the 
expression levels and tissular localization of these genes in the adult mouse 
retina in order to establish a reference framework to elucidate the possible 
role of specific DUBs in retinal development and disease. 
It was important to determine the expression state of the DUBs in the 
mouse retina since it had not been previously reported. Thus, real time 
quantitative PCR (RT qPCR), in situ hybridization and fluorescent 
immunohistochemistry studies in adult mouse retinas were designed and 
performed, so that a map of mRNA and protein expression and localization 
in the mammalian retina was drawn.  
These analyses allowed defining an expression framework for 
deubiquitinating enzyme genes in the mouse retina. 
A quantitative real time PCR (RT qPCR) was performed on mouse 
neuroretinas to assess the mRNA expression levels of all DUBs. The 
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complete DUB list (87 genes) of the mouse genome including members of 
the five aforementioned families (namely, 11 JAMM, 4 MJD, 15 OTU, 4 
UCH, and 53 USP genes) were analyzed, together with two reference genes, 
Rhodopsin and Cerkl, previously reported of being expressed at high and low 
levels in the mouse retina, respectively 66. The expression levels were 
normalized to Gapdh expression.  
The relative expression levels are shown in Figure 13 as the mean and 
standard deviation of the Z-score, which was calculated for the whole set of 
genes for direct comparison among them and between different samples. An 
arbitrary Z-score of zero corresponds to the mean value of expression for all 
the DUBs analyzed in the retina. Thus, genes with positive values have an 
expression above the mean, whereas genes with negative values show less 
expression than the mean (e.g. most USP genes). 
The results showed that Prpf8 was the highest expressed gene from the 
JAMM subfamily, followed by Eif3h and Psmd7. Both Atxn3 and Josd2 
rendered the highest expression levels within the MJD subfamily. 
Concerning the OTU subfamily, Otub1 and Tnfaip3 produced the higher 
expression levels, followed by Otud7b, Vcpip1, Otud4 and Otud5; whereas the 
levels of Otud6a were considered as negligible. Uchl1 was the most highly 
expressed gene from the UCH family (and also with respect to all DUB 
genes), while Uchl3 and Uchl5 are lowly expressed in the retina. Finally, the 
genes from the large USP subfamily showed the lowest level of expression 
among all the DUB genes. Some USPs (20%) were highly expressed and 
showed positive Z-scores (Usp5, Usp6, Usp10, Usp12, Usp19, Usp21, Usp22, 
Usp33, Usp47 and Usp52) whereas 25% of the USPs showed lower levels 
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than the mean (Usp8, Usp9Y, Usp17, Usp18, Usp26, Usp27, Usp29, Usp35, 
Usp43, Usp44, Usp45,Usp50, and Usp51) (Figure 13). 
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Once the expression levels of all the DUB family members were assessed, we 
characterized and compared their expression pattern within the different 
layers of the mouse retina. Given the high number of genes to be analyzed 
and the fact that antibodies for all the proteins are not always available or 
reliable, gene expression by mRNA localization using in situ hybridization 
(ISH) was performed for most of the genes. Later on, protein localization of 
selected DUB members was assessed by fluorescent immunohistochemistry. 
For ISH, antisense (AS) riboprobes against a large group of DUBs were used 
on mouse retinal cryosections (Figure 14). As negative controls, the 
corresponding sense riboprobes (S) of each gene were generated and 
hybridized in parallel using the same conditions (see Annex I S1 Fig). The 
staining time was adjusted for each set of antisense/sense riboprobes, so that 
a maximum signal was obtained in the antisense retinal sections with 
minimum background in the sense control counterparts (for instance, Prpf8 
and Tnfaip3 in situ stained in much less time than Uchl5, Usp8 and Usp18, 
 87 
which required half a day). Rhodopsin was used as a positive control because 
of the reported high expression in the retina and its well-known localization 
in the inner segment of the photoreceptors.  
Notice that the large USP subfamily contains 57 members in the mouse 
genome. However, only a set of genes was considered for ISH. 
Representative ISH results are displayed in Figure 14. Our selection criteria 
included genes with relevant ocular phenotypes previously described in 
systematic knockdown analyses of DUBs in Drosophila 67 and zebrafish 68. 
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Most DUBs are ubiquitously expressed throughout the layers of the murine 
retina, which would be compatible with a general role in the neuronal cell 
metabolism and regulation and thus, not restricted to particular retinal 
neurons. Nonetheless, specific patterns of expression were detected for 
particular DUBs. For instance, a strong hybridization signal in the plexiform 
layers was observed for Uchl3, Uchl5, Usp2, Usp9X, including in some cases 
the inner segment of the photoreceptor layer, as detected for Amsh, Josd3, 
Atxn3 and Usp47. Some DUBs appear to be highly expressed in the GCL 
(Csn5, Poh1, Prpf8, Josd2, Otud1, Vcpip1, Usp11, Usp5 and Usp19) in contrast 
to the pattern generated by Usp8, Usp13, Usp30, Usp45 and Usp54, which 
yielded virtually no mRNA localization signal in the ganglion cells.  
Several DUB genes of the USP family (Usp5, Usp13, Usp19 and Usp34) were 
previously reported to be differentially expressed in the Retinal Pigmented 
Epithelium (RPE) by transcriptome analysis 69. To assess their specific 
pattern of expression, and given that pigmented cells mask positive 
hybridization signals, ISH on albino retinas from CD-1 mice was performed 
(Annex I, S2 Fig), by another member of the group (M. J. López-Iniesta). 
Although these four genes are expressed in this non-neuronal layer, their 
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expression is not restricted to the RPE. In fact, Usp5 and Usp19 are very 
highly expressed throughout the retina (Figure 14). Comparison of the retinal 
expression pattern for these four genes did not show any detectable 
difference between C57BL/6J (wild-type black) and CD-1 (albino) mice 
strains. 
Several genes, namely Amsh-like, Brcc36, Jamm2, Mysm1 and Psmd7 (JAMM 
group) and Otud3, Yod1, Zranb1 (OTU group), did not render reproducible 
and reliable ISHs, even though several riboprobes spanning different gene 
regions were used. In most cases (e.g. Amsh-like, Brcc36, Jamm2, Mysm1, and 
Otud3) very low levels of expression were obtained and the signal was too 
faint to be distinguished from the negative control (sense riboprobe), or the 
sense and antisense riboprobes both produced signals of similar intensity. 
The ISH results of these genes are not presented in the present work.  
Taking the ISH results together, an atlas of expression for DUBs in the 
retina of adult mouse was drawn. In general, all analyzed genes except Otud1 
are expressed in the photoreceptors, and their mRNAs are localized in a wide 
range of intensities in the inner segment (perinuclearly) and the outer 
plexiform layer. Among layers, the GCL showed the most different pattern 
of gene expression. Notably, some DUBs, such as Usp45, Usp53 and Usp54, 
are only detected in photoreceptors (PhR -inner segments, ONL 
(photoreceptor nuclei and perinuclei) and OPL (photoreceptor synapsis), 
whereas nearly no hybridization could be detected in the rest of retinal layers, 
which would suggest specific roles for these DUBs in this highly specialized 
photosensitive cells. 
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Family Gene PhR ONL OPL INL IPL GCL 
JAMM JAMM3    
 
      
 
 
AMSH   
 
        
 
PRPF8   
 
        
 
EIF3H             
 
CSN5             
 
POH1   
 
        
  AMSH- like             
                
MJD ATX3             
 
JOSD3             
 
JOSD1       
 
    
  JOSD2             
                
OTU TNFAIP3             
 
OTUD7b         
 
  
 
OTUB2   
 
      
 
 
OTUD7a             
 
VCPIP1             
 
OTUB1         
 
  
 
OTUD5           
 
 
ZRANB1   
 
  
 
    
 
OTUD4   
 
      
 
  OTUD1             
                
UCH UCH-L3   
 
        
 
UCH-L5           
 
 
BAP1             
  UCH-L1             
            
 
  
USP USP47           
 
 
CYLD 
[USPL2]           
 
 
USP8           
 
 
USP30   
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Family Gene PhR ONL OPL INL IPL GCL 
USP USP2   
 
  
 
    
 
USP19     
 
      
 
USP20             
 
USP5             
 
USP22             
 
USP36             
 
USP9X       
 
    
 
USP54       
 
  
 
 
USP53       
   
 
USP45       
   
 
USP18             
 
USP28             
 
USP13   
 
  
 
    
 
USP25   
 
  
 
  
 
  USP34             
 
These ISH results prompted us to confirm and more accurately define 
protein localization by fluorescent immunohistochemistry of a group of 
selected DUBs. Of note, due to very specialized morphology of 
photoreceptors, the mRNA localization might be different to where the 
encoded proteins are localized and exert their function (e.g. the mRNA of 
rhodopsin is localized in the ribosome-rich photoreceptor inner segment 
whereas the protein is highly abundant in the membranous disks of the outer 
segment).  
The criteria of DUB selection for immunohistochemistry detection were 
based on: 1) interesting ISH pattern, 2) relevance for eye phenotype in 
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animal models, 3) putative functional diversification in phylogenetically 
closely related enzymes (see next section), and 4) antibody commercial 
availability and affinity. Twenty one DUBs were selected (gene list is detailed 
in the Material and Methods), but unfortunately, only 14 immunodetections 
rendered a reproducible and reliable signal (Figure 15 and Annex I, S3 Fig).  
Overall, immunodetection confirms the ISH results since protein is detected 
in the same retinal cell layers (Figure 15). Besides, comparing RT qPCR to 
ISH and immunohistochemistry results, high levels of retinal expression 
correlated with a ubiquitous expression pattern. On the other hand, some 
particular protein locations are worth mentioning as indicative of distinct 
functions in specific cellular compartments. OTUD4 is highly detected in the 
axonal processes of bipolar and other retinal cells, supporting its 
involvement in neurodegeneration in human 70. USP25 is mainly detected in 
the inner plexiform and ganglion cell layer. USP9X and TNFAIP3 are 
particularly detected (but not exclusively) at the outer photoreceptor 
segment. Besides, USP22 is localized in the nucleus of ganglion cells, and 
perinuclearly in the rest of retinal neuronal somas. For details, merge and 
separate immunodetection images are in Annex I, S3 Fig. Overall, 
immunodetection is much more indicative of protein functional localization 
but appears to be less successful than ISH in complex tissues. 
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Recent analyses have shown that the Ubiquitin signalling system predates the 
eukaryotic origin, since the core components of the pathway are present in 
Archaea. Moreover, early-branching unicellular eukaryotes already display the 
full set of Ub ligase and DUB families22. A massive expansion of ligases and 
proteases involved innovation and incorporation of new protein domains, 
particularly at the origin of multicellularity and associated with the diversity 
of proteins and protein roles in different cell types. We aimed to provide a 
comprehensive picture of the DUBs during the diversification of metazoans, 
related to the retinal and neuronal function. 
Completely sequenced genomes from 14 species (from cnidarians to 
vertebrates) were queried with the catalytic region of each enzyme family (as 
defined in Pfam) in search of orthologs. This work was performed in 
collaboration with Dr. Iñaki Ruiz-Trill and Xavier Grau Bové at the Institut 
de Biologia Evolutiva (CSIC – Pompeu Fabra). Phylogenetic trees were 
generated using the retrieved sequences, and the statistical support for each 
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node is also indicated (Figure 16 A, B, C, D and E). For the sake of clarity, 
protein nomenclature is according to human DUBs. Highly similar sequences 
that expanded recently (during the pre-vertebrate/vertebrate expansion) and 
clustered together appear collapsed. 
The presence of an identified ortholog in each species/clade is represented 
with a black dot. Vertebrate species that present all the paralogs in a 
collapsed branch are circled in black. White dots mark the presence of 
homologs that could not be confidently assigned to a characterized DUB 
type, either because they are sister-group to various known DUB paralogs 
(and therefore represent the pre-duplication homolog), or because statistical 
support is too low to confidently cluster them with a specific ortholog. 
Question marks represent statistically supported clades that cannot be 
assigned to any known DUB (or group of paralogous DUBs).  
Protein motifs (as defined in Pfam) including the catalytic domain are drawn 
next to each branch to illustrate the diversity/conservation in protein 
architecture within each family. For detailed and complete phylogenetic trees, 
see Annex I, S3 File. 
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Notably, the phylogenetic distribution of OTU DUBs reveals two different 
groups that appeared at the origin of eukaryotes: OTUs with peptidase C65 
domains (OTUB1 and OTUB2 in animals) and those with OTU domain 22 
(Figure 16 D). Given that 1) these two catalytic domains diverged long 
before the origin of metazoans, 2) OTUB1/B2 protein domain architectures 
are clearly different from the other OTUs, 3) OTUB homologs are present in 
all metazoan clades, and 4) this split does not occur in any other family of 
DUBs, a new classification might be in order to acknowledge a new 
subfamily of DUBs. 
The JAMM family has clear sequence assignment in all the analyzed animals, 
even though some species have secondarily lost some DUB members, e.g. 
Acropora (cnidarian), C. elegans (nematode), Drosophila (insect) Saccoglossus 
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(hemichordate), and Petromyzon (sea lamprey, an early-branching vertebrate). 
These species also show specific gene loss for other DUB families, pointing 
to a divergent evolution in their lineages. On the other hand, a clear 
expansion within each DUB family has occurred in the vertebrate lineage 
(Figure 16 and Figure 17). When these duplicated members have rapidly 
diverged, the DUB protein sequences are in separate branches, but the 
common ancestry becomes evident since there a single ancestral ortholog is 
present in the rest of clades (white dots). This is the case within the UCH 
(UCHL1 and UCHL3) and MJD families (JOSD1 and JOSD2).  
When the duplicated sequences have diverged but still branch closely 
together in the phylogenetic tree, the vertebrate paralogs have been collapsed 
into a single branch for easy phylogenetic comparison (indicated by black 
circles in Figure 16). This is particularly evident for USPs, where we can 
identify a single ancestral sequence in all clades, although several members 
are present in vertebrates (e.g. USP4/11/15; USP22/27X/51; 
USP17/36/42). The ATXN3 gene deserves specific mention, since its close 
paralog, ATXN3L, is a retroposon, that is, a gene generated by a very late 
retrotransposition event within the primate lineage.  
The DUB gene expansion in animal phylogeny is visually summarized in the 
heat map of Figure 17. Colour intensity reflects the number of genes per 
genome. Finally, it becomes evident that a burst of gene expansion within all 
DUB families was at the basis of the vertebrate lineage. Nonetheless, the 
innovation in the protein architectures, with the acquisition of new domains 
accompanying the DUB catalytic domains, pre-dates the origin of vertebrates 
in all the analyzed families–as vertebrate-like domain arrangements are often 
identified in the other animal clades. In fact, extensive phylogenetic analyses 
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of the Ub and SUMO signalling pathway proteins showed that: 1) very early 
on the explosion of eukaryotes, and intrinsic to the origin of multicellularity, 
all the DUB families present in animals already showed composite domain 
architectures, and 2) animal-specific domain arrangements were already 
present in their unicellular ancestors 22. 
 
 
Since the aim of the present work was to study DUB expression in the retina 
as a means to suggest relevant genes for hereditary visual disorders and/or 
potential genes important for retinal development, an extensive bibliography 
search was performed to compare the reported phenotypes of several animal 
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models (Drosophila, zebrafish, mouse) and human diseases, associated to gene 
mutations, knockouts or knockdowns of DUBs. Early developmental 
lethality, neuronal phenotype (during developmental stages, but also 
neurodegeneration) and retinal alterations were noted when available (Figure 
16 A, B, C, D and E). For a detailed phenotypic trait list, see Annex I, S2 
Table and references therein. In general, when the mutation or knockdown 
of a particular gene produces a relevant phenotype in one of the analyzed 
taxa, it usually replicates or provides a similar alteration in the other analyzed 
organisms. In the cases of neuronal phenotype, there is an accompanying 
alteration in the eye (the optic vesicle is an evagination of the neural tube, 
and the retina forms part of the central nervous system). However, most 
phenotypic assessment in the eye describes only gross alterations, but a 
detailed retinal study has not yet been reported for most animal models. 
One of our aims was to determine how DUBs are involved in photoreceptor 
development. As no previous data was available at that moment on the 
expression of these enzymes in the mouse retina, a first approach was to 
perform expression analyses (see section 1 of the present chapter) on P60 
adult mouse retinas. This age resulted adequate as a first approach and to 
define the working frame in a young though completely functional retina; 
however, it gave no insights into the relevance of these enzymes during the 
development of this sensory organ.  
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Thus, further time points were required to properly assess the developmental 
variations of the DUBs expression and consequently, evaluate whether any 
of them could be involved in the development of the mouse retina. To this 
end, we performed in silico comparative analyses using high throughput 
RNA-sequencing data.  
The RNA-sequencing from different stages of mouse wild type (WT) and 
knockout (KO) retinas; as well as on different human retina developmental 
stages was performed in Dr. Anand Swaroop’s group, who kindly shared the 
raw data with us. For mouse WT retinas, RNA-seq data was available at 
stages Embryonic 11 (E11), E12, E14, E16, post-natal 0 (P0), P2, P4, P6, 
P10, P14 and P21. Data from P2 and P21 stages of mouse Crx -/- and Nrl -
/- knockout retinas was also available; as it was from flow-sorted mouse 
photoreceptors at P0, P2, P4, P10, P14 and P21, separated into Rod-like cells 
and in Cone-like cells. Regarding the human retina, RNA-seq data was 
available for day 52 post-fertilization (D52), D53, D57 (two different 
samples: D57.1 and D57.2), D67 (two different samples: D67.1 and D67.2), 
D70, D80, D87, D94 (two different samples: D94.1 and D94.2), D105, 
D107, D115, D125, D132 and D136. 
We performed a comprehensive analysis and comparison of DUB expression 
levels using these transcriptomic data. Results for the expression levels of all 
known DUBs in the retina are summarized in Figure 18 as a Heatmap 
representing the average log2 of FPKM (Fragments per Kilobase of exon per 
Milion reads) values, were dark blue indicates very low expression, while dark 
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red indicates high expression of a particular gene at a particular 
developmental stage.  
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A throughout analysis was performed to select which DUB genes could be 
good candidates to participate in retinal development. This RNA-seq data 
was analysed together with 1) chromatine immunoprecipitation sequencing 
(ChIP-seq) data on adult retinas; 2) RNA-seq expression data on other 
mouse tissues; and 3) detailed reads of RNA-seq data on P28 in flow-sorted 
rods and cones. These additional datasets on DUB genes were also kindly 
provided by Dr. Anand Swaroop.  
ChIP-seq was performed on DNA from adult mouse retina, cross-linked and 
immunoprecipitated with antibodies against either CRX or NRL, in order to 
determine target gene promoters where CRX and NRL were bound. On the 
other hand, RNA-seq data of mouse tissues provided clues on the spatial 
pattern and tissular specificity of DUB gene expression (data not shown): for 
instance, a broadly expressed gene might have a more general role than a 
gene expressed only in the central nervous system (CNS). 
All these data was contrasted with previously published bibliography on 
DUB genes as well as with the retinal and neuronal phenotypes described in 
section 2.2 of the present chapter. 
Overall, a total of 12 genes were pre-selected as possible candidates to be 
involved in developmental decisions in the retina. In fact, one of the main 
criteria for including a gene on this list was differential expression between 
cones and rods. The prioritized gene list is shown in Table 11 .  
To narrow down the list for further assays, we made a second selection with 
the five most interesting DUB genes, indicated in gray in Table 11: Josd1, 
Otud7b, Usp22, Usp46 and Usp48. All data applied for selection of these last 5 
DUBs is summarized in Figure 19. 
  
DUB RNA-seq on total RETINAa 
ChIP-
seqb 
RNA-seq on 
TISSUESc 
PHENOTYPEd BIBLIOGRAPHY 
JOSD1 
Decrease during development in 
whole retina and in rods, but not in 
cones. 
CRX 
Adrenal Gland, 
Cerebellum, Spleen, 
Thymus 
3dpf: funny eyes shape, 
abnormal retinotectal 
projection (ZF) 
Almost no bibliography. 
OTUD7B 
Low expression throughout 
development with a small increase 
from P10. 
Continuously expressed in rods. 
- Testis - 
NFκB signaling. 
Oncogene: via 
deubiquitination of EGFR 
PAN2 
(USP52) 
Highly expressed in the retina. 
Shut down in rods at P21, but 
maintenance in cones. 
CRX 
Cerebellum, CNS, 
Testis, Cortical Plate, 
Frontal Cortex, Limb, 
Liver, Placenta, Testis, 
Urinary Bladder 
- mRNA Deadenylation. 
USP10 
Decrease in rods from P10, but not 
in cones. 
CRX 
NRL 
Cerebellum, CNS, 
Cortical Plate, Female 
Gonad, Frontal 
Cortex, Limb 
CNS necrosis (ZF) 
DNA damage. 
CANCER: Adrenal tumours, 
tumour-associated marker in 
grastrocarcinoma, p53 
regulation. 
NFκB signaling. 
USP11 
Stricking shut down in rods and not 
in cones. 
- 
Cerebellum, CNS, 
Cortical Plate, Frontal 
Cortex, Gonadal Fat 
Pad, Kidney, Large 
Intestine, Placenta, 
Testis 
- 
Transport to the Golgi 
and Protein folding. 
NF-kappa-B. 
DNA repair after –double-
stranded DNA breaks. 
Possibly related to X-
linked retinal disorders.71 
USP14 
Stable expression in retina, with a 
slight shut down only in rods. 
- 
Cerebellum, CNS, 
Cortical Plate, Frontal 
Cortex, Liver, Placenta, 
Testis 
(Neuronal) slower adults, 
early death (D). 
Reduced USP14 levels  
tremors, abnormal brain 
Parkinson. 
Oncogene: breast, 
hepatocellular carcinoma, 
lung adenocarcinoma. 
 morphology, altered 
synaptic transmission and 
increased apoptosis (H). 
Lowers apoptosis. 
USP15 
Stable expression in retina, with a 
slight shut down only in rods. 
NRL 
Adrenal Gland, 
Cerebellum, CNS, 
Colon, Cortical Plate, 
Heart, Kidney, Large 
Intestine, Limb, Testis 
2dpf: small eyes, and 4dpf: 
unshaped eyes (ZF). 
Interferon signaling. 
Mitophagy. 
Oncogene through TGFβ. 
USP20 
Very low levels of expression in 
whole retina, with a slightly shut 
down in rods from P10. 
- Kidney, Thymus 
Earlier adult death (D). 
3dpf: small eyes (ZF). 
NFκB signaling. 
β2 adrenergic receptor 
recycling. 
Tyroid hormone activation. 
USP22 
Highly expressed throughout 
development with a shut down in 
rods from P10. 
CRX Testis 
(Neuronal) slower adults, 
early death (D). 
-/- Homozygotes are 
embryonic lethal (M). 
ONCOGEN: liver, colon, 
lung, gastric, nasopharyngeal, 
pancreas (Via histone and 
p53 regulation). 
 
USP39 
Slight shut down both in retina and 
rods from P10, but not in cones. 
CRX CNS, Limb, Testis 
Larval death (D). 
2dpf: small eyes (ZF). 
Cancer: promotes cell 
proliferation. 
USP46 
Low expression in rods and strong 
shut down in rods, but high 
expression in postnatal cones. 
- 
Adrenal Gland, Colon, 
Duodenum, Female 
Gonad, Kidney, 
Mammal Gland, Spleen, 
Subcutaneous 
Adipose, Thymus 
- 
Neurotransmission circuits 
involved in behaviour. 
USP48 
Strong difference between rods (low) 
and cones (high) expression. 
CRX 
Cerebellum, CNS; 
Placenta 
3dpf: small eyes (ZF). Almost no bibliography. 
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Fluorescent immunohistochemistry was performed to evaluate the different 
patterns of expression of the five selected DUBs in three different stages: P4, 
P10 and P21. Results in Figure 20 show that JOSD1, USP22 and USP46 are 
detected ubiquitously in the retina of the three analyzed developmental 
stages, even at P4 stage, where retinas are still immature and have merely two 
rows of nuclear layers – being the outer layer considerably thicker. 
However, in the case of OTUD7B and USP48 expression, proteins are only 
detected at P10 and P21. The expression pattern of OTUD7B is clearly 
consistent with the RNA-seq data, since RNA values increase through all the 
developmental stages analyzed. 
 
 
 
 
 
 
 113 
 
114 
To functionally assess the role of the selected DUBs, an in vivo silencing 
experiment was performed in murine retinas. These experiments are very 
time consuming, therefore we selected three out of the five candidates: 
JOSD1, USP46 and USP48, which were those showing a higher IHC 
fluorescent signal in the photoreceptor layer throughout all the analyzed 
stages.  
In order to silence the selected genes, two shRNA constructs against murine 
JOSD1 or USP46 were jointly injected and electroporated into the subretinal 
space of P1 mice. For USP48, two siRNA were used instead, as no 
commercial shRNA constructs were available. Also and for each gene, either 
the two shRNA plasmids or siRNA molecules were injected together with a 
reporter EGFP-expression construct (Green Fluorescent Protein cloned 
downstream to a constitutive Ubiquitin promoter) to detect positively 
electroporated cells. Retinas were dissected from mice at P10 and P21 stages, 
fixed and sectioned for analysis. A total of 22 retinas were electroporated. 
However, only 5 resulted GFP-positive: two retinas injected with anti-
JOSD1 shRNAs; two injected with anti-USP48 siRNAs; and another one 
injected with anti-USP46 shRNAs. 
Fluorescent IHC on sections was performed to identify possible 
morphological aberrations in the retinal structure caused by the silencing 
effects of the electroporated shRNA. Antibodies against JOSD1 and USP46 
were respectively used to detect changes in protein expression and 
localization; while a GFP antibody was used to detect and increase the signal 
of GFP-positive cells, as a means to detect positively electroporated cells. 
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Finally, PNA (Peanut Aglutinin) was used to label cone photoreceptors and 
DAPI, to counter-stain cell nuclei. 
No morphological differences were observed in the GFP-positive retinas 
silenced for either JOSD1 or USP46 when compared to non-electroporated 
control (CTRL) retinas (Figure 21 A). Nonetheless, note that in USP46 
silenced retinas, retinal rosettes were observed (Figure 21 B). Commonly, 
these rosettes - round clumps in the centre of the image- are formed by the 
aberrant invagination of the PhR layer during development and excess 
growth. However, we should not consider them as a consequence of the 
silencing of any particular gene, as they are also caused by the microinjection 
procedure per se, irrespective of the gene. Figure 21 B shows the images of 
IHC using antibodies against β-3-Tubulin (β3TUB), a common marker of 
the GCL. 
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Notably, retinas injected with USP48 shRNAs showed severe morphological 
retinal alterations, with a prominent PhR overgrowth (Figure 22 B) and 
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rosettes also affecting the INL (Figure 22 C). Figure 21 A, B and C are 
images obtained from sections of the same retina.  
 
 
As previously mentioned, the electroporation experiments rendered very low 
electroporation efficiency, resulting in a small amount of retinas that could 
be analyzed. The results obtained in the knockdown of Usp48 were very 
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promising and thus, further replicates needed to be performed. Given the 
low efficiency obtained in the siRNA subretinal electroporation, we decided 
to perform intravitreal injections with a more stable molecule, namely AONs 
(Antisense Oligonucleotides).  
AONs are small RNA modified molecules that are used in genetic therapy 
approaches72,73 and that can enter the cells without external factors. They are 
designed to bind complementarily to mRNA transcripts and either alter 
splicing outcomes, or drive targeted cleavage of the mRNA, efficiently 
causing a knockdown of gene expression (Figure 23). Moreover, the use of 
vitreal injection minimizes both, retinal damage due to the technical 
procedure, and animal manipulation. Once more, we decided to target Josd1, 
Otud7b and Usp48 with two independent AONs. 
 
 119 
Therefore, AONs were designed following previous reports74 and Dr. 
Alejandro Garanto-Iglesias kind advice. Briefly, AONs were unique 20 bp 
RNA antisense oligonucleotides sequences, designed 1) on open secondary 
structures (calculated using Mfold web service: 
http://unafold.rna.albany.edu/?q=mfold/RNA-Folding-Form); 2) coincident with 
Exonic Splicing Enhancer sites (ESEs; calculated in: http://rulai.cshl.edu/cgi-
bin/tools/ESE3/esefinder.cgi?process=home). Free energy of the AON and of its 
interaction with the target sequence was calculated to find the most stable 
binding these two sequences (calculated in the web server: 
http://rna.urmc.rochester.edu/RNAstructureWeb/Servers/Predict1/Predict1.html).  
A part from the aforementioned targeted genes, two further AON were 
designed against Crx, to be used as a positive control. At the present 
moment, tests on the efficiency of the AONs are being performed in 661W 
cells. The best fitted AON per each of the genes will be used for in vivo 
vitreal injection in P0 mice and possible morphological aberration will be 
analyzed via fluorescent immunohistochemistry.  
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The main objective of this work was to determine how deubiquitinating 
enzyme genes participate in the regulation of retinal development or retinal 
cell fate. As aforementioned, the retina is a tissue with a complex architecture 
and thus, an intricate genetic and functional regulation is bound to be 
deployed during development. In this context, post-translational 
modifications, e.g. ubiquitination, may play an important role in a finely 
tuned gene regulation. To study these implications, we aimed to establish a 
cell culture system that allowed us to characterize the function of the DUBs 
on retinal promoters.  
Note that the whole set of deubiquitinating enzymes sums up to 90 genes in 
the mouse genome and that we intended to evaluate their contribution to the 
regulation of specific retinal promoters; therefore, a high-throughput assay 
had to be performed. We then considered the selection of a suitable system 
for testing the relevance of DUBs: a) in vertebrates, with a set of DUB genes 
similar to humans (for instance mouse or zebrafish), a high-throughput 
knockdown study would entail a large economic and time effort; b) in 
invertebrates, such as Drosophila or planarians, a knockdown assay would be 
feasible in terms of the required time, but both the limited amount of DUB 
genes present in their genomes and their retinal structure differ significantly 
from the number of DUBs and the retina structure found in humans or 
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mouse. Therefore, we opted for a high-throughput assay in a mammalian cell 
culture system where we could control the parameters. 
Since our goal was to study the role of DUBs in the retina, we also took into 
account that: i) primary cultures of neuronal cells, particularly highly 
specialized cells such as photoreceptors, is not an easy task; and ii) genetic 
manipulation of DUB gene expression (either over-expression of silencing) 
requires transfection, which is very difficult to achieve at a high percentage in 
neuronal cells; therefore, we decided to recreate a retina-like cell 
environment in an easy to maintain and transfectable cultured cell line. To 
recreate a retina-like cell milieu, we designed a cell system based in the 
cotransfection of two elements: 1) the use of retinal specific gene promoters, 
such as those of S opsin or Rhodopsin, regulated by 2) one or several retinal 
transcription factors (TF) (which were produced by expression constructs). 
For easy assessment of changes in the activity of these retinal promoters, 
they were cloned into a pGL3-promoter vector (Promega), which contains the 
firefly luciferase gene as a reporter gene downstream to the cloning site. The 
luciferase gene produces a protein that emits light at 560 nm, which can be 
detected with a luminometre. Then, if the co-transfected TF bound the 
promoter, it would regulate (trans-activate or repress) the activity of the 
downstream luciferase gene; and thus, we would be able to indirectly 
quantify the activity of the corresponding transcription factor by determining 
changes in the amount of the luciferase produced.  
In brief, the TFs included in our study were CRX, NR2E3, NRL and 
NR1D1, all of them previously described as cojointly playing a key role in 
determining the photoreceptor fate. The selected promoters used to drive 
the expression of luciferase were those of S opsin, M opsin and Rhodopsin. We 
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planned to use several combinations of promoters and TFs in different 
transfection conditions, thereby mimicking a basic retinal genetic context.  
Finally, we addressed our main question: Do DUBs participate in relevant 
retinal cell developmental decisions, such as those in determining rod and 
cone fates? To answer this question we planned to knockdown one by one 
all the DUB genes in a high-throughput experiment, using the described 
system. To perform the knockdown of endogenous DUBs we resourced to 
several silencing approaches (siRNA, shRNA or the Gapmer® technology). 
We surmised that in our cell system, were any DUB involved in the 
regulation of certain retinal promoters due to the regulation of the post-
translational modification of TFs, we could observe and quantify changes in 
the luciferase values (Figure 24) 
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To determine which cell line was the most suitable to attain our aims, Real 
Time PCR (RT qPCR) in several mammalian cell lines was performed. The 
basal expression levels of the genes whose promoters we intended to use as 
well as the genes encoding the TFs we planned to include in our study were 
assessed. Our cell line selection included: 1) the mouse precursor of cones 
661W, 2) the rat transformed ganglion RGC5, 3) the human retinoblastoma 
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Y-79, 4) the MIO-M1 human Müller cells, 5) HEK293 (Human Embryonic 
Kidney), and 6) HEK293T (Human Embryonic Kidney transformed with 
SV40 virus T antigen). Note that the last two cell lines are not retinal-derived 
types, however, they were included as they were previously used in other 
retinal transcription factor studies44,75. In addition, wild type P60 mouse 
retinas were used as a reference for expression levels. The relative expression 
of the genes is plotted in Figure 25, expressed as the log10 after normalization 
to the housekeeping gene Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH).  
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The criterion we favoured to select any cell line for further assays considered 
that cells had to present a combination of both, a relative gene expression 
that allowed a quantifiable genetic manipulation as well as ensured proper 
control of the transfection system. Thus, low levels of expression of retinal 
genes were positively evaluated, in general. Observing RT qPCR results, 
661W cells were those with a closer pattern of expression to that obtained in 
the mouse retina (Figure 25 A and B), but endogenous gene expression levels 
were too high to control the expression of transfected genes. Something 
similar happened with the Y-79 cell line, which showed low levels of the 
retinal genes, but high levels of the transcription factors (Figure 25 C). In 
conclusion, mouse 661W and human Y-79 cell lines were discarded for this 
assay. Human MIO-M1, HEK293T and HEK293 cells were the most 
interesting candidates since they all presented low levels of the analyzed 
genes (Figure 25 D, E and F), particularly MIO-M1 and HEK293.  
To determine which cell line was more suitable for our technical 
requirements, different transfections with pEGFP reporter vector and 
several commercial liposome-based transfection reagents were performed to 
select the brand (liposomal composition) with higher transfection efficiency 
in our conditions (Figure 26). Tested cationic liposomes included FUGENE 
HD Transfection Reagent (Roche), Lipofectamine 2000 (Invitrogen), Metafectene Pro 
(Biontex), TransFast Transfection Reagent (Promega) and TransIT-Neural (Mirus). 
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Finally, HEK293 was chosen as the best cell line for the requirements of our 
cell culture assay. These cells had a genetic context that allowed us to easily 
manipulate and control transfection conditions, and showed good 
transfection efficiency, especially when using Metafectene Pro (Biontex) 
liposomes.  
Another technical point to address was the determination of the amount of 
DNA required in transfections, particularly since several constructs had to be 
co-transfected in the same assay. Previous work carried by Cheng et al. 
(2004)75 and Peng et al. (2005)44 presented very different ratios of 
promoters:TFs (0.3 µg:1 µg; and 2 µg:50-200 ng, respectively). Therefore, 
128 
several transfections with different DNA ratios were carried out to establish 
the best combination in our hands (Table 4 in Materials and Methods).  
These tests were performed prior to the RT qPCR results on cell lines. We 
first performed transfections on HEK293T cells using the ratios reported in 
Cheng and Peng articles. This preliminary test was performed using the 
Rhodopsin promoter and the transcription factor CRX. However, despite it 
was a previously described system, several problems emerged when 
validating and reproducing luciferase results (not shown). 
Eventually, after determining that MIO-M1 and HEK293 were the most 
suitable cell lines, the promoter activity in response to the transfected TFs 
was evaluated in both cell types. For this experiment, 0.3 µg of the promoter 
and 0.5 µg of the TF expression constructs were used, following the protocol 
established by a former PhD student of our lab (Dr. Pomares, as specified in 
her DEA, Diploma d’Estudis Avançats). In the case of HEK293, Rhodopsin, S 
opsin, M opsin and Gnat promoters were tested alone or in co-transfection 
with either CRX or CRX plus NR2E3. For the assay in MIO-M1 cells, the 
Rhodopsin promoter was tested either alone, co-transfected with CRX, or with 
CRX plus NR2E3. Results are expressed as luciferase values normalized 
using β-galactosidase (Figure 27). 
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In HEK293 cells a high activation of the S opsin promoter by CRX was 
observed, being more moderate for the M opsin and Gnat promoters, and 
barely detectable for the Rhodopsin promoter (Figure 27 A). On the other 
hand, activation of the Rhodopsin promoter by CRX was clearly observed in 
MIO-M1 cells, whereas the addition of NR2E3 to CRX caused a severe 
repression (Figure 27 B).  
Rhodopsin promoter activation by CRX and repression by the combination 
of CRX and NR2E3 observed in the MIO-M1 cell line is similar to what has 
been previously described to in the events leading to rod determination 
during the development of the mouse retina. On the other hand, activation 
of the S opsin promoter with no activation of the Rhodopsin promoter when 
co-transfected with CRX is equivalent to the regulation of the default cone 
pathway also described in the development of the mouse retina. For these 
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reasons, a transfection system using MIO-M1 was deemed as a possible rod 
model; while the system using HEK293 might serve as a cone model. 
Nonetheless, due to their lower transfection efficiency results, MIO-M1 cells 
were discarded as a first option, and HEK293 was selected as the cell line to 
perform our high-throughput DUB silencing assays.  
In summary, in our conditions HEK293 cells were chosen to be co-
transfected with the S opsin promoter and CRX (as TF), as our best basal 
cell system to assay the possible effect of DUB genes knockdown in the 
control of retinal promoters by retina-specific TFs. Furthermore, our results 
allowed us to establish a cell culture model that somehow mimicked some of 
the conditions of a developmental retinal cell in which CRX activates the S 
opsin but does not activate the Rhodopsin gene. On the plus, HEK293 cells are 
easy to work with and manipulate, and they usually render reproducible 
results that can be statistically analyzed. 
 
After establishing the transfection parameters in HEK293 cells, the next step 
was to perform high-throughput silencing assays using the established cell 
system. These assays were considered as a first screening step to identify 
possible DUB enzymes as candidates for the regulation of the S opsin 
promoter in the development of photoreceptors. We used two different 
high-throughput approaches, based on a short hairpin RNA (shRNA) library 
and a small interfering RNA (siRNA) collection to selectively knockdown 
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one by a one a large selection of deubiquitinating enzymes and SUMO 
pathway genes. 
The use of shRNA-expression plasmids is a common RNA interference-
silencing method. It is characterized by relatively low degradation and 
turnover rates and thus, it represents an optimum system when working with 
cell culture as well as in in vivo approaches. Considering these characteristics, 
shRNA-mediated knockdown was one of the mechanisms we selected to 
interfere with the endogenous DUB expression in our system, and detect the 
subsequent effect on the transactivation/repression of photoreceptor-
specific promoters. A high-throughput knockdown study was performed at 
the CIC-Biogune (Bilbao) facilities (Dr. E. Berra), since a large shRNA 
library against all human genes was available. We made a selection of 
interesting ubiquitin and SUMO pathway genes to be silenced. 
A total of 43 genes were selected for this study, 27 belonging to the SUMO 
pathway and 16 to the DUB family (Table 12). All SUMO pathway genes 
were included on the list whilst DUBs were selected depending on their 
mRNA expression pattern in the retinal layers, as observed in the in situ 
hybridization results– namely, we picked those genes that showed expression 
in the photoreceptor layer and had a neat hybridization signal (see section 1.2 
in Results – Chapter 1). 
When available, a maximum of three different shRNAs against several 
regions were used per gene. Also, two different controls for the silencing 
procedure were used: one shRNA against a random non-complementary 
sequence, shSIMA, as a negative control; plus several shRNAs against CRX, 
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as a positive control. In the case of CRX, five different shRNAs were used, 
and since they were not cloned into the same vector as the rest of the 
shRNA library, a second random non-complementary shRNA had to be 
added as a control, named shSCRAMBLE. Moreover, the pcDNA empty 
vector was used as a transfection negative control. All transfections were 
performed including the S opsin promoter-luciferase together with CRX (as 
TF) expression constructs. 
 
SUMO GENES 
 
DUBs 
SUBSTRATES 
 
E3 LIGASES 
 
PROTEASES 
 
JOSD2 UCHL1 
 UCHL3 SUMO1 
 
PIAS1 HDAC7 
 
DESI1 
 
ATXN3 
SUMO2 
 
PIAS2 MUL1 
 
DESI2 
 
BAP1 USP12 
SUMO3 
 
PIAS3 RASD2 
 
SENP1 
 
STAMPB USP11 
E1 LIGASES 
 
PIAS4 TOPORS 
 
SENP2 
 
USP9X TNFAIP3 
SAE1 
 
RANBP2 TLS 
 
SENP3 
 
USP25 USP47 
SAE2 
 
CBX4 TRAF-7 
 
SENP5 
 
USP45 PRPF8 
E2 LIGASE 
 
MMS21 USPL1 
 
SENP6 
 
USP54 OTUD7B 
UBC9 
 
HDAC4 
  
SENP7 
   
Previous to performing the complete high-throughput study, CRX was 
silenced on its own as a proof of sensitivity for the luciferase system. A 
striking statistically significant decrease in luciferase levels was observed 
when silencing CRX (shCRX compared to shSCRAMBLE; p-value 
<0,0001). Besides, this decrease was more evident with time, as it was higher 
after 72 h than 48 h post-transfection. (Figure 28) 
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Four different independent high-throughput silencing replicate experiments 
were performed, each one containing three technical replicates per silenced 
gene. Per gene, two to three different shRNAs against different coding 
regions were assayed in the same well to improve silencing. Mean values of 
luciferase normalized to β-galactosidase activities for the four experimental 
replicates are plotted in Figure 29. After performing statistic analysis by the 
Dunnett’s test, no significant differences were observed between the 
silencing among all the genes and the control. However, some genes such as 
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UBC9, PIAS2, PIAS3, SENP1, SENP3, DESI1, TRAF7, USP11 and 
PRPF8, showed a clear trend in their variation, when compared to the 
control. 
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Concerning the fact that no statistical differences were observed, it is worth 
noting that shSIMA results were not consistent with those obtained with the 
other negative control, shSCRAMBLE, when they should be quite similar. In 
fact, shSIMA luciferase values were lower than the observed in the 
alternative negative control, which suggested a silencing context effect of this 
vector upon the S opsin promoter (even when no shRNA was expressed). 
This observation made it difficult to assess statistical differences between the 
effect of DUB gene silencing and the shSIMA negative control. For this 
reason, and as an attempt to clarify these results, another knockdown assay 
was performed focusing our efforts on the genes that presented some 
suggestive trend when compared to the control.  
At the University of Barcelona, a deconvolution assay was performed, 
transfecting separately each of the shRNAs that targeted a particular gene 
(three different shRNAs were jointly tested per most genes in the high-
throughput screening). Three replicates of the experiment were performed, 
each of them containing three independent replicates. In the case of SENP3, 
DESI1 and USPL1 only a single shRNA construct was available and so, for 
these cases the deconvolution experiment was a replicate of the high-
throughput test. Experimental conditions and controls were the same as 
those used in the high-throughput assay. As an experimental reference, the 
transfection of all the shRNA per gene in a single well was also used.  
The folds of luciferase mean values of the three experiments, normalized to 
β-galactosidase, compared to the shSIMA control are plotted in Figure 30. 
Unfortunately, this deconvolution assay did not help to shed light on the 
previously obtained results. Nearly in all cases, each individual shRNA 
showed the opposite behaviour that the one obtained when using the three 
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shRNA of each gene together; e.g. most of the genes showed a repression of 
the S opsin promoter when using all shRNA together, but each shRNA 
showed activation of the promoter when transfected separately. This 
behaviour was observed in all genes except for TRAF7. Light gray bars 
indicate that shRNA luciferase values show a consistent behaviour –either an 
increase or a decrease– as those obtained in the high-throughput experiment; 
whereas black bars indicate that the result was opposite. It is worth 
mentioning that when transfecting all shRNA together, results were 
reproducible from the high-throughput assay, except for DESI1.
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Since the technical difficulties did not allow obtaining consistent results and 
shSIMA was the only negative control available and could not be substituted 
(another vector would have probably produced statistically significance in at 
least a few number of genes), no further experiments could be performed 
using the shRNA library. 
Despite the shRNA results were rather disappointing because of they did not 
show any statistical significance, we still intended to elucidate whether any of 
the deubiquitinating enzyme genes were responsible or else, had a plausible 
relationship with the regulation of photoreceptor development. Therefore, to 
complement data obtained from the shRNA knockdown assay and to 
evaluate the efficacy and consistency of other silencing methods, transfection 
with small interfering RNA (siRNA) was also performed in our cell system. 
It is worth mentioning that siRNA is introduced as a small double stranded 
RNA molecule, and it is a transient silencing method, less stable within cells 
than shRNA, but also commonly used in cell culture and in in vivo assays. In 
our experiments, two different siRNA targeting different regions per gene 
against a total of 35 USP family genes, were tested. All of them were kindly 
provided by Dr. Jose Antonio Rodríguez Pérez at Universidad del País Vasco 
(Table 13).  
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USP 1 USP 8 USP 15 USP 25 USP 36 
USP 2 USP 9 USP 16 USP 29 USP 37 
USP 3 USP 10 USP 18 USP 30 USP 42 
USP 4 USP 11 USP 19 USP 31 USP 44 
USP 5 USP 12 USP 20 USP 32 USP 46 
USP 6 USP 13 USP 22 USP 33 USP 47 
USP 7 USP 14 USP 24 USP 34 CYLD 
 
Similarly to the assays using shRNA, in these knockdown assays HEK293 
cells were co-transfected with the S opsin promoter, CRX as a TF, and the 
siRNAs corresponding to each DUB that targeted the expression of the 
endogenous genes. A random siRNA-sequence, siSCRAMBLE, was used as 
a negative control. No CRX silencing control was performed; instead 
GAPDH silencing was used as a positive control.  
As a proof-of-principle, before attempting the high-throughput test, we first 
tested the efficiency of siRNA gene silencing in the endogenous expression 
of USP5 and USP19 in HEK293 cells. These two genes were selected since 
they were highly and lowly expressed in the mouse retina, respectively (see 
results of section 1.1 from Results – Chapter 1). The effect on the mRNA 
levels was assessed by specific RT qPCRs. Relative expressions were 
normalized to β2-Microglobulin (Figure 31). 
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A knockdown effect of 50% was observed for GAPDH expression, which 
was used as a control; and a very effective knockdown (down to 10% of the 
basal expression) was detected for USP5. However, the basal expression of 
USP19 was barely detectable in HEK293 cells and therefore, the knockdown 
effect could not be reliably assessed. 
Once the efficiency of gene knockdown using siRNAs had been validated, 
we finally got to perform the high-throughput siRNA silencing assay. Again, 
as in the case of the shRNA assay, four independent experiments were 
conducted, each of them including three replicates per sample (Figure 32). 
Unfortunately, the four different experiments did not render any 
reproducible or plausible results, for high levels of variability between 
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experiments were observed. To illustrate this striking variability, the values 
obtained in each experiment have been plotted in Figure 32. Luciferase 
values were normalized to β-galactosidase values in each independent 
experiment. 
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Given this unusual variability, no statistical analysis could be performed and 
so, we had to look at the results in a different manner. In an attempt to make 
sense of the results, only those values from the two closest experiments were 
considered, that is, the two central values (experiments #2 and #3) in Figure 
33. When taking into account only these values, the knockdown of USP18 
rendered statistically significant differences; while USP1, USP3, USP46 and 
USP47 showed a suggestive trend (though not yet significant). Mean 
luciferase values of these two experiments normalized to β-galactosidase 
values are plotted in Figure 33. 
 
 
 
Since some DUBs showed suggestive changes in luciferase expression after  
siRNA-mediated knockdown, we decided to confirm the assays in a smaller 
scale. The siRNA-mediated knockdown of USP1, USP3, USP18, USP46 and 
USP47 by siRNA were analyzed again, checking the effect on the regulation 
of the S opsin promoter by CRX. No clear reproducible results were obtained 
(Figure 34 A). Since one of the possible effects of DUBs is the edition and 
rescue of ubiquitinated proteins targeted for proteasome degradation, we 
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checked whether the knockdown of these specific DUBs by siRNA could 
alter the protein stability of CRX. Therefore, we checked CRX levels on 
siRNA transfected cell lysates (Figure 34 B). We could detect a significant 
reduction in the CRX protein levels when silencing USP18 (Figure 34 C); 
which is consistent with the reduction of luciferase values in the siRNA 
silencing screening. 
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These experiments showed that the knockdown of USP18 affected CRX 
protein levels. Therefore, the regulation of CRX by USP18 appeared as a 
good starting point to further investigate the involvement of this DUB in 
retinal development. Despite this promising result, later transcriptome 
analysis by high-throughput RNA-sequencing (section 3.1 in Results – 
Chapter 1) of different retinal developmental stages barely detected any 
Usp18 retinal expression levels throughout all the stages and species (mouse 
and human) analyzed. Unfortunately, the endogenous expression of USP18 
in HEK293 cells did not correlate with its level of expression in retinal cells. 
If expression of USP18 and CRX apparently did not coincide during 
development, any possibility of physiological relevance for the regulation of 
CRX (a key retinal-specific TF) via USP18 would be extremely low. 
Therefore, we decided not to pursue this seemingly spurious interaction.   
Up to then, all silencing methods evaluated triggered several technical 
difficulties that could not be overcome. On one hand, shRNAs seemed to 
shed promising results but the unique negative control interfered with the 
luciferase reads, and made it impossible to find statistical differences. On the 
other hand, siRNA experiments rendered extremely variable results between 
independent experiments. In addition, the statistically differences found in 
CRX levels after USP18 knockdown did not seem to bear physiological 
relevance. For this reason, alternative methodologies needed to be 
approached in order to elucidate the role of DUB genes in the regulation of 
retinal development.  
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Simultaneously to using siRNA and shRNA, a new gene knockdown 
technology was also tested, namely, Gapmers®. Gapmers® (from 
heretofore, Gapmers) are synthetic antisense DNA oligonucleotide probes 
flanked by two 2’-O modified RNA regions. When they target a particular 
mRNA molecule by sequence complementarity, the cell detects an mRNA-
DNA double strand hybrid, thereby inducing RNAse H activity, which 
results in cleavage of the mRNA strand of the hybrid and ensures the 
expression knockdown of the target gene. Their application ranges from in 
vitro cell cultures to in vivo assays, making them a good tool for gene 
functional analyses (Figure 35). Thereby, if the shRNA/siRNA assays 
resulted with a good DUB candidate; the silencing effects would have been 
tested in in vivo retinal explants.  
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To test the efficiency of this new system, we performed control assays by 
attempting Gapmer-mediated silencing of well-known retinal genes CRX, 
NR2E3 and PIAS3 in our HEK293 cell system. CRX and NR2E3 are 
known modulators of photoreceptor cell promoters – CRX is an activator of 
the S opsin gene and other cone-related genes; while NR2E3 is an activator of 
rod-specific genes. Concerning PIAS3, it is the SUMO E3 ligase responsible 
for SUMOylating NR2E3 thereby switching its function from activator of 
rod-specific genes to repressor of cone-specific genes. While the relationship 
between NR2E3 and PIAS3 has been previously addressed; it is yet unclear 
whether PIAS3 somehow interacts with or modulates the function CRX. 
On one hand, CRX and PIAS3 were separately silenced in our S opsin 
promoter – CRX system (Figure 36 A); and on the other, NR2E3 and PIAS3 
were silenced in the same transfection system together with NR2E3 as an 
extra mediating TF (Figure 36 B). In all cases, three different Gapmers 
against three different regions per gene were used in a single condition. A 
random sequence Gapmer, Ctrl NegA, was used as a silencing negative 
control. The assay was performed in three separate experiments, each of 
them containing three independent samples. Cells were harvested and 
luciferase activity was measured 48h post-transfection.  
150 
 
** 
 151 
 
As revealed by the quantification of the luciferase activity, the S opsin 
promoter was almost completely silenced when CRX was silenced, as 
expected. However, the silencing of PIAS3 did not affect the activation of 
the promoter (Figure 36 A). As seen in Figure 36 B, the S opsin promoter 
activity was increased when NR2E3 was co-transfected and expressed 
together with CRX. However, the sole presence of NR2E3 was not sufficient 
to activate the promoter in the absence of CRX (Nr2e3 + gCRX in Figure 36 
B). In this part of the experiment, the knockdown of PIAS3 had, again, no 
effect on the activation of the S opsin promoter by CRX co-expressed with 
NR2E3. 
Further validation of the gene knockdown was performed by Western blot, 
using antibodies against CRX (Figure 36 C) and PIAS3 (Figure 36 D); in 
both cases, tubulin was used as a loading control. According to our results, 
the gene silencing efficiency was much higher for the Gapmer against CRX 
than that for PIAS3, since the endogenous CRX levels were more 
diminished compared to those of the controls. After applying t-Student test 
analysis, no statistical differences could be detected in the reduction of CRX 
or PIAS3 protein levels when compared to the controls (p-value >0,05). In 
the case of CRX, no protein band was detected whatsoever in the 
immunodetection when silencing it with Gapmers; therefore, further 
experimental replicates need to be performed, to increase the sample number 
and be able to reach statistical differences. 
When assessing CRX protein levels by Western blot (Figure 36 C), a 
statistically significant increase was found when using Gapmers against 
PIAS3 (p-value <0.01). Nonetheless, this increase in CRX protein levels 
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caused by the absence of PIAS3 might have been a technical artefact, for 
Gapmers against PIAS3 were proved to be ineffective, as previously 
mentioned (Figure 36 D). 
When planning this approach, we first intended to test the silencing 
efficiency of Gapmers in a cell culture environment and afterwards, in an in 
vivo approach using mouse retinal explants. Once the efficiency was tested, 
the reasonable step was to silence any candidate DUB that we might have 
identified in our cell culture system assay. However, as no solid candidate 
gene was obtained at this point, no further experiments with Gapmers were 
performed.
 
 153 
While validating the silencing efficiency of the Gapmers technology, two 
extremely close bands of CRX were detected (using an anti-CRX protein 
antibody, data not shown). Since we intended to immunodetect over-
expressed CRX in transfected cultured cells, or even the endogenous CRX 
basal protein expression in HEK293, we did not expect several protein 
isoforms; thus, the finding was suggestive and warranted further 
consideration. To determine whether the double CRX band was due to any 
technical artefact, we immunodetected endogenous levels of CRX on mouse 
661W, human MIO-M1, Y-79, HEK293 and HEK293T cells; together with 
mouse P30 and P60 retinal extracts (Figure 37). 
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In the low exposure immunodetection results, an upper mirror band was 
observed in both mouse P30 and P60 retinas; while a clear double band 
appeared in human Y-79 cells. Expression in the rest of type cells was too 
low to be assessed. However, in a higher exposure picture, CRX was 
detected in all cells, which all presented the mentioned mirror band, except 
for 661W cells, where the protein was not detected. Furthermore, in P30 and 
P60 retinas two faint, additional higher molecular weight bands were 
observed above the previously detected ones. 
The two bands observed in the P30 and P60 stages correspond to the two 
mouse isoforms of CRX already reported, with a calculated molecular weight 
(MW) of 32.38 kDa and 34.98 kDa. Nonetheless, there is one single isoform 
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reported in humans, with an approximate molecular weight of 32.27 kDa. 
Therefore, the two bands detected in the HEK293 and HEK293T human 
cell lines probably corresponded to post-translationally modified forms of 
the protein. Relevant to this argument is the fact that CRX constructs 
transfected in HEK293 cells, also result in two immunodetected separate 
bands, regardless of the fact that the construction was expressing a single 
isoform as a cDNA sequence, and that no alternative splicing could be 
plausibly envisioned. The fact that CRX is post-translationally modified also 
in vivo was supported by the fainter higher molecular weight bands detected 
on retinal samples, which could be explained by modification with ubiquitin 
moieties or other post-translational modifications.  
Concerning the two endogenous CRX-detected bands observed in cultured 
Y-79 human retinoblastoma cells, they might be explained as an abnormal 
transcription or alternative splicing event derived from their cluttered 
kariotype, which includes hypertriploidy with dicentric chromosomes and 
chromosomal breaks.   
From the above mentioned results, a possible post-translational modification 
of CRX via a small peptide-conjugation was suspected. To determine which 
type of pos-translational modification was tagging CRX, we designed 
immunoprecipitation assays. At first, and in order to determine whether the 
conjugation of a SUMO moiety was the possible post-translational 
modification of CRX, we performed an immunoprecipitation assay. In this 
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experiment, HEK293 cells were transfected with either 1) CRX, 2) CRX and 
HA-SUMO1, 3) CRX and HA-SUMO2, or 4) HA-SUMO2 alone. CRX was 
tagged with an XPRESS epitope; while SUMO constructs were tagged with 
an HA epitope, which was also used to immunoprecipitate SUMO from 
cellular lysates. Subsequently, samples were separated by electrophoresis, and 
immunoblotted against the XPRESS epitope to detect CRX in the 
immunoprecipitation outputs. As seen in Figure 38, no CRX band was 
detected in the outputs from the immunoprecipitation against SUMO-HA; 
thus, the post-translational modification observed in CRX was not due to the 
addition of a SUMO moiety.  
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Simultaneously to the SUMO immunoprecipitation, we set up several 
immunoprecipitation assays to detect possible interactions with ubiquitin 
moieties. As in the case of SUMO, HEK293 cells were transfected with CRX 
and HA-ubiquitin or with HA-ubiquitin alone. To enrich the lysate in 
ubiquitinated proteins, a new condition was created adding MG132 to cells, 
to inhibit proteasomal degradation. An HA-antibody was used to 
immunoprecipitate ubiquitinated proteins, and subsequently, samples were 
immunoblotted against CRX. As a control, an immunoprecipitation test was 
also performed against CRX. In this case, a clear CRX band was detected in 
the outputs of both immunoprecipitations, demonstrating that CRX is post-
translationally modified with ubiquitin (Figure 39). 
 
α
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To further investigate CRX ubiquitination sites and possible ubiquitin 
machinery linked to it, immunoprecipitation of CRX and consequent mass 
spectrometry assays were performed. Different independent approaches 
were carried out. In the first experiment, CRX was immunoprecipitated from 
HEK293 cells transfected with both CRX and HA-Ubiquitin constructs. In 
the second immunoprecipitation assay, P60 wild type mouse retinas were 
analyzed. No ubiquitinated peptides could be detected in any of the 
subsequent mass spectrometry assays, probably due to technical sample 
limitations.  
To improve the sample quality, a third experiment was performed. HEK293 
cells were transfected again together with CRX and HA-ubiquitin constructs, 
plus MG132, in order to inhibit proteasomal degradation and favour 
ubiquitinated protein forms; besides, siRNA against USP18 was also co-
transfected. At that moment, our working hypothesis was that USP18 
(catalytically active) could rescue and increase the amounts of the key 
transcription factor CRX. However, no CRX ubiquitinated peptides were 
detected in this third experiment. Raw mass spectrometry data on CRX 
immunoprecipitation from adult WT mouse retina lysates can be found in 
the Annex II of the present work. CRX does appear in the list but no 
ubiquitinated peptides could be assigned to CRX. 
Moreover, mass spectrometry was also performed to detect possible CRX 
interactors. As CRX is a transcription factor, most of the peptides found 
corresponded to transcriptional and translational protein complexes (Figure 
40). From all the rest of interactors, both in cell culture and in retina, it is 
worth mentioning that deubiquitinating enzyme OTUB1 was detected in a 
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relatively high number of peptide counts; and also was OTUD6B. The 
finding of these two DUB enzymes in the immunoprecipitation of CRX 
turned them into good candidates for CRX regulation; besides, note that no 
peptide corresponding to USP18 was detected. Future work will consider on 
the function of OTUB1 and OTUD6B in CRX post-translational regulation. 
 
 
 
 
Finally, we could demonstrate via co-immunoprecipitation assays that CRX 
was post-translationally modified by at least one ubiquitin moiety. 
Experiments with transfected HEK293 cells transfected with CRX and 
treated with proteasomal inhibitor MG132, showed that one of the roles of 
CRX ubiquitination is to determine its protein fate to proteasomal 
degradation. Furthermore, mass spectrometry experiments showed that CRX 
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immunoprecipitated with ubiquitin system machinery, including 
deubiquitinating enzymes OTUB1 and OTUD6B.  
Future experiments need to be performed to determine the ligases and 
DUBs involved in the CRX ubiquitination and to clarify further physiological 
implication of this protein modification with Ub. With these results, we will 
be able to establish a new regulation point –due to post-translational 
modification of the CRX transcription factor– in photoreceptor 
development learning more about how this biological process occurs and 
possibly finding new clues for the aetiology of some retinal diseases. 
  
  
 
 
 
 
 
 
Discussion 
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The ubiquitin pathway is currently viewed as one of the most dynamic and 
versatile cell regulatory system in eukaryotes. Perturbations in the ubiquitin 
pathway are involved in many human disorders, among which cancer and 
neurodegeneration76,77 have been extensively reported and investigated. 
Disruption of the ubiquitin pathway mainly causes accumulation of 
misfolded proteins or dysfunction of protein homeostasis, leading to cell 
cycle disruption or cell death. In this context, deubiquitinating enzymes 
(DUBs) may play a major role due to their ability to regulate the ubiquitin 
pathway and make it a reversible process. As supported by reports of 
systematic DUB knockdown in zebrafish embryos and flies67,68 described in 
the results section of the present work, disruption of DUB genes has 
dramatic consequences for the animal taxa analyzed, either during 
development or in adult stages. 
In mammals, several comprehensive surveys of DUBs have been reported 
resulting in a wide range of DUB structure, localization and function 
description. A recent review focused on the expression levels of DUBs in 
human organs and disease phenotypes associated to DUB mutations in 
humans and animal models29. However, despite their importance, detailed 
expression and functional analysis for most DUBs on particular tissues or 
organs, such as the retina, is still missing. 
One of the main objectives of the present work was to fill this gap and 
produce a descriptive atlas of DUB expression, delineate an evolutionary and 
phenotypic landscape of the complete set of DUBs in the adult mouse retina, 
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and thus provide a reference framework for DUB enzymes in this neuronal 
tissue.  
Before knowing any roles DUBs might play in retina, our starting point was 
to describe the actual expression of DUBs in the adult mouse retina. Real 
Time RT-PCR (RT-qPCR), in situ hybridization and fluorescent 
immunohistochemistry experiments were performed to that end, which 
eventually allowed us to establish a defined DUB expression landscape. 
Notably, a wide variety of gene expression patterns were observed, pointing 
to specific retinal functions for each DUB. 
First, it is important to understand that when working with such a particular 
tissue as it is the retina, certain technical aspects had to be taken into 
account: 1) the amount of tissue obtained per animal is very low and 2) the 
size and structural complexity of the retina, make it a very delicate working 
material. Therefore, we had to set up the methodology standards for the Real 
Time-qPCR and in situ hybridization procedures. For the first, three different 
retinal samples per each biological replicate had to be used, instead of one, to 
achieve both enough material and technical robustness for performing the 
RT qPCR. In the case of in situ hybridization, a big effort was invested in 
adapting the protocol to the fragility of the retinal sections. It is also worth 
noting that approaching RT qPCR as a high-throughput analysis has been 
largely improved in the last years, however, for in situ hybridization we had to 
consider reducing the number of analyzed genes to get as much information 
as possible and optimizing the time and effort invested. Moreover, the 
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number of analyzed DUBs was even narrowed when assaying protein 
localization, adapting it to the commercially available and functional 
antibodies. 
Taken as a whole, we obtained highly valuable information on the expression 
of the DUBs in the adult mouse retina yet it represents a first approach. The 
techniques used allowed us to gain a general overview on the expression 
pattern of DUB genes in the adult mouse retina; however, other techniques 
need to be performed to finely define the expression in each one of the 
seven retinal cell types, as well as their subcellular localization. If these results 
were available, we would be able to hypothesize and learn more consistently 
about the role DUBs play in retinal physiology and development. In the 
following Discussion sections the possible roles of DUB enzymes in the 
mouse retina will be discussed, considering together information obtained 
from our results and from previously reported data.  
Genes such as Brcc36, Poh1, Bap1, Otub2, and Usp44 showed relatively low 
mRNA levels according to the RT qPCR results. This was consistent with 
their previously reported physiological role, since they are recruited to 
complexes that regulate DNA repair and mitosis checkpoints56 during 
replication events; and the adult retina (from P21 onwards) is formed 
basically by post-mitotic and differentiated cells. The comparison of these 
results with those obtained in our RNA sequencing (RNA-seq) analyses 
helped to reinforce the data obtained in the mRNA expression results. In the 
cases of Poh1, Bap1 and Usp44, a decrease of expression throughout 
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development was observed, thus supporting their functional role in 
replicative cells.  
For the latter, some considerations must be also taken into account: the 
levels of expression of Poh1 were considerably higher in the RNA-seq results 
than those observed in the RT qPCR. Both techniques are useful to quantify 
RNA levels and similar results are expected; therefore, these disparities might 
be due to technical differences in the corresponding protocols. Concerning 
Otub2, the expression in RNA-seq was indeed low, but a slight increase 
during development was observed; which indicate that it might not really be 
involved in the regulation of mitosis or the response to DNA damage during 
replication. Brcc36 RNA-seq data was not processed. In any case, further 
experiments need to be performed to validate the physiological relevance of 
these hypotheses.  
As the retina is a neural tissue, it is conceivable that some DUB genes have a 
general neural function and are as important for the retina as they are for the 
rest of the nervous system. Indeed these might be the case for Otub1, Usp22 
and Usp33, which are highly expressed in the retina, and have been 
previously described to be differentially expressed in the human brain29. 
Something similar occurs with Uchl1, Atxn3 and Usp6, with differential 
expression in the human brain and high levels of expression in our RT qPCR 
results (although this is not so apparent in the RNA-seq data). Note that 
Uchl1, Otub1 and Atxn3 have been related to neurodegenerative diseases in 
human78,79, namely Parkinson's disease (Uchl1 and Otub1) and cerebellar 
ataxia (Atxn3), whose symptoms also include vision degeneration. 
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On the other hand, some genes are lowly expressed in the retina but have 
been described to be differentially expressed in the human brain, like Mysm1, 
Usp26, Usp29, Usp35 or Usp51; suggesting a specific role in the CNS which 
does not include the retinal tissue. It is worth noting however, that a slight 
malfunction of a barely expressed gene might have functional implications 
for the retina, since high oxidative stress and protein turnover rates make the 
retina a very sensitive tissue, with a lower threshold to disease compared to 
other tissues. 
In situ hybridization and fluorescent immunohistochemistry showed that 
most DUBs are globally expressed, although a handful of them are 
differentially expressed in specific retinal layers. For instance, Usp45, Usp53 
and Usp54 did show retinal layer specificity, as they were mainly expressed in 
the photoreceptors (PhR inner segment, ONL and OPL), suggesting a 
specific role for these genes in these highly specialized neurons and 
underscoring their role as potential candidates for visual disorders. The low 
expression of these genes observed in the RT qPCR might be explained by 
their expression being restricted to this layer, since photoreceptor cells 
represent a small percentage of the entire retina. 
Complementary to the mRNA localization revealed by in situ hybridization, 
fluorescent immunohistochemical localizations also pointed to specific 
functions for some DUBs: e.g. OTUD4, which is highly localized in axons; 
TNFAIP3, highly expressed in the photoreceptor outer segment and GCL; 
and USP22, whose localization is mainly nuclear and perinuclear. These 
results again suggest that these genes may be good candidates for particular 
retinal phenotypes. On the other hand, they might also play a more general 
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role in the cellular physiology, since Tnfaip3 and Otud4 knockdown in 
zebrafish resulted in severe developmental alterations68, and Usp22 causes 
pup death in homozygous mice. Moreover, Otud4 is mutated together with 
Rnf216 in cerebellar ataxia and hypogonadotropic hypogonadism (Gordon 
Holmes syndrome)70. 
Not only, the localization patterns differ between some genes, but also a 
wide range of DUB expression levels was detected by Real Time qPCR, even 
between evolutionary close genes. Thus Otud7a, Tnfaip3 and Zranb1 showed 
low, medium and high levels of mRNA expression respectively; or the close 
Usp31 and Usp43 show medium and very low expression levels respectively. 
This variety of levels and patterns of expression in the mouse retina strongly 
suggest that DUBs have either substrate specificity, cell type specificity or 
might be required for differential requirements in the different retinal layers, 
and argue against DUB functional redundancy, as proposed after DUB 
knockout early experiments in yeast. 
As previously mentioned, the data obtained from RT qPCR, in situ 
hybridization and IHC in P60 mice retinas were a good starting point to 
define DUB gene and protein expression in adult mice retina. However, once 
these data was obtained and analyzed, further question aroused mainly about 
how this expression might vary during retinal development. Learning more 
about these variations, would help us understand which DUB genes might be 
important at which developmental stages. We could have approached this 
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question measuring RNA levels of the different developmental stages via RT 
qPCR, however, this would have supposed a major investment in time, cost 
and effort. Moreover, investing in a high-throughput RNA-sequencing was, 
at that moment, beyond our economic limits; fortunately, we were able to 
use Dr. Swaroop’s data for our analysis.  
As in the case of RT qPCR, RNA-Seq data revealed a wide variety of 
expression patterns: some DUB genes were only expressed at early 
embryonic stages while others were expressed throughout the development 
and adult stages, or not expressed at all. Some DUB genes showed activation 
in the transcription only from birth, and others showed differences when 
comparing rod and cone development, overall pointing to their possible 
involvement in the regulation of retinal development. Below, we discuss this 
variation and their possible implications in the physiology of the developing 
retina. 
RNA-seq analysis showed clear variations in the expression levels of DUB 
genes during mouse retinal development. For instance, Usp37 or Josd3 
(Traf1d), highly expressed in embryonic stages but whose expression was shut 
down after birth; or Zranb1 or Usp32, whose expression was extremely low at 
embryonic stages but clearly increased around and after birth date.  
A possible explanation for these differences in gene expression is that Usp37 
and Josd3 function might be important for the differentiation of certain cell 
types; thus, when those cells are finally differentiated, the action of these 
genes are no longer needed and consequently their expression levels drop. In 
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this context, the most feasible scenario is that they participate in the 
differentiation of cells like ganglion, horizontal or amacrine cells, which fully 
differentiate in mouse embryonic stages. Concerning Zranb1 and Usp32, their 
increase from birth might be explained by two different possibilities: 1) either 
they are important for differentiation of rods, which peak by P2; or 2) they 
are rod-specific genes and thus, as the number of rods increases, their 
expression levels consequently increase. 
Note that the cellular heterogeneity found in the retina makes it difficult to 
determine which gene is important for any particular cell type. Most RNA-
seq data and RT qPCR data have been generated from total retinas, and 
consequently, genes expressed in most abundant cell types are 
overrepresented. Despite large efforts in recent years, the isolation and 
culture of precise retinal cell types has still to overcome technical difficulties, 
since these cells are very fragile and sensitive to environmental changes. 
However, the research group of Dr. Swaroop has long-standing expertise in 
isolating rod- and cone-like photoreceptors and they could approach 
differential transcriptomic analyses, making lists of genes that might be 
important for each type of cell. 
Besides, genes such as Usp14, Usp10, Josd1, Usp22 or Usp39 switch off their 
expression in rods from P6, even though their expression is constant over 
time in cones. Therefore, these genes might be important for the 
maintenance of early photoreceptor fate, and when rods are finally 
differentiated, they might be no longer needed while cones might still express 
photoreceptor default pathway genes over time. Of note, becoming a cone is 
the default pathway, and the differentiation of rods needs active transcription 
of differential proteins. Another interesting case is Usp48, which is barely 
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expressed in rods at any of the analyzed stages, but its expression is always 
present in cone cells; defining a role in cone photoreceptor cells 
maintenance. 
Usp11 presents a remarkable expression pattern during development. 
Considering the whole retina, its expression lowers slightly at final 
developmental stages, coincidentally with an expression switch-off observed 
in rods. Thus, the decrease observed in the total retina might be a 
consequence of the increase in the relative amount of rod cells in the retina 
rather than a general decrease of its expression in all cell types. As previously 
mentioned, the techniques used so far do not allow more precision to solve 
this issue. 
Whether deubiquitinating enzymes participate together with specific TFs in 
key steps of the retinal development is still unclear and further experiments 
need to be performed. However, the RNA-seq results and the previous 
report of SUMO participating in NRL and NR2E3 modulation46,47, together 
with knockout and knockdown models in zebrafish68 and mice suggest the 
implication of DUBs in this tightly controlled regulatory network.  
To determine functional implication of selected DUB genes in the 
developing retina, we decided to directly assess this question in an in vivo 
experiment using mice. We could have also used cultured cells or retinal 
explants, but working directly with functional tissue would give us a 
completely physiologic framework; which we thought it was the best context 
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to analyze gene function. For this reason, we opted to silence genes via 
subretinal electroporation in P1 mice using shRNA and siRNA constructs.  
The results obtained from the mouse subretinal electroporation experiments, 
although preliminary, showed no retinal affectation when knocking down 
Josd1 and Otud7b genes; however, retinal rosettes were observed when 
silencing Usp48. This observed phenotype was interesting, since rosettes 
originate from the invagination of the distal retina and they are mostly due to 
cell overgrowth, and appear when retinal damage has occurred.  
We wanted to prove these rosettes were generated due to the action of the 
siRNA used against Usp48 and not due to damage caused during injection. 
However, we had obtained a very low cell electroporation efficiency in the 
retina when proceeding with subretinal microinjections. For this reason, we 
analyzed the possibility of using alternative methods, such as the vitreal 
injection. siRNA are not stable enough as to be injected vitreally and thus, 
we had to find further silencing methods. 
Therefore, we designed new assays using a novel silencing method, the 
AONs (Antisense OligoNucleotides). With this, we aimed to obtain an 
increased transfection efficiency and a higher sample number to analyze and 
statistically support possible phenotypic aberrations. 
Despite we have not yet performed these assays, we are optimistic about the 
results we might get because we have evidences in favour of a possible 
involvement of Usp48 in retinal development since it shows: 1) a differential 
expression pattern in cone and rod development, with a shut down in rods at 
postnatal stages; 2) an strong ChIP seq peak with CRX (which means that 
the retinal-specific CRX TF binds to the Usp48 promoter; 3) an altered 
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retinal phenotype when silenced in zebrafish; and 4) no previous functional 
or physiological role. For want of stronger evidences, we currently 
hypothesize that Usp48 in maintenance of cone physiology.  
As mentioned, SUMO modifications have already been associated to the 
regulation of retinal transcription factors, such as NR2E3 and NRL. The 
SUMOylated fraction of these two TFs targets different retinal promoters 
and exerts the opposite function than the non-tagged fraction46. Considering 
that ubiquitin is structurally and functionally very close to SUMO, we 
hypothesized that ubiquitin –and the whole set of enzymes of the cycle, 
including deubiquitinating enzymes– similarly participated in the regulation 
of retinal promoters. Therefore, one of the main objectives of this thesis was 
to identify DUBs that might regulate key retinal genes via the regulation of 
the transactivation activity of retinal-specific transcription factors. We 
reasoned that the effect of post-translational modifications (such as 
ubiquitin) on TFs would be best checked by their transcriptional effect on 
the target promoters, and that this effect could be dissected and statistically 
evaluated if we used a reporter measurable gene (such as luciferase) to detect 
changes in transcriptional activity, and an in vitro cell system amenable to 
control conditions and parameters.  
Moreover, considering the relatively large number of DUB genes described 
in the mouse and human genome (close to one hundredth), if we were to 
analyze all of them we would have to resort to high-throughput experimental 
approaches. The use of any animal model for high-throughput studies would 
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have implied a great investment of unavailable economical and temporal 
resources; thus, cell culture came out as the best of options. This rationale 
prompted us to generate a cell culture system easy to transfect, in which to 
“simulate” a retinal-like background to test the retinal TF activation upon a 
target promoter driving the expression of a reporter gene. 
The cell system we devised was based on the transfection of a retinal-specific 
promoter cloned upstream of the reporter luciferase gene, so that when the 
cotransfected the luciferase reporter together with retinal transcription factor 
constructs, variations on luciferase activity could be measured. If this basic 
system worked out, later on we could test the effect of DUBs’ knockdown 
using RNA silencing methodologies. We surmised that most variations in the 
luciferase activity would be small and hard to be detected, thus, it was 
important to control as many variables as possible. For this reason, a 
thorough set up was planned in which cells, liposomes (our transfection 
vector of choice), retinal promoters and transcription factors were to be 
tested, in order to obtain the most optimized system. 
Previous reports on luciferase activity experiments using retinal promoters 
had been already performed44,75, and were taken as reference. Despite 
HEK293T were the cultured cells used in those seminal articles, retina-
derived cultured cells appeared as the most physiological approach for the 
planned study. Therefore, the expression levels of retinal relevant genes were 
tested in 661W cone precursor cells, retinoblastoma Y79 cells, human 
precursor Müller MIO-M1 cells; together with HEK293 and HEK293T. 
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However, analysis experiments showed HEK293 as the best suitable cell 
lines; apart from that, they are also easy to handle and genetically manipulate.  
Concerning the combination of retinal promoters and TFs, several tests were 
made taking into account previous works75,44. However, after assaying several 
transfection combinations, luciferase measurements for each condition were 
mostly highly variable and non reproducible. Finally, the combination of 
CRX (as the TF) and the S opsin promoter rendered the more reproducible 
results, which correlated with the physiological activity of CRX in the retina, 
where CRX activates the S opsin promoter.  
Thus, our basic working in vitro system was: 1) HEK293 cells transfected 
with 2) the S opsin promoter (driving the expression of luciferase) 3) activated 
by CRX, a trans-activation activity that was quantified as an 
increase/decrease of luciferase activity. Once the system was set up, DUB 
and SUMO metabolism genes would be silenced using an exhaustive shRNA 
plasmid library, and changes on the luciferase activity reads would reflect 
activation/inactivation of the S opsin promoter due to the regulation of  the 
CRX TF via conjugation of ubiquitin or SUMO. 
To perform the knockdown high-throughput assay, a selected shRNA library 
was used. Constructs against DUBs and SUMO pathway genes were used in 
the established transfection system. Unfortunately, after performing four 
experimental replicates no statistical differences could be observed after 
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silencing the selected genes. The levels of luciferase activity were rather 
“wild” and variable between replicates.  
Looking closely to the results, the vector used as a control for the shRNA 
library, unexpectedly favoured some luciferase activity on its own. As 
previously mentioned, the negative control had to be cloned in the same 
vector as the rest of the tested shRNAs. We could not avoid using this 
control if using the high-throughput shRNA library. Even though we could 
not obtain statistically significant results in our attempts, it is feasible that if 
we could have changed the vectors for expression of the shRNAs to other 
vectors that did not interfere with our system, we could have identified some 
candidate while using the shRNA screening in our cell system. As it was, this 
is merely hypothetical. 
Although these results were somewhat discouraging, deconvolution 
experiments were performed to determine if more consistent results could be 
obtained when using single shRNA constructs per condition. Again, not only 
no statistically differences were obtained, but also no consistency in the 
activation/inactivation of the S opsin promoter was observed. For instance, in 
some cases the luciferase activation obtained for a single transfected shRNA 
against a particular gene was the opposite to that observed when the three 
constructs for the same gene were transfected together.  
We concluded that either the system was intrinsically too variable to measure 
any retinal TF activity with some consistency, or the expression from the 
shRNA constructs was drifty and therefore, extremely sensitive to 
environmental parameters that we were not controlling. In most cases, more 
intra- than inter-variability was detected and consequently, no further 
experiments were carried out using shRNA constructs. 
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To test another silencing method and possibly obtain more consistent results 
than those from the shRNA high-throughput silencing, siRNAs were 
assessed in our transfection system. siRNAs were available for 35 USP genes, 
and high-throughput silencing experiment was again performed. 
In this case, the four experimental replicates performed rendered highly 
variable results, not within each experiment, but rather between the 
independent replicates. Therefore, the statistical analysis was incongruous as 
the standard deviation between experiments achieved maximum values. To 
sort out this high variability issue, only the values of luciferase activity from 
the two closest experiments results were considered. Dunnett’s statistical test 
showed that USP18 was the only tested USP with statistically significative 
differences compared to the control and the rest of DUBs. Therefore, we 
considered it a good candidate to contribute to the regulation of the S opsin 
promoter by CRX. 
Several experiments were performed to assess the effects of USP18 upon 
CRX protein stability and ability to transactivate the S opsin promoter. The 
reduction of CRX protein levels when USP18 was silenced was apparent. 
This was a very interesting result, as it meant that somehow USP18 was 
participating on the regulation of protein levels of CRX. However, the results 
of RNA-seq in physiological conditions in the developing retina, in the adult 
retina in mouse and human, as well as in cone and rods did not support that 
USP18 was expressed in the retina. Therefore, the results obtained regarding 
the control of USP18 upon CRX protein stability were biochemically sound 
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(Figure 41) but unfortunately, did not seem to bear any real physiological 
sense in the retina. 
 
In general, the cell system we designed had a good theoretical basis, since the 
bibliography supported: on the one hand, the study of retinal promoters via 
luciferase activation by retinal TFs44,75, and on the other hand, the assay of 
knockdown methods in cell culture models had been widely proven. 
However, we detected several weak points throughout the procedures to 
study DUB function in the regulation of retinal promoters.  
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One main problem was the variability observed in the luciferase activity 
measurements, both in the initial experiments for deciding which 
combination of retinal promoter and TFs to be used; and later on, in the 
silencing experiments. This variability was eliminated or not disruptive in 
those cases were there was a strong transactivating effect of the TF upon the 
promoter, as was the case of CRX and the S opsin promoter. Nonetheless, 
when looking closer to the possibly small variations caused by the silencing 
of DUB genes, the results were not solid enough.  
The possible causes for these non-conclusive results might have been that: 1) 
the whole devised cell system to study retinal gene regulation via DUBs was 
quite an indirect approach, which accumulated many control points that 
could fail; 2) the luciferase activity measurements might not be sensitive 
enough to detect faint changes; or 3) the silencing efficiency of shRNAs and 
siRNAs were not evaluated for each of the corresponding molecules on its 
own since a high-throughput screening was approached, which might have 
implied that effective silencing might not have been optimal for all the 
siRNA analyzed.  
One must take into account, after all, that the system intended to evaluate 
the role any deubiquitinating enzyme might play on the regulation of a small 
proportion of CRX molecules. Thus, the knockdown of part of the active 
DUB protein might affect merely a small fraction of the ubiquitinated CRX 
molecules in the pool of CRX, and therefore, have a very slight effect on the 
promoter regulation, which need strongly unbiased and repetitive results to 
be detectable and statistically significant. On top of that, the detection 
system, with so many components, might not be sensitive enough to faint 
changes, so that no differences can be assessed when comparing to controls. 
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On the other hand, we should rationally consider the possibility that there is 
no such relationship between DUB enzymes, CRX transactivation activity 
and the S opsin promoter regulation. However, we must conclude that the 
present work does not provide enough scientific evidence to assure such 
affirmation. Therefore, our first hypothesis still stands up for evaluation, and 
further experiments should be performed using other functional approaches. 
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While working on USP18-dependent regulation of CRX protein stability, two 
different but close molecular weight bands were observed when performing 
Western blotting against CRX. To discard technical artefacts, more 
immunodetection assays were performed in several types of cells and mouse 
retinal samples. In all cases, the two bands were observed, and even two 
further upper bands were also detected in retina samples. Mice have only one 
single CRX mRNA isoform described, hence, a single protein should be 
translated and these observed bands ought to correspond to post-
translational modifications of CRX. Furthermore, cultured cells were 
transfected with one construct containing a single cDNA isoform. Yet, two 
bands were again detected reinforcing the post-translational modification 
hypothesis. 
Previous experience indicated that most possibly, this pattern of bands might 
correspond to post-translational modification with ubiquitin or ubiquitin-like 
peptides. Therefore, cell culture transfections including either CRX and HA-
ubiquitin, or CRX and SUMO1 or SUMO2 constructs were undertaken. 
Subsequent immunoprecipitations against Ub or SUMO demonstrated that 
there was a fraction of CRX peptides that were indeed ubiquitinated while 
none were SUMOylated in our conditions. 
Moreover, inhibition of proteasomal activity with MG132 treatment 
demonstrated that CRX was degraded via proteasome, meaning that 
ubiquitination tags CRX and targets this TF to proteasomal degradation. 
Concerning the interaction of DUBs with CRX, OTUB1 and OTUD6B 
were detected in the Mass Spectrometry experiments using whole retina 
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lysates; pointing them as possible regulators of the ubiquitination cycle of 
CRX (Figure 42). Were this regulation to occur, the hypotheses on how this 
control might work include: 1) that the two enzymes work to modulate CRX 
function via ubiquitin (Figure 42 A); 2) that the two enzymes modulate other 
proteins’ function that might be working together in a complex with CRX 
(Figure 42 B); 3) that the two enzymes rescue CRX from proteasomal 
degradation (Figure 42 C). Of course, it might well be that both enzymes 
work together to fulfil a specific function, but most probably each of them 
might be exhorting only one. Overall, both enzymes might well be involved 
in CRX protein stability and function.  
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While OTUB1 has been linked to cancer proliferation prognosis and very 
little is known about OTUD6B, none of them have been related to retinal 
function. As previously mentioned, OTUB1 contains other functional 
domains within its sequence and therefore, its function among CRX might 
not be related to its deubiquitinating activity. Overall, although the regulation 
of CRX protein is still unclear, we have provided some evidences that 
ubiquitination might be one of the mechanisms to regulate this TF activity or 
protein stability. Our results are intriguing enough to demand further work 
to unveil the exact mechanisms of interaction between CRX and these two 
DUB enzymes, the ligases involved in the reciprocal process of 
ubiquitination and the possible consequences of their interactions. 
  
 
 
 
 
 
 
Conclusions 
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1. From the analysis of the involvement of deubiquitinating enzymes 
(DUBs) in the mouse retina: 
I. The deubiquitinating enzymes (DUBs) present a wide range of 
expression in the adult WT mouse retina. This diversity is widespread 
among all 5 DUB families analyzed. 
II. The analyzed DUBs present different mRNA expression pattern in 
the layers of the adult WT mouse retina. Most DUBs present a 
consistent mRNA expression in the photoreceptor layer (PhR), outer 
nuclear (ONL) and outer plexiform layers (OPL); while presence is 
the ganglion cell layer (GCL) is more variable. 
III. The analyzed DUBs present a protein localization that correlates with 
that observed in mRNA localization experiments.  
IV. Sequence and functional conservation analysis of DUBs through 
phylogenetic and phenotypic studies showed that a burst of gene 
expansion within all DUB families was at the basis of the vertebrate 
lineage. 
V. The mutation or knockdown of a particular DUB gene that produces 
a relevant phenotype in one of the analyzed taxa, it usually replicates 
or provides a similar alteration in other analyzed organisms. In the 
cases of neuronal phenotype, there is an accompanying alteration in 
the eye. 
VI. Transcriptomic analysis of DUBs’ mRNA expression in the retina 
during development showed that DUB genes present differential 
expression patterns throughout retinal development in mouse and 
human. Some of the genes also presented differences of mRNA 
expression between the development of cones and rods. 
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VII. Josd1, Otud7b, Usp22, Usp46 and Usp48 were selected as good 
candidates for regulating mouse photoreceptor development 
VIII. Preliminary analysis of the functional role of selected DUBs in mouse 
retinal development, via in vivo gene retinal electroporation, showed 
silencing of Usp48 caused retinal malformations by P21. Further 
experiments need to be performed to statistically validate these 
results. 
2. From the design of an in-vitro retinal-like cell system to study the 
role of DUB enzymes on the regulation of retinal promoters: 
I. A cell culture system was established to study the possible regulatory 
role of DUBs upon retinal promoters. In this system HEK293 cells 
were selected to be co-transfected with 1) the S opsin promoter cloned 
upstream of a luciferase gene, and 2) CRX, acting as an activating 
transcription factor. 
II. High-throughput silencing of DUBs in the devised cellular system 
with shRNAs and siRNAs did not render consistent or reproducible 
results. Some of the analyzed genes seemed to act upon the S opsin 
promoter – CRX system (a tendency not yet statistically significant). 
Further experiments need to be performed to confirm these 
tendencies. 
III. USP18 seemed to participate in the regulation of CRX half-life. 
Nonetheless, RNA-seq data barely detected any reliable expression of 
USP18 in any developmental stage of the mouse and human retina. 
Therefore, the possible physiological relevance for the regulation of 
CRX via USP18 in the retina is extremely low. 
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IV. Gapmers® showed to be an efficient but rather expensive silencing 
technology.  
3. From the identification of CRX post-translational modifications, 
particularly ubiquitination. 
I. CRX is not post-translationally modified by SUMO 1 or SUMO2 in 
transfected human HEK293 cells. 
II. CRX is post-translationally modified by ubiquitination in transfected 
human HEK293 cells. 
III. Treatment of cells with the MG132 inhibitor showed that CRX 
ubiquitination is associated to its proteasomal degradation. Further 
experiments need to be performed to assess further roles of CRX 
ubiquitination. 
IV. Immunoprecipitation experiments followed by mass spectrometry 
assays showed that CRX binds the deubiquitinating enzymes OTUB1 
and OTUD6B. Future experiments need to be performed to 
determine the ligases and DUBs involved in the CRX ubiquitination. 
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eCollection 2016. 
Ubiquitination is a relevant cell regulatory mechanism that determines 
protein fate and function. Most data has focused on the role of ubiquitin as a 
tag molecule to target substrates to proteasome degradation, and on its 
impact in the control of cell cycle, protein homeostasis and cancer. Only 
recently, systematic assays have pointed to the relevance of the ubiquitin 
pathway in the development and differentiation of tissues and organs, and its 
implication in hereditary diseases. Moreover, although the activity and 
composition of ubiquitin ligases has been largely addressed, the role of the 
deubiquitinating enzymes (DUBs) in specific tissues, such as the retina, 
remains poorly known. In this work, we performed a systematic analysis of 
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the transcriptional levels of DUB genes in the adult mouse retina by RT 
qPCR and analyzed the expression pattern by in situ hybridization and 
fluorescent immunohistochemistry, thus providing a unique spatial reference 
map of retinal DUB expression. To provide a wider view of possible DUB 
roles in the retina, we aimed to relate the evolutionary landscape and gene 
expansions within the DUBs families with the reported phenotypes in the 
eye and other neural tissues. Overall, our results constitute a reference 
framework for further characterization of the DUB roles in the retina and 
suggest new candidates for inherited retinal disorders. 
Although I have performed most of the work of this article, several other 
people in Dr. Marfany’s group have contributed to some figures, as well as 
Xavier Grau-Bové from Dr. Ruiz-Trillo’s group. My personal contribution 
has been: a) the Real Time qPCR for all DUB genes (Figure 13; Article 
Figure 1); b) in situ hybridization of all OTU family members and several 
genes from the JAMM, UCH and USP families (Figure 14; Article Figure 2); 
c) immunohistochemistry for all analyzed genes (Figure 15; Article Figure 3); 
d) bibliographic analysis of retinal and neuronal phenotypes in mutant animal 
models and in human: phenotypes in Figure 16 (article Figure 4) and  article 
Supplementary Table 2). 
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Abstract
Ubiquitination is a relevant cell regulatory mechanism to determine protein fate and func-
tion. Most data has focused on the role of ubiquitin as a tag molecule to target substrates to
proteasome degradation, and on its impact in the control of cell cycle, protein homeostasis
and cancer. Only recently, systematic assays have pointed to the relevance of the ubiquitin
pathway in the development and differentiation of tissues and organs, and its implication in
hereditary diseases. Moreover, although the activity and composition of ubiquitin ligases
has been largely addressed, the role of the deubiquitinating enzymes (DUBs) in specific tis-
sues, such as the retina, remains mainly unknown. In this work, we undertook a systematic
analysis of the transcriptional levels of DUB genes in the adult mouse retina by RT-qPCR
and analyzed the expression pattern by in situ hybridization and fluorescent immunohis-
tochemistry, thus providing a unique spatial reference map of retinal DUB expression. We
also performed a systematic phylogenetic analysis to understand the origin and the pres-
ence/absence of DUB genes in the genomes of diverse animal taxa that represent most of
the known animal diversity. The expression landscape obtained supports the potential sub-
functionalization of paralogs in those families that expanded in vertebrates. Overall, our
results constitute a reference framework for further characterization of the DUB roles in the
retina and suggest new candidates for inherited retinal disorders.
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Introduction
Ubiquitination is a dynamic regulatory mechanism that controls cell processes such as protein
quality control (via proteasome degradation), cellular signalling, transcriptional regulation or
DNA repair [1–3]. As ubiquitination is reversible, cells deploy a large set of enzymes to conju-
gate (E1, E2 and E3 ligases) and deconjugate (deubiquitinating enzymes) ubiquitin moieties
[4]. The human genome contains several hundreds of ubiquitin ligases, and close to 80 deubi-
quitinating enzymes (DUBs), indicating that: i) ubiquitination is a highly regulated process,
and ii) substrate recognition specificity is inherent to the system.
Most data on the physiological relevance of ubiquitin has focused on its role as the tag mole-
cule to target substrates to proteasome degradation, its role in cell cycle control and cancer, as
well as its involvement in the molecular basis of neurodegenerative disorders [5,6]. Besides, a
number of high-throughput approaches have focused on finding substrates for either ligases
[7] or deubiquitinating enzymes (DUBs) [8]. Nonetheless, most high-throughput studies have
been performed in vitro using mammalian cell cultures, and only recently, systematic assays in
animal models have indicated the relevance of the ubiquitin pathway in the development, dif-
ferentiation and maintenance of tissues and organs [9,10].
One of the tissues that requires a tight gene and protein regulation is the retina. The retina
consists of structured layers of highly specialized neurons in the eye that capture and process
light stimuli enabling vision [11]. Such a fine architecture turns retinal differentiation into an
extremely complex mechanism that must be accurately regulated [12], and in which ubiquitin
and ubiquitination play a relevant role. In fact, mutations in the genes encoding the E3 ligases
TOPORS [13–15] and KLHL7 [16,17]; and in PRPF8, which belongs to the JAB1-MPN--
MOV34 (JAMM) family of DUBs, are causative of the most prevalent retinal hereditary dystro-
phy, retinitis pigmentosa (RP). Moreover, protein homeostasis via the ubiquitin-proteasome
system is also relevant to other retinal diseases and specific altered protein degradation has
been associated to Stargardt's disease, age-related macular degeneration, glaucoma, diabetic
retinopathy, and retinal inflammation (reviewed in [18]).
Lately, DUBs are becoming the focus of attention given that their specificity in substrate
selection makes them key checkpoints of protein degradation and fate. Moreover, their fewer
numbers (compared to E2 and E3 ligases) makes their functional analysis more feasible. An
increasing number of reports propose DUBs as pharmacological targets in disease: cancer [19–
21] and neurodegenerative diseases [6]. DUBs are classified into five different subfamilies
depending on their catalytic domains [22]: Machado-Joseph Disease protein domain proteases
(MJD), Ovarian Tumor proteases (OTU), Ubiquitin C-Terminal Hydrolases (UCH) and Ubi-
quitin-Specific Proteases (USP) are cysteine proteases, whereas JAB1/MPN/MOV34 family
proteases (JAMM) are Zn2+ metalloproteases; overall adding up to 90 genes in the human
genome, of which only 79 are predicted to be functional [1].
A recent review compiled the gathered knowledge of the functional roles of individual
DUBs, focusing on their subcellular localization, levels of expression in human tissues, and
gene mutation phenotype in human and model organisms [23], yet a comprehensive study on
the expression pattern of DUBs in highly specialized tissues, such as the retina, has not been
performed. Besides, previous comparisons of DUB mutant phenotypes in different model
organisms attempt to directly assign, without a phylogenetic framework, orthology and func-
tion between invertebrate and vertebrate genes. Some of these assignments may need revision
under robust phylogenetic data, since ubiquitin ligase and protease families have expanded in
eukaryotes [24], and subfunctionalization and neofunctionalization are known to occur after
gene expansion.
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Thus, we here aimed to draw an expression pattern map for DUB genes in the mouse retina,
by using RT-qPCR, in situ hybridization and immunohistochemistry. We have also applied
comparative genomics to infer the basic protein domain architecture within the DUB subfami-
lies and illustrate their diversification within metazoans. These data combined with the
reported phenotypes will help to identify relevant retinal genes and potential new candidates
for retinal diseases. Overall, we provide a comprehensive reference framework on DUB func-
tion and their roles in neuronal tissues that will be useful for future functional and evolutionary
studies.
Material and Methods
Ethics statement
All procedures in mice were performed according to the ARVO statement for the use of ani-
mals in ophthalmic and vision research, as well as the regulations of the Animal Care facilities
at the Universitat de Barcelona. The protocols and detailed procedures were evaluated and
approved by the Animal Research Ethics Committee (CEEA) of the Universitat de Barcelona
(our institution), and were submitted and also approved by the Generalitat de Catalunya (local
Government), with the official permit numbers DAAM 6562 and 7185.
Animal handling, tissue dissection and preparation of samples
Murine retina samples and eye slides were obtained from 2 month-old C57BL/6J (wild-type)
and CD-1 (albino) animals. Animals were euthanized by cervical dislocation. Some retinas
were dissected and immediately frozen in liquid nitrogen, while the rest were fixed in 4% para-
formaldehyde (PFA) for 2 h at room temperature (RT), washed, cryoprotected overnight in
acrylamide at 4°C, embedded in O.C.T. (Tissue-Tek, Sakura Finetech, Torrance, CA), frozen in
liquid nitrogen and sectioned at -17°C.
RNA extraction and cDNA synthesis
For each sample, retinas from three different animals were pooled. Therefore, up to 9 animals
in three independent replicates were analyzed. Retinas were homogenized using a Polytron PT
1200 E homogenizer (Kinematica, AG, Lucerne, Switzerland). Total RNA was extracted using
the High Pure RNA Tissue Kit (Roche Diagnostics, Indianapolis, IN) following the manufac-
turer’s instructions with minor modifications (increasing the DNAse I incubation step).
Reverse transcription reactions were carried out using the qScript cDNA Synthesis Kit (Quanta
Biosciences) following the manufacturer’s protocol.
RT-qPCR
Quantitative reverse transcription PCR (RT-qPCR) was performed using the LightCycler1 480
SYBR Green I Master Mix (Roche Applied Science) and a LightCycler1 480 Multiwell Plate
384. The final reaction volume was 10 μl. Raw data was analyzed with the LightCycler1 480
software using the Advanced Relative Quantification method. Gapdh expression was used to
normalize the levels of expression. Rho and Cerkl were considered as reference genes with high
and low levels of expression, respectively, in the mouse retina. Three independent samples rep-
licates were analyzed for each gene. Differences in gene expression levels within the same sam-
ple and between the samples were directly compared by their Z-score values. The mean and
standard deviation of the Z-scores are plotted in Fig 1. The name and sequence of all the prim-
ers used for RT-qPCR and in situ hybridization are listed in S1 Table.
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In situ hybridization
For in situ hybridization (ISH), 16–18μm sections were recovered on commercial Superfrost
Plus glass slides (Electron Microscopy Sciences, Hatfield, PA), dried 1 h at RT, rinsed three
times for 10 min with phosphate-buffered saline (PBS), treated with 2 μg/ml proteinase K for
15 min at 37°C, washed twice for 5 min with PBS, and fixed with 4% PFA. Acetylation with 0.1
M triethanolamine-HCl (pH 8.0) containing first 0.25%, and then 0.5% acetic anhydride, was
performed for 5 min each. Hybridization was carried out overnight at 55°C with digoxigenin-
labelled riboprobes (2 μg/ml) in 50% formamide, 1 x Denhardt’s solution, 10% dextran-sulfate,
0.9 M NaCl, 100 mMTris-HCl (pH 8.0), 5 mM EDTA (pH 8.0), 10 mM NaH2PO4, and 1 mg/
ml yeast tRNA. For each gene, cDNA fragments generated by RT-PCR of approximately 400-
700bp were subcloned into the pGEM-T1 Easy Vector (Promega) and sense and antisense
riboprobes were generated from the flanking T7 RNApol promoter. The name and sequence of
all the primers used for RT-qPCR and in situ hybridization are listed in S1 Table.
After hybridization, the slides were washed in 2x SSC for 20 min at 55°C, equilibrated in
NTE (0.5 M NaCl, 10 mM Tris-HCl pH 8.0, 5 mM EDTA) at 37°C, and then treated with
10 μg/ml RNase A in NTE at 37°C for 30 min. Subsequently, the sections were washed at 37°C
in NTE for 15 min, twice in 2x SSC and 0.2x SSC for 15 min each, equilibrated in Buffer 1 (100
mM Tris-HCl pH 7.5, 150 mMNaCl), and blocked in Blocking Buffer (1% BSA and 0.1% Tri-
ton X-100 in buffer 1) for 1 h at RT. An anti-digoxigenin-AP conjugate antibody (1:1000;
Roche Diagnostics, Indianapolis, IN) in Blocking Buffer was incubated overnight at 4°C. The
sections were then washed twice in Buffer 1 for 15 min, once in Buffer 2 (100 mM Tris-HCl pH
Fig 1. Relative expression levels of the five subfamilies of DUB enzymes.Gene expression values are the average of three independent samples
(measured in three replicates), each sample contained retinas from three individuals. The expression levels are obtained as a ratio withGapdh expression
(used for normalization) per 104. The Z-score has been calculated for the whole set of genes per each sample, and mean and standard deviation has been
obtained, so that the results can be directly compared among them. Negative values indicate when genes are expressed below the global mean of the gene
expression obtained in the analysis, and positive values when genes are more highly expressed. To simplify the comparison, the graph starts at the negative
values, being 0 the mean value of gene expression for the whole set of genes (87 in total) in each sample. JAMM- JAB1/MPN/MOV34 motif proteases;MJD-
Machado-Joseph Disease protein domain proteases; UCH- Ubiquitin C-Terminal Hydrolases;OTU- Ovarian Tumor proteases;USP- Ubiquitin-Specific
Proteases.
doi:10.1371/journal.pone.0150364.g001
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9.5, 150 mMNaCl), and once in Buffer 2 supplemented with 50 mMMgCl2 (5 min each) prior
to adding the BM Purple AP Substrate (Roche Diagnostics, Indianapolis, IN). For each gene,
antisense and sense ISH staining reactions were processed in parallel. The reaction was stopped
in 1x PBS. Sections were cover-slipped with Fluoprep (Biomérieux, France) and photographed
using a Leica DFC Camera connected to a Leica DM IL optic microscope (Leica Microsystems,
Germany).
Fluorescent immunohistochemistry
For retina immunofluorescence, 16 μm sections were recovered on commercial Superfrost Plus
glass slides (Electron Microscopy Sciences, Hatfield, PA), dried 30–45 min at RT, washed 10
min with PBS and blocked for 1 h with Blocking Buffer (2% Sheep Serum and 0.3% Triton X-
100, in PBS 1x). Primary antibodies were incubated overnight at 4°C with Blocking Buffer.
After incubation, slides were washed with PBS (3 x 10 min) and treated with DAPI (Roche
Diagnostics, Indianapolis, IN) (1:300) and with secondary antibodies conjugated to either
Alexa Fluor 488 or 561 (Life Technologies, Grand Island, NY) (1:300). After secondary anti-
body incubation slides were washed again in PBS (3 x 10min). Sections were mounted in Fluo-
prep and analyzed by confocal microscope (SP2, Leica Microsystems).
Primary antibodies and dilutions used were: 1:50 Rabbit anti-JOSD2 (Aviva Systems Biol-
ogy); 1:50 Rabbit anti-JOSD3 (Aviva Systems Biology), 1: 50 Rabbit anti-ATXN3 (in house, a
gift from Dr. S. Todi); 1:20 Rabbit anti-BAP1 (Abcam); 1:100 Rabbit anti-OTUD4 (Abcam
ab106368), 1:100 Rabbit anti-PRPF8 (Abcam ab79237), 1:100 Rabbit anti-TNFAIP3 (Abcam
ab74037), 1:100 Rabbit anti-UCHL3 (Abcam ab126703), 1:100 Rabbit anti-USP9X (Abcam
ab19879), 1:100 Rabbit anti-USP13 (Abcam ab109264), 1:50 Rabbit anti-USP16 (Abcam
ab135509), 1:100 Rabbit anti-USP22 (Abcam ab4812), 1:300 Rabbit anti-USP25 (in house),
1:250 Rabbit anti-USP28 (ABGEN AP2152b).1:500 for Mouse anti-Rhodopsin (Abcam, Cam-
bridge, UK). Antibodies against AMSH (Biorbyt orb101007), JAB1 (Abcam ab12323), OTUB1
(Abcam ab76648), OTUD1 (Abcam ab122481), POH1 (Abcam ab8040), USP5 (Abcam
ab154170) and USP45 (Novusbio H00085015) did not produce reproducible results.
Phylogenetic analyses
Protein sequences from each enzyme group were queried in complete genome sequences of 14
animal taxa (Homo sapiens,Mus musculus, Danio rerio, Petromyzon marinus, Branchiostoma
floridae, Saccoglossus kowalevskii, Strongylocentrotus purpuratus, Drosophila melanogaster,
Daphnia pulex, Caenorhabditis elegans, Lottia gigantea, Capitella teleta, Nematostella vectensis
and Acropora digitifera) using the HMMER 3.1 algorithm. For each analyzed enzyme family
(USP, UCH, OTU, MJD and JAMM) we searched all proteins containing the Hidden Markov
motifs of their catalytic region as defined in Pfam (UCH/UCH_1, Peptidase_C12, OTU/Pepti-
dase_C65, Josephin and JAB domains, respectively). Protein domain architectures of each
retrieved protein were then computed using Pfamscan 1.5 and Pfam 27 database [25] of protein
domains.
We aligned the catalytic region of each enzyme family using Mafft 7 L-INS-i [26](optimized
for local sequence homology), and inspected each alignment matrix manually. The most suit-
able evolutionary model for the analyses, selected with ProtTest 3.4 [27], was LG+ Γ. We used
RaxML 8.1.1 [28] to infer Maximum Likelihood trees of each family, with 100 bootstrap repli-
cates as statistical supports. Complete sequences, alignments and phylogenies are provided in
S1–S3 Files. Manual inspection of the trees allowed us to identify subfamilies, named after their
human orthologs, based on their bootstrap support and conservation of protein domain
architectures.
DUB Retinal Expression, Phylogenetic and Phenotypic Analyses
PLOS ONE | DOI:10.1371/journal.pone.0150364 March 2, 2016 5 / 18
Results
Expression level of deubiquitinating enzymes in the mouse retina
A RT-qPCR was performed on mouse neuroretinas to assess the expression levels of the whole
set of 87 mouse genes that encode the deubiquitinating enzymes belonging to the five afore-
mentioned families (11 JAMM, 4 MJD, 15 OTU, 4 UCH, and 53 USP genes). Two reference
genes, Rhodopsin and Cerkl, were included in the analysis due to their previously reported high
and low levels of expression in the mouse retina, respectively [29]. The relative expression lev-
els have been normalized to the expression of Gapdh, and the Z-score was calculated for the
whole set of genes per each sample, so that they could be directly compared among them and
between different samples. The results (mean and standard deviation of the Z-scores per each
gene) are plotted in Fig 1, ordered by DUB family. A Z-score of zero indicates the mean value
of expression for all the DUBs analyzed in the retina. Thus, genes with positive values have an
expression above the mean, whereas genes with negative values show less expression than the
mean (e.g. most USP genes).
The results showed that Prpf8 was the highest expressed gene from the JAMM subfamily,
followed by Eif3h and Psmd7. Both Atxn3 and Josd2 rendered the highest expression levels
within the MJD subfamily. Concerning the OTU subfamily, Otub1 and Tnfaip3 produced the
higher expression levels, followed by Otud7b, Vcpip1, Otud4 and Otud5; whereas the levels of
Otud6a were considered as negligible. Uchl1 was the most highly expressed gene from the
UCH family (and also with respect to all DUB genes), while Uchl3 and Uchl5 are lowly
expressed in the retina. Finally, the genes from the large USP subfamily showed the lowest level
of expression among all the DUB genes. Some USPs (20%) were highly expressed and showed
positive Z-scores (Usp5, Usp6, Usp10, Usp12, Usp19, Usp21, Usp22, Usp33, Usp47 and Usp52)
whereas 25% of the USPs showed lower levels than the mean (Usp8, Usp9Y, Usp17, Usp18,
Usp26, Usp27, Usp29, Usp35, Usp43, Usp44, Usp45,Usp50, and Usp51) (Fig 1).
Expression map of the DUBs in the mouse retina
Once the expression levels of all the DUB family members were assessed, we characterized and
compared their expression pattern within the different layers of the mouse retina. We first
decided to detect gene expression by mRNA localization using in situ hybridization (ISH) and
then performed fluorescent immunohistochemistry of selected proteins.
For ISH, antisense (AS) riboprobes against a large group of DUBs were used on mouse reti-
nal cryosections (Fig 2). As negative controls, the corresponding sense riboprobes (S) of each
gene were generated and hybridized in parallel using the same conditions (see S1 Fig). The
staining time was adjusted for each set of antisense/sense riboprobes so that a maximum signal
was obtained in the antisense retinal sections with minimum background in the sense counter-
parts (for instance, Prpf8 and Tnfaip3 in situs stained in much less time than Uchl5, Usp8 and
Usp18, which required half a day). Rhodopsin was used as a positive control because of the
reported high expression in the retina and its well-known localization in the inner segment of
the photoreceptors. The large USP subfamily contains 57 members in the mouse genome but
only a set of genes was considered for ISH. Representative ISH results are displayed in Fig 2.
Our selection criteria included genes with relevant ocular phenotypes in systematic knockdown
analyses of DUBs in Drosophila [9] and zebrafish [30].
Most DUBs are expressed ubiquitously throughout the layers of the murine retina, which
would be compatible with a general role in the neuronal cell metabolism and regulation and
thus, not restricted to particular retinal neurons. Nonetheless, specific patterns of expression
were detected for particular DUBs. For instance, a strong hybridization signal in the plexiform
DUB Retinal Expression, Phylogenetic and Phenotypic Analyses
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layers was observed for Uchl3, Uchl5, Usp2, Usp9X, including in some cases the inner segment
of the photoreceptor layer, as detected for Amsh, Josd3, Atxn3 and Usp47. Some DUBs appear
to be highly expressed in the GCL (Csn5, Poh1, Prpf8, Josd2, Otud1, Vcpip1, Usp11, Usp5 and
Usp19) in contrast to the pattern generated by Usp8, Usp13, Usp30, Usp45 and Usp54, which
yielded virtually no mRNA localization signal in the ganglion cells.
Several DUB genes of the USP family (Usp5, Usp13, Usp19 and Usp34) were previously
reported to be differentially expressed in the Retinal Pigmented Epithelium (RPE) by transcrip-
tome analysis [31]. To assess their specific pattern of expression, and given that pigmented
cells mask positive hybridization signals, we also performed ISH on albino retinas from CD-1
mice (S2 Fig). Although these four genes are expressed in this non-neuronal layer, their expres-
sion is not restricted to the RPE. In fact, Usp5 and Usp19 are very highly expressed throughout
the retina (Fig 2). Comparison of the retinal expression pattern for these four genes did not
show any detectable difference between C57BL/6J (wild-type black) and CD-1 (albino) mice
strains.
Several genes, namely Amsh-like, Brcc36, Jamm2,Mysm1 and Psmd7 (JAMM group) and
Otud3, Yod1, Zranb1 (OTU group), did not render reproducible and reliable ISHs, even though
several riboprobes spanning different gene regions were used. In most cases (e.g. Amsh-like,
Brcc36, Jamm2,Mysm1, and Otud3) we obtained very low levels of expression and the signal
was too faint to be distinguished from the negative control (sense riboprobe), or the sense and
antisense riboprobes both produced signals of similar intensity. The ISH results of these genes
are not included here.
Taking the ISH results together, we drew an atlas of expression for DUBs in the retina of
adult mouse. In general, all analyzed genes except Otud1 are expressed in the photoreceptors,
and their mRNAs are localized in a wide range of intensities in the inner segment (perinu-
clearly) and the outer plexiform layer. Among layers, the GCL showed the most different pat-
tern of gene expression. Notably, some DUBs, such as Usp45, Usp53 and Usp54, are only
detected in photoreceptors (PhR -inner segments, ONL (photoreceptor nuclei and perinuclei)
and OPL (photoreceptor synapsis), whereas nearly no hybridization could be detected in the
rest of retinal layers, which would suggest specific roles for these DUBs in this highly special-
ized photosensitive cells.
These ISH results prompted us to confirm and define more accurately protein localization
within the retinal cell layers by fluorescent immunohistochemistry, since in cells with a highly
specialized morphology, mRNA and protein localization might be different (e.g. the mRNA of
rhodopsin is localized in the ribosome-rich photoreceptor inner segment whereas the protein
is highly abundant in the membranous disks of the outer segment). We selected a group of
DUBs for immunohistochemistry based on: i) particular ISH patterns, ii) relevance for eye phe-
notype in animal models, iii) putative functional diversification in phylogenetically closely
related enzymes (see next section), and iv) antibody commercial availability and affinity. We
selected 21 DUBs (the list of genes is detailed in the Material and Methods), of which 14 immu-
nodetections rendered a reproducible and reliable signal (Fig 3 and S3 Fig).
Overall, the immunodetection confirms the ISH results since protein is detected in the same
retinal cells than mRNA (Fig 3). Comparing RT-qPCR to ISH and immunohistochemistry
results, high levels of retinal expression correlated with a ubiquitous expression pattern.
Fig 2. In situ hybridization of genes encoding DUB enzymes on retinal cryosections. Sections from wild-type C57BL/6J mouse retinas were hybridized
using digoxigenin-labelled antisense riboprobes. Their corresponding sense riboprobes (negative controls) stained for the same length of time (lower panels
in each row) are in the S1 Fig. The antisense Rhodopsin probe, which strongly labels the inner photoreceptor segment, was used as a positive control for the
assay.RPE- Retinal pigmented epithelium; Phr- Photoreceptor cell layer;ONL- Outer nuclear layer;OPL. Outer plexiform layer; INL- Inner nuclear layer,
IPL- Inner plexiform layer;GCL- Ganglion cell layer.
doi:10.1371/journal.pone.0150364.g002
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Besides, some protein locations are worth mentioning as indicative of distinct functions in spe-
cific cellular compartments. For instance, OTUD4 is strongly detected in the axonal processes
of bipolar and other retinal cells, supporting its involvement in neurodegeneration in human
[32]. USP25 is mainly detected in the inner plexiform and ganglion cell layer; while USP9X
and TNFAIP3 are particularly detected (but not exclusively) at the outer photoreceptor seg-
ment. Besides, USP22 is localized in the nucleus of ganglion cells, and perinuclearly in the rest
of retinal neurons. For details, merge and separate immunodetection images, see S3 Fig.
DUB phylogenetic analysis, protein domain architecture and neuronal
phenotypes
To provide a rational framework for gene expression patterns in extended families, it is crucial
to have an understanding of the origin and phylogenetic closeness between the different DUB
genes. Therefore, we performed a bioinformatic survey of DUB protein sequences across ani-
mal taxa. A recent phylogenetic analysis of the ubiquitin system across eukaryotes already
showed that a massive expansion of ubiquitin ligases and proteases, which involves innovation
and incorporation of new protein domains, occurred at the origin of animal multicellularity
[24]. This was likely associated with the diversity of proteins and protein roles in different cell
types. We here provide a comprehensive picture of the DUB families during the diversification
of metazoans, related to previously described neuronal function, with an emphasis on eye and
retinal phenotype.
Completely sequenced genomes from 14 species (from cnidarians to vertebrates) were que-
ried with the catalytic region of each enzyme family (as defined in Pfam) in search of orthologs.
Phylogenetic trees were generated using the retrieved sequences, and the statistical support for
each node is also indicated (Fig 4A, 4B, 4C, 4D and 4E). For the sake of clarity, protein nomen-
clature is according to human DUBs. Highly similar sequences that expanded recently (during
the pre-vertebrate/vertebrate expansion) and clustered together appear collapsed. The presence
of an identified ortholog in each species/clade is represented with a black dot. Vertebrate spe-
cies that present all the paralogs in a collapsed branch are circled in black. White dots mark the
presence of homologs that could not be confidently assigned to a characterized DUB type,
either because they are sister-group to various known DUB paralogs (and therefore represent
the pre-duplication homolog), or because statistical support is too low to confidently cluster
them with a specific ortholog. Question marks represent statistically supported clades that can-
not be assigned to any known DUB (or group of paralogous DUBs). Protein motifs (as defined
in Pfam) including the catalytic domain are drawn next to each branch to illustrate the diver-
sity/conservation in protein architecture within each family. For detailed and complete phylo-
genetic trees, see S3 File.
Notably, the phylogenetic distribution of OTU DUBs reveals two different groups that
appeared at the origin of eukaryotes OTUs with peptidase C65 domains (OTUB1 and OTUB2
in animals) and those with OTU domain [24] (Fig 4D). Given that i) these two catalytic
domains diverged long before the origin of metazoans, ii) OTUB1/B2 protein domain architec-
tures are clearly different from the other OTUs, iii) OTUB homologs are present in all meta-
zoan clades, and iv) this split does not occur in any other family of DUBs, a new classification
might be in order to acknowledge a new subfamily of DUBs.
Fig 3. Comparison of mRNA and protein immunodetection of selected DUBs in mouse retinal cryosections.Most analyzed genes render a consistent
expression pattern when comparing mRNA and protein localization in the wild type mouse retina. The merge immunohistochemistry show DUBs
immunodetected in red, and nuclei counter-staining with DAPI (in blue). Details in S3 Fig. RPE- Retinal pigmented epithelium; Phr- Photoreceptor cell layer;
ONL- Outer nuclear layer;OPL. Outer plexiform layer; INL- Inner nuclear layer, IPL- Inner plexiform layer;GCL- Ganglion cell layer.
doi:10.1371/journal.pone.0150364.g003
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The JAMM family has clear sequence assignment in all the analyzed animals, even though
some species have secondarily lost some DUB members, e.g. Acropora (cnidarian), C. elegans
(nematode), Drosophila (insect) Saccoglossus (hemichordate), and Petromyzon (sea lamprey,
an early-branching vertebrate). These species also show specific gene loss for other DUB fami-
lies, pointing to a divergent evolution in their lineages.
On the other hand, a clear expansion within each DUB family has occurred in the vertebrate
lineage (Figs 4 and 5). When these duplicated members have rapidly diverged, the DUB protein
sequences are in separate branches, but the common ancestry becomes evident since a single
ancestral ortholog is present in the rest of clades (white dots in Fig 4). This is the case within
the UCH (UCHL1 and UCHL3) and MJD families (JOSD1 and JOSD2). When the duplicated
sequences have diverged but still branch closely together in the phylogenetic tree, the vertebrate
paralogs have been collapsed into a single branch (black circles in Fig 4). This is particularly
evident for USPs, where we can identify a single ancestral sequence in all invertebrate clades
whereas several members are present in vertebrates (e.g. USP4/11/15. . .). Note that in the case
of USP 18/41, a duplication event occurred only in the case of humans; as it is a single-species
case, we have not included any black box on the figure. The ATXN3 gene deserves specific
mention, since its close paralog, ATXN3L, is a retrogene, that is, a gene generated by a very late
retrotransposition event within the primate lineage.
The DUB gene expansion in animal phylogeny is visually summarized in the heat map of
Fig 5. Color intensity reflects the number of genes per genome. It becomes evident that a burst
of gene expansion within all DUB families was at the basis of the vertebrate lineage. Nonethe-
less, the innovation in the protein architectures with the acquisition of new domains accompa-
nying the DUB catalytic signatures, pre-dates the origin of vertebrates in all the analyzed
families, as vertebrate-like domain arrangements are often identified in other animal clades.
To complement our DUB expression study in the retina and in order to suggest relevant
genes for hereditary visual disorders, we have compared the reported DUB mutant phenotypes
of several animal models and human diseases, and viewed them under our new phylogenetic
framework. We have specifically searched for early developmental lethality, neuronal pheno-
type and retinal alterations when available (Fig 4A, 4B, 4C, 4D and 4E). In the cases of neuronal
phenotype, there is an accompanying alteration in the eye. However, most phenotypic assess-
ment in the eye report only gross alterations, but a detailed retinal study has not yet been
described for most animal models. For a detailed phenotypic trait list, see S2 Table and refer-
ences therein.
In general, we observe that families with ancestral genes that have not been expanded in ver-
tebrates (particularly the JAMMs) have a ubiquitous expression profile in the retina, suggesting
a basic cell function. Moreover, mutations of these real orthologs produce consistent pheno-
types through the analyzed taxa, arguing in favor of functional and evolutionary conservation.
In contrast, for close paralog DUB genes arisen by duplication events in the vertebrate lineage,
Fig 4. Phylogenetic analysis of DUB genes and neuronal/retinal phenotype. Protein sequences from the catalytic region of each enzyme group were
queried in complete genome sequences of 14 animal taxa and aligned. The protein domain architectures including the catalytic and accessory domain motifs
are represented next to each DUBmember (A, JAMM; B, MJD; C, OTU; D, UCH; and D, USP). Black dots indicate presence of the ortholog, whereas white
dots indicate homologs that cannot be confidently assigned to a DUB type (see Results). Question marks represent statistically supported clades of
uncharacterized DUBs. DUB sequences that are highly similar and cluster closely together appear collapsed under a common name. In general,
invertebrates have a single representative member of the collapsed branch, whereas vertebrate genomes show one member of each paralog (species
circled in black). Acropora digitiferaUSP homologs were excluded from the analysis as they impaired the resolution of the USP phylogeny. Genes reported
to produce an abnormal neuronal phenotype when mutated are circled in magenta, whilst genes producing abnormal eye or retinal phenotype are circled in
green. Genes whose mutation is lethal during developmental stages are circled in blue. An schematic summary of the DUBmRNA localization in the mouse
retina (from ISH) is also presented next to the corresponding family. The intensity of the color indicates hybridization signal intensity. Retinal layers appear
indicated as in Fig 2.
doi:10.1371/journal.pone.0150364.g004
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different patterns of retinal gene expression are often observed. A good example is OTUD7A/B
(with one ancestral gene in most animals, and expanded in vertebrates), where OTUD7A is
more highly expressed in the GCL and plexiform layers, whereas OTUD7B is more expressed
in the photoreceptors. Similarly, UCHL3 and UCHL1 (both specific to vertebrates and associ-
ated to neuronal phenotypes) are expressed differently. Notably, UCHL3 (detected in the GCL
and photoreceptors by ISH and immunodetection) produces eye specific retinal alterations,
supporting subfunctionalization of these two paralogs. Other examples are included in the
discussion.
Discussion
The ubiquitin-proteasome system (UPS) is currently viewed as one of the most dynamic and
versatile cell regulators in eukaryotes. Perturbations of this system are known to be at the basis
of many human disorders, particularly cancer and neurodegeneration [5,33]. Due to their abil-
ity to deconjugate ubiquitin, DUBs play a major regulatory role in the UPS. The disruption of
DUB genes has dramatic consequences for the animal taxa analyzed, either during develop-
ment or in adult stages, as shown by reports of the systematic DUB knockdown in zebrafish
embryos and flies [9,30].
In mammals, several comprehensive surveys of DUBs have been reported resulting in: in sil-
ico inventories of the DUBs in the human genome [22,34]; identification of protein interactors
by cell-based proteomics analysis [8]; studies of subcellular localization [1]; functional involve-
ment in maintaining genome integrity in cells [35]. A recent review reported the expression
levels of DUBs in human organs and the disease phenotypes associated to DUB mutations in
humans and animal models [23]. Despite their importance, detailed expression and functional
Fig 5. Counts of classified DUB homologs. Heatmap representing the number of classified genes in each
analyzed genome. Increasing intensity reflects increasing number of genes. Only orthologs marked with
black dots in Fig 4 are considered. Acropora digitiferaUSP homologs, excluded from the phylogenetic
classification, are marked as not analyzed (NA).
doi:10.1371/journal.pone.0150364.g005
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analysis for most DUBs on particular tissues or organs, such as the retina, is still missing. We
here aimed to fill this gap and produced a descriptive landscape of the expression of the com-
plete set of DUBs in the mouse retina by combining mRNA and protein localization. We have
also delineated a detailed evolutionary history of the different DUB families using phylogenetic
analysis. We compared their protein domain architectures, and considered the neuronal and
retinal phenotypes associated to each gene mutation/knockdown. We thus provide a reference
framework for researchers interested in this visual tissue, either in physiological or in disease
conditions, and suggest new avenues of research in DUBs as excellent candidates for retinal/
visual hereditary disorders.
Differential levels of DUB gene expression in the adult mouse retina
Some genes that are barely expressed in the mouse retina (e.g. Brcc36, Poh1, Bap1, Otub2, and
Usp44) are reported to be induced in replicative cells instead, being recruited to DNA damage
sites where they regulate DNA repair and mitosis checkpoints [35]. These results are consistent
with the fact that the adult retina is mostly formed by differentiated cells.
Among the genes highly expressed in the adult retina, Uchl1, Atxn3, Otub1, Usp6, Usp22
and Usp33 are also highly expressed in the brain [23]. In fact, Uchl1, Otub1 and Atxn3 are
involved in neurodegenerative diseases in human, namely Parkinson's disease and cerebellar
ataxia [6,36], thus indicating a relevant role in neurodegeneration. Our ISH results showed
ubiquitous mRNA localization through all the retinal layers for these three genes, supporting a
possible basal function in the retina. On the other hand, other DUB genes that are highly
expressed in the brain [23], such asMysm1, Usp26, Usp29, Usp35 and Usp51, were barely
expressed in the adult mouse retina; and genes that showed very low levels of expression when
analyzed by qPCR within this work such as Usp2, Usp25, Usp45, Usp53 and Usp54 rendered eye
phenotype when knocked-down in zebrafish [30]. Note that we performed RT-qPCR in whole
adult neuroretinas at P60, and the role of these genes during development might be more rele-
vant than in the adult stage. It is also worth noting that Usp45, Usp53 and Usp54 did show layer
specificity, as they were mainly expressed in the photoreceptors (PhR inner segment, ONL and
OPL), suggesting a specific role for these genes in photoreceptors and underscoring their role
as potential candidates for visual disorders.
Immunohistochemical localizations also point to specific functions for some DUBs, e.g.
OTUD4 is highly localized in axons; TNFAIP3 is highly expressed in the photoreceptor outer
segment and GCL, and USP22 protein localization is mainly nuclear and perinuclear, thus sug-
gesting that these genes may be good candidates for particular retinal phenotypes.
Phenotypic comparison of DUB mutants and gene expression profiles
under the new evolutionary framework
Animal models have been generated by gene disruption (mouse) or knockdown (Drosophila,
zebrafish) for some DUBs. When the DUB function is extremely relevant for cell cycle or cell
differentiation, a lethal/early and extensive neuronal phenotype is consistently apparent in dif-
ferent organisms, as it is the case for most JAMMs and several USPs (see Fig 4 and S2 Table).
In vertebrates, when some mutants show neuronal/brain affectation, a retinal/eye phenotype is
also one of the accompanying phenotypic traits (examples are found in all the families). In fact,
multiple vertebrate USP genes are present in paralogs (probably arising from the several
rounds of genome duplication at the base of their linage), whereas their invertebrate relatives
have a single homolog (black boxes in Fig 4). Therefore, it is not surprising that most USP
knockdowns are lethal in Drosophila (where only a single member is present), whereas in verte-
brates, the mutant phenotype mostly affect specific tissues, probably related to the larger
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panoply of USP members and a higher functional diversification. For instance, in zebrafish the
knockdown of Usp33 (whose close relative homolog is Usp20) alters the nervous system devel-
opment including the eye [9], which is consistent with a reported subcellular localization asso-
ciated to microtubules and centrosomes; whereas the knockdown of the only member USP20/
33 in Drosophila is lethal. Something very similar occurs with the knockdown of Usp53 (whose
close relative homolog is Usp54), which affects brain and eye development in zebrafish,
whereas the knockdown of the single USP53/54 member is lethal in Drosophila (Fig 4B and S2
Table). For all the DUB families, orthologs share both high sequence similarities and consistent
mutant phenotypes in vertebrates; overall, pointing to their functional conservation and sup-
porting mouse and zebrafish models for assessing DUB roles in the human retina.
The knockdown phenotypes in different species are sometimes partially overlapping
between neuronal and retinal alterations, probably due to subfunctionalization of different
paralogs due to duplication events. For instance, Usp5 and Usp13 (encoding enzymes that
expanded and diverged in the vertebrate lineage, and sharing 59.5% amino acid identities in
human) showed a distinct pattern of expression in the mouse retina, with Usp5 being highly
expressed in the GCL in contrast to Usp13, which is barely expressed in this layer and the pro-
tein is mostly localized in the inner plexiform layer, thus indicating different roles despite
sequence similarity. The knockdown of any of them severely alters zebrafish embryonic devel-
opment and causes neurodegeneration (even though only the Usp5 knockdown showed a clear
eye phenotype), whereas in Drosophila the disruption of the single member Usp5/13 alters eye
development by increasing photoreceptor apoptosis, thus recapitulating neurodegeneration
and retinal phenotype. Similarly, the close paralogs Usp16 and Usp45 have a contrasting
expression pattern, with the former in GCL and plexiform layers, and the latter restricted to
the photoreceptor cell layer, supporting again subfunctionalization or neofunctionalization of
the vertebrate paralogs. Of note, the knockdown of Usp45 in zebrafish shows reduced eyes.
Interestingly, fat facets (the ortholog of Usp9X, involved in endocytosis in the Notch pathway)
limits the number of photoreceptors in Drosophila [37], while the human homolog USP9X has
been involved in neurodegeneration, mental retardation, epilepsy and autism, as well as in can-
cer [38], but not yet in visual disorders. Nonetheless, the strong immunodetection in the outer
segment of photoreceptors would indicate that it is also a good candidate for retinal
dystrophies.
Finally, the only DUB-related gene that has been directly involved in human inherited reti-
nal degeneration and causative of autosomal dominant Retinitis Pigmentosa is PRPF8, the
JAMM-family member with the highest level of expression in the retina. Notably, PRPF8
(which is not properly a DUB since it is catalytically inactive) forms part of the splicing
machinery [39]. Even though PRPF8 is a housekeeping gene, its haploinsufficiency might cause
a shift in the splicing patterns, which in turn alters the highly sensitive photoreceptors and trig-
gers their apoptosis. Knock-in mice bearing human missense mutations also display retinal
degeneration, thus strengthening the significance of this JAMM-gene in the retina [40].
Conclusions
In summary, our results show that data on the expression of the deubiquitinating enzyme gene
family cannot be directly extrapolated between tissues or organs since cell requirements might
be completely different, particularly in highly specialized and structured tissues, such as the ret-
ina. Therefore, in large families of seemingly redundant enzymes (such as DUBs) the integra-
tion of systematic expression maps together with a robust phylogenetic analysis and available
phenotypic information provides an insightful reference framework for further functional
characterization. This framework may be helpful for researchers working in the ubiquitin-
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related field as well as for those working in the molecular bases of neurological and retinal
disorders.
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Supplementary Figure 2. In situ hybridization of genes encoding DUB 
enzymes on CD-1 (albino) mouse retina cryosections, using digoxigenin-
labelled antisense riboprobes (top panels in each row) and their 
corresponding sense riboprobes (negative controls) stained for the same 
length of time (lower panels in each row). RPE- Retinal pigmented 
epithelium; Phr- Photoreceptor cell layer; ONL- Outer nuclear layer; 
OPL. Outer plexiform layer; INL- Inner nuclear layer, IPL- Inner 
plexiform layer; GCL- Ganglion cell layer.  
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- Zip file containing the dub catalytic domain sequences (per family) used for 
the phylogenetic analysis in fasta format. 
- Zip file containing the sequence alignments obtained per each DUB family. 
Zip file containing the complete phylogenetic trees with their 
corresponding bootstraps. 
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 Real Time qPCR In Situ Hybridization 
Family Gene Orientation Sequence (5’-3’) Gene Orientation Sequence (5’-3’) 
 Gapdh* Fw tgacaatgaatacggctacagcaa   
 Rv tactccttggaggccatgtagg 
 Rho Fw gcccttctccaacgtcacag Rho* Fw gcccttctccaacgtcacag 
 Rv gcagcttcttgtgctgtacgg Rv gcagcttcttgtgctgtacgg 
JAMM Amsh Fw attgttcaagagttcgggaagg Amsh Fw caccgagactacaaatcagctatc 
  Rv gggggccacatctacacaagg  Rv gggggccacatctacacaagg 
 Amsh-
like 
Fw gctgctatgcctgaccatacaga Amsh-
like 
Fw gagaacccagaggcccggacta 
  Rv gacctgaagtaacggcgtggggtg  Rv gacctgaagtaacggcgtggggtg 
 Brcc36 Fw gcggcgttctgacaagagaaagg Brcc36 Fw aacacaaagactggccgggta 
  Rv ataccagccaacaactctcatggg  Rv cgatgcaggaaccaaagcag 
 Csn5 Fw ttccgggagtggtatggcccag Csn5 Fw ttccgggagtggtatggcccag 
  Rv cgccgccaggatttctttcttgttg  Rv gtgtactaacatcaatcccggag 
 Eif3h Fw catgtttgaagaagtgccgattg Eif3h Fw NP 
  Rv gtgcttatccgccacagctgac  Rv NP 
 Jamm2 Fw cctgcctgaatgctgtaaagattg Jamm2 Fw cctgcctgaatgctgtaaagattg 
  Rv agtaagatggctgccagaattctgt  Rv tcctctcttacttctcctctgtg 
 Jamm3 Fw cctgttcctcgaggcctgt Jamm3 Fw tccatggcagctcccgagtct 
  Rv tcaatgtcctgcaagcaaggagggta  Rv ctcctccaacagcagttcttcc 
 Mysm1 Fw tgtctctgctctgtgccaactg Mysm1 Fw NP 
  Rv cacctctcctgctgagaaacca  Rv NP 
 Poh1 Fw acatgtggatgtcttatgacttca Poh1 Fw caatgctaatatgatggtcttgg 
  Rv gcgccactgacagctctctacgt  Rv gccactgacagctctctacg 
 Prpf8 Fw gcgtggaattacccctctgc Prpf8 Fw NP 
  Rv cacccgctgcttcgttactg  Rv NP 
 Psmd7 Fw  Psmd7 Fw NP 
  Rv  Amsh Rv NP 
MJD Atxn Fw gccctgtggagctatcctcaat Atxn Fw gccctgtggagctatcctcaat 
  Rv actcccccttctgccattctc  Rv gagggcactctgctctttcaga 
 Josd1 Fw ccatggtctctgcaggtctga Josd1 Fw ccatagtttgggacagagttggg 
  Rv tgctcaggattaacatgcaagc  Rv tgctcaggattaacatgcaagc 
 Josd2 Fw gtgcgaggtgctattggtggt Josd2 Fw gccgacgaaatctgcaagag 
  Rv gcagcagatcagcttgtgttca  Rv gcagcagatcagcttgtgttca 
 Josd3 Fw gaacaccaccttaaggaatgcttg Josd3 Fw ggcatcggatagagctggagat 
  Rv gtatttgtgcctccgactgtca  Rv gtatttgtgcctccgactgtca 
231 
OTU Otub1 Fw agcaggtggacaagcagacctc Otub1 Fw agcaggtggacaagcagacctc 
 Rv cagtcgcaggtagaccacaagg Rv cctctgtacatgtctagcgcc 
 Otub2 Fw gccacttaccttgccttgctgc Otub2 Fw acattctatccattcttcgggatca 
 Rv acagggtggtcccatggttatc Rv agaagtcagctcggttcctgatg 
 Otud1 Fw catggggcagatgctgaatgtg Otud1 Fw agaagctagccctgtacctgg 
 Rv ggcccagatagtggatcatgg Rv ggcccagatagtggatcatgg 
 Otud3 Fw gatgcggaggagaaccatga Otud3 Fw tccacatcgcctaccgctac 
  Rv tgccttcatttctgccctga  Rv tgccttcatttctgccctga 
 Otud4 Fw cctgttcccgtgtatcctcaga Otud4 Fw cctgttcccgtgtatcctcaga 
 Rv catcggtgcaaggacagtcac Rv tccaaaggcaaatccaattctcc 
 Otud5 Fw ctgagcaccctgaactgcat Otud5 Fw gcctaccgtcatttaagccagg 
 Rv tgaaggaggtttggcaagagcta Rv tgaaggaggtttggcaagagcta 
 Otud6a Fw cgagatggagcagaggcacaa Otud6a Fw NP 
 Rv gctgtaaccgaatccacactgc Rv NP 
 Otud6b Fw ccgggaagaaaggatagcagagg Otud6b Fw NP 
 Rv ggctgccaatatttgagcaagtt Rv NP 
 Otud7a Fw tctgacggattcggaacacaag Otud7a Fw cttgcacagccagagtctcc 
 Rv tggctaaccgggcattgtcg Rv ggcgacgctcccgacgc 
 Otud7b Fw atgatccagcgttaccttgcag Otud7b Fw gggcctgatgcacagcaagg 
 Rv ccctccattcatgatcttcctc Rv ccctccattcatgatcttcctc 
 Parp11 Fw tgctatccccatccagctttg Parp11 Fw NP 
 Rv tgcttcccaatttgagtgactg Rv NP 
 Tnfaip3 Fw ataatggattctgtgagcgttgc Tnfaip3 Fw tttgagcttgttcagcacgaatac 
 Rv gaaggcaggcttggcactttc Rv gaaggcaggcttggcactttc 
 Vcpip1 Fw atggggtgtgcctcaggaccttatt Vcip1 Fw gaaacgaagggaccgaagaatc 
 Rv ctgcaaacttctgtctcctccaa Rv tgctgctgaaagtgctgctta 
 Yod1 Fw cagcgtaacttccctgatccaga Yod1 Fw gaaggaccgaggccgagtc 
 Rv cttcatcagctaattccagtgcttg Rv cgggtagccaacgaggattc 
 Zranb1 Fw tcccagacctaataacattgaagca Zranb1 Fw ggtggaagtagtcctttgatatg 
 Rv ctccatcgagctctgtcttgctc Rv ctccatcgagctctgtcttgctc 
UCH Bap1 Fw tcctgggagtgggagtgacat Bap1 Fw ctgcttcctgagcattgaggag 
  Rv ctgcttcctgagcattgaggag  Rv gctgtgactcttgagatttgtg 
 Uch-l1 Fw gattaaccccgagatgctgaac Uch-l1 Fw cgcttcgccgacgtgctagg 
  Rv ggatggcactgagcccagag  Rv gcccatcgagctcgtacaga 
 Uch-l3 Fw tatgcgcgcagtgttactcctctt Uch-l3 Fw tatgcgcgcagtgttactcctctt 
  Rv tcgttccacaggcattgctgat  Rv ggcatcctctaacaacgtctcatc 
 Uch-l5 Fw agatgtgattcgacaagtgcacaa Uch-l5 Fw ggggtcttcaccgagctcat 
  Rv agatgtgattcgacaagtgcacaa  Rv agatgtgattcgacaagtgcacaa 
USP Usp1 Fw ggacaccattcaccgacaatag Usp1 Fw NP 
  Rv aacgcctgtttggtcactggat  Rv NP 
232 
 Usp2 Fw acctgaagcgattctcagaatc Usp2 Fw gatggtctccacaatgaggtg 
  Rv ctctcaagtccaggtctctta  Rv ctctcaagtccaggtctctta 
 Usp3 Fw ccgctggttccatttcaatgac Usp3 Fw NP 
  Rv ctggcctgacgctccacataa  Rv NP 
 Usp4 Fw tggtgaggacgatcagggaga Usp4 Fw NP 
  Rv aggagttcacgaggctgaagg  Rv NP 
 Usp5 Fw cacccatgctggacgaatccg Usp5 Fw cggatgagcccaaaggtagcct 
  Rv gccccgctgtttcccgtatag  Rv gccccgctgtttcccgtatag 
 Usp6 Fw cggaagtatctggagctgagc Usp6 Fw NP 
  Rv cagtccatctttcggcccttc  Rv NP 
 Usp7 Fw gatgatgacgtggtatccaggtg Usp7 Fw NP 
  Rv catataggcatttgtgcagtgtc  Rv NP 
 Usp8 Fw caacgagcacctggatgacc Usp8 Fw tatttggaggatcaggaccagc 
  Rv acgatgatggactcgttgagc  Rv acgatgatggactcgttgagc 
 Usp9X Fw ttaaaaggaaatggacctgggc Usp9X Fw tcaagaatgcagtcttcgatca 
  Rv gctttgcactggaggagacc  Rv gctttgcactggaggagacc 
 Usp9Y Fw gtggacttgggctatggaatgg Usp9Y Fw NP 
  Rv gtactggaggagaccagttgc  Rv NP 
 Usp10 Fw atgcccaggacttgtgacagc Usp10 Fw NP 
  Rv cctggcatcgcctcctagtg  Rv NP 
 Usp11 Fw gcctggcagaaccataaacgac Usp11 Fw NP 
  Rv cattgccacaatcagggcacac  Rv NP 
 Usp12 Fw accagcttcaccggtacacga Usp12 Fw NP 
  Rv ctgtcagggttggtcgcatct  Rv NP 
 Usp13 Fw cactggactggatcttcagcc Usp13 Fw tgatgaaccagttgatagaccc 
  Rv gcctcagacacgatgttggca  Rv gcctcagacacgatgttggca 
 Usp14 Fw atggaattgccatgtggattgac Usp14 Fw NP 
  Rv gggcatctttgagttcaggcac  Rv NP 
 Usp15 Fw cgcgcagtcacttaaggagca Usp15 Fw NP 
  Rv ccatcagtgtgtaccagctgac  Rv NP 
 Usp16 Fw agcacttgcgggagaagtgga Usp16 Fw NP 
  Rv ggccatccaaatccttctggtta  Rv NP 
 Usp17L8 Fw ctgccaatgacaagcccagtc Usp17L8 Fw NP 
  Rv cagggctgcattcaggtagca  Rv NP 
 Usp18 Fw acgcaggagtccctgatttgc Usp18 Fw NP 
  Rv cagaggctttgcgtccttatcaa  Rv NP 
 Usp19 Fw cctggctctggtgtggcgga Usp19 Fw NP 
  Rv cagcagagcctggatcttcagc  Rv NP 
 Usp20 Fw cggcatgaggtgatgtactcct Usp20 Fw tggctggccttcatcgtgg 
  Rv cagggacgtgcactccttgg  Rv cagggacgtgcactccttgg 
233 
 Usp21 Fw ccgagtgggagccaagatacc Usp21 Fw NP 
  Rv cctgggaggcaaaggtcgtaa  Rv NP 
 Usp22 Fw tctaccccattctggcccttg Usp22 Fw NP 
  Rv ttcgcaggcagtctgtgagag  Rv NP 
 Usp24 Fw gtgtgcccagacaggatgctc Usp24 Fw NP 
  Rv ggttctcctcccactcctgg  Rv NP 
 Usp25 Fw agagcagccatcaagaagtgac Usp25 Fw ccaccgggagagccggtggat 
  Rv atcttcaagatcatgtgacgcct  Rv atcttcaagatcatgtgacgcct 
 Usp26 Fw cgcaaggtggatccaacaaagt Usp26 Fw NP 
  Rv tagtggcctccattgggactg  Rv NP 
 Usp27X Fw tctggacttgcctggctcttg Usp27X Fw NP 
  Rv agtggtgatgcctgggatgtg  Rv NP 
 Usp28 Fw catgaggagtactccaggctct Usp28 Fw catgaggagtactccaggctct 
  Rv catgctgaaggcgagggtcac  Rv acaccaggtaggacaatgcttc 
 Usp29 Fw ccagcgcagaagtgaacaagg Usp29 Fw NP 
  Rv ttctctgctttgccgcctctg  Rv NP 
 Usp30 Fw ctgccacagtgcctctgcat Usp30 Fw actggaagtctcagcaccct 
  Rv aactgcacgtgctcgtgcc  Rv aactgcacgtgctcgtgcc 
 Usp31 Fw ctgacagagccagcgtcacct Usp31 Fw NP 
  Rv acgtgcttgccatccactctg  Rv NP 
 Usp32 Fw caccgactctgcctacattctt Usp32 Fw NP 
  Rv ctcgtgtccgccatcttcttg  Rv NP 
 Usp33 Fw tcctccgacctccagttgttc Usp33 Fw NP 
  Rv gtgtcctcagaactacaaagagc  Rv NP 
 Usp34 Fw atggcaggtttgacgactgt Usp34 Fw tgacgaaggagcaactcctgt 
  Rv tcggattcatcttcagctagtg  Rv tcggattcatcttcagctagtg 
 Usp35 Fw catggtggcctctctggtcaa Usp35 Fw NP 
  Rv agcccgggaaccgaaacacc  Rv NP 
 Usp36 Fw gcatcgacacgctcctccca Usp36 Fw gcatcgacacgctcctccca 
  Rv gcaccctcaccctccgagc  Rv ctcttcatcctgctgtggctc 
 Usp37 Fw agaggtgctggcagctgtgtt Usp37 Fw NP 
  Rv gtgtccggactgctggttgg  Rv NP 
 Usp38 Fw cagcttcgttacccagtgctca Usp38 Fw NP 
  Rv gacaaaggcagctgttgctgga  Rv NP 
 Usp39 Fw caagccgtccacaagaacacc Usp39 Fw NP 
  Rv tgatgaagcacgtggatcctg  Rv NP 
 Usp40 Fw ctgaggacacagctacgcatc Usp40 Fw NP 
  Rv tcaaggagccagcagtccatc  Rv NP 
 Usp41 Fw  Usp41 Fw NP 
  Rv   Rv NP 
234 
 Usp42 Fw acaacgtcgacttcccccagt Usp42 Fw NP 
  Rv tctgaggactcggccccatag  Rv NP 
 Usp43 Fw gactcgggagcctcaacaaca Usp43 Fw NP 
  Rv tggtgaagacaggagagtcgg  Rv NP 
 Usp44 Fw gagcccagttccccgtacag Usp44 Fw NP 
  Rv agcatggcaaacggtgagacc  Rv NP 
 Usp45 Fw agcctcactgacggcagcg Usp45 Fw agcctcactgacggcagcg 
  Rv aggctgcttggaagcgatc  Rv gacaggactggactgagcat 
 Usp46 Fw accgggtggtcttccctctg Usp46 Fw NP 
  Rv aacgaccacagcaaccaggtc  Rv NP 
 Usp47 Fw gtccatgtcacagcttgccatc Usp47 Fw gagagtacagagttaaagtgtgcc 
  Rv gctttccaacacaagctcctgg  Rv gctttccaacacaagctcctgg 
 Usp48 Fw gcagcagcaggatgcacaaga Usp48 Fw NP 
  Rv ctgctgcacaacattccgaaca  Rv NP 
 Usp49 Fw caggagcctggagctcattca Usp49 Fw NP 
  Rv cccacttcccagaccacatga  Rv NP 
 Usp50 Fw actttggagatctggatggtgg Usp50 Fw NP 
  Rv tcactgactcgggtgtcatcaa  Rv NP 
 Usp51 Fw gacctgggtagcagtgccaaa Usp51 Fw NP 
  Rv gaaagcaggccacaatcggtaa  Rv NP 
 Usp52 Fw cggaagtatctggagctgagc Usp52 Fw NP 
  Rv cagtccatctttcggcccttc  Rv NP 
 Usp53 Fw ggagtccatgcatgacccagg Usp53 Fw tgaacaactggacgggtagctg 
  Rv tgaacaactggacgggtagctg  Rv catctgtgagaactgctgggct 
 Usp54 Fw cacgtgcaacctgcctagaa Usp54 Fw gaagagagcactgtcgctgg 
  Rv tccagttcagaggtctcctgc  Rv tccagttcagaggtctcctgc 
 Cyld Fw tcccaggcagtgccgcatc Cyld Fw tcccaggcagtgccgcatc 
  Rv tgcttgatcttcccagctgag  Rv gaatgttgaagccattctgacc 
 
 
 JAMM 
 
D. melanogaster 67 D. rerio 80 M. musculus H. sapiens 
Neuronal 
phenotype 
Retinal 
phenotype 
Neuronal phenotype 
Retinal 
phenotype 
Neuronal phenotype 
Retinal 
phenotype 
Neuronal 
phenotype 
Retinal 
phenotype 
AMSH ND ND   
Loss of neurons in the 
hippocampus and 
cerebral cortex 81 
 
Microcephaly-
capillary 
malformation 
syndrome 
(OMIM) 
 
AMSH-
Like 
        
BRCC36 ND ND       
CSN5     
-/- homozygotes die 
soon after implantation 
and exhibit growth-
retardation, decrease in 
cell proliferation, and 
an increase in cell 
apoptosis. 
   
CSN6 Pupal death  
1dpf: cns necrosis, fused 
somite; 4dpf: small size and 
short body, small head, 
pericardial edema, unconsumed 
egg yolk with no yolk extension, 
shorten notochord length, 
dysmorphic axis, 
underdeveloped tail 
4dpf: small 
eyes 
-/- homozygotes are 
embryonic lethal 29 
   
EIF3H 
Pan-neural 
knockdown is 
       
 developmentally 
lethal 
JAMM2         
JAMM3         
MYSM1 ND ND 
1dpf: cns necrosis, curled tail 
developed; 3dpf: narrow head; 
closed otoliths, abnormal yolk 
shape with short yolk extension, 
abnormal notochord shape, 
slightly curled tail, ratty caudal 
fin 
3dpf: funny 
eyes shape 
    
POH1 Larval death        
PRPF8      
Retinal 
degeneration in 
heterozygotes, 
more severe in 
homozygotes 29 
 
autosomal 
dominant 
retinitis 
pigmentosa 
PSMD7   
1dpf: serious cns necrosis; 
2dpf: small and short body, 
underdeveloped head, 
preicardical edema, shorten 
notochord, thin trunk, fused 
somite, shorten and fatty tail, 
shorten yolk extension 
 
-/- homozygotes are 
embryonic lethal 29 
   
 
MJD 
 
D. melanogaster D. rerio M. musculus H. sapiens 
Neuronal 
phenotype 
Retinal 
phenotype 
Neuronal phenotype 
Retinal 
phenotype 
Neuronal phenotype 
Retinal 
phenotype 
Neuronal phenotype 
Retinal 
phenotype 
ATX3 ND ND 
1dpf: cns necrosis, fused 
somite; 3dpf: reduced 
body length, dysmorphic 
axis development, 
malformed and shorter tail 
   
Neurodegenerative 
disease SCA3 79 
 
JOSD1 ND ND 1dpf: serious cns necrosis, 3dpf: funny     
 slightly trunk and tail 
necrosis, fused somite, 
shorten tail; 3dpf: small 
head, strange yolk shape, 
abnormal notochord 
shape, irregular floorplate, 
hemorrhage at tail region, 
fused somite, shorten and 
curled tail 
eyes shape, 
abnormal 
retinotectal 
projection 
JOSD2   
1dpf: abnormal head 
shape, fused somite; 4dpf: 
small and short body, 
strange head shape, 
tectum enlarged, 
pericardial edema, 
unconsumed egg yolk, fat 
and short yolk extension, 
dysmorphic axis 
development, abnormal 
notochord shape, curled 
tail 
     
JOSD3 ND ND ND ND     
 
OTU 
 
D. melanogaster D. rerio M. musculus H. sapiens 
Neuronal 
phenotype 
Retinal 
phenotype 
Neuronal phenotype 
Retinal 
phenotype 
Neuronal phenotype 
Retinal 
phenotype 
Neuronal 
phenotype 
Retinal 
phenotype 
OTUB1   
1dpf: cns necrosis, fused 
somite; 2dpf: small and 
short body, round yolk 
shape with thin yolk 
extension, thin trunk, 
curled tail 
     
OTUB2 ND ND ND ND     
OTUD1 ND ND ND ND     
OTUD3 ND ND 
1dpf: slightly cns and 
trunk necrosis, fused 
     
 somite; 3dpf: serious 
dysmorphic 
development of axis and 
notochord, curled tail   
OTUD4   
1dpf: underdeveloped 
trunk; 3dpf: small and 
short body, reduced 
pigementation, cns 
necrosis,  dysmorphic 
notochord shape, thin 
trunk, slightly curled tail 
(Tse) 
3dpf: 
undeveloped 
eye (Tse). 
Reduction 
in size of the 
optic tecta 
and 
cerebellum 
(Margolin 
2013) 
  
Mutated, together 
with RNF216, in 
cerebellar ataxia 
and 
hypogonadotropic 
hypogonadism 
(Gordon Holmes 
syndrome) 70  
 
 
OTUD5   
1dpf: cns necrosis, fused 
somite; 3dpf: reduced 
pigement, small and 
short body, pericardial 
edema, thin and short 
yolk extension, slightly 
bent body 
 
Abnormal embryo turning and 
developmental patterning 29 
   
OTUD6a ND ND ND ND     
OTUD6b         
OTUD7a ND ND       
OTUD7b ND ND 
ND 
1dpf: underdeveloped 
trunk and notochord, 
fused somite; 3dpf: 
small and short body, 
slightly trunk necrosis, 
fused and curled tail 
ND     
PARPF11   
1dpf: cns necrosis, fused 
somite; 4dpf: strange 
head shape, small and 
short body, dysmorphic 
axis shape, thin trunk 
curled tail, ratty caudal 
     
 fin 
TNFAIP3 ND ND 
1dpf: trunk and tail 
necrosis; 4dpf: 
abnormal head shape, 
pericardial edema, axis 
and notochord 
problems, thin trunk, 
unconsumed egg yolk 
with no yolk extension, 
short and curled tail 
     
VCPIP1 ND ND 
1dpf: underdeveloped 
trunk and notochord, 
shorten and fused tail; 
4dpf: small and small 
body, small head, thin 
trunk, abnormal somite 
shape, curled and thin 
tail 
4dpf: small 
eyes 
    
YOD1   
No early phenotype; 
3dpf: short and edema 
body, pericardial 
edema, unconsumed 
egg yolk with fat and 
shorten yolk extension, 
underdeveloped liver 
and gut, abnormal axis 
and notochord shape, 
fused somite, short and 
curled tail 
     
ZRANB1 
Pharate adult 
and young adult 
death (Sokol) 
 
1dpf:fused somite, 
curled tail developed; 
3dpf: shorten body 
length, abnormal 
notochord shape, no 
yolk extension, curled 
tail 
     
 
 UCH 
 
D. melanogaster D. rerio M. musculus H. sapiens 
Neuronal 
phenotype 
Retinal 
phenotype 
Neuronal phenotype 
Retinal 
phenotype 
Neuronal phenotype 
Retinal 
phenotype 
Neuronal phenotype 
Retinal 
phenotype 
BAP1   
1dpf: serious cns and 
trunk necrosis, fused 
somite; 4dpf: 
hemorrhage in head, 
unconsumed egg yolk, 
abnormal notochord 
shape, curled tail 
 
-/- homozygotes are 
embryonic lethal(Clague) 
   
UCHL1 ND ND   Gracile axonal dystrophy 79  
Linked to PD and 
other diseases 
79Childhood-Onset 
Neurodegeneration 
With Optic Atrophy: 
Progressive visual loss 
due to optic atrophy at 
around age 5 years, 
followed by spasticity, 
cerebellar ataxia, 
peripheral neuropathy, 
and myokymia, 
consistent with 
systemic 
neurodegeneration 
and deficits at the 
neuromuscular 
junction (OMIM) 
 
UCHL3   
1dpf: slightly trunk 
necrosis, fused somite; 
3dpf: small and short 
body,  pericardial 
edema, fat and short 
yolk extension, 
abnormal notochord 
shape,  curled and 
malformed tail 
3dpf: 
reduced 
eye 
pigment 
Learning and working 
memory deficits 79  
Retinal 
degeneration 
79 
  
 UCHL5 
Pupal and pharate 
adult death (FUNC: 
NEUROGENESIS) 
 
1dpf: cns necrosis, 
abnormal head shape, 
fused somite; 4dpf: 
thick looking jaw, 
enlarged otolith, 
pericardial edema, thin 
yolk extension, slightly 
body bent and curled 
tail, ratty caudal fin 
 
Prenatal lethality, severely 
abnormal brain 
development 29 
   
 
USP 
 
D. melanogaster D. rerio M. musculus H. sapiens 
Neuronal 
phenotype 
Retinal 
phenotype 
Neuronal phenotype 
Retinal 
phenotype 
Neuronal phenotype 
Retinal 
phenotype 
Neuronal 
phenotype 
Retinal 
phenotype 
USP 1 
(Neuronal) 
Slower Adults  
 
No early phenotype; 
3dpf: abnormal 
notochord 
development, body 
bent, thin trunk and 
curved tail  
 
Elevated perinatal 
lethality, male 
infertility. Fancony 
anemia 29 
   
USP 2 
Pan-neuronal 
knockdown leads 
to reduced 
locomotion and 
earlier adult 
death 79 
      
Upregulated 
in high-
grade 
gliomas 79 
USP 3 ND ND 
1dpf: serious cns 
necrosis, fused somite; 
2dpf: small and short 
body, underdeveloped 
head, reduced 
pigmentation, enlarged 
tectum, thin trunk, 
body bent, abnormal 
notochord 
development, curled 
and fused tail 
2pdf: 
underdeveloped 
eyes 
    
 USP 4 ND ND 
ND 
1dpf: cns necrosis; 
2dpf: small and short 
body,  small head, 
unconsumed yolk with 
thin extension, 
notochord problem, 
curled tail 
ND 
2dpf: small eyes 
    
USP 5 
Pupal 
death(Sokol) 
 
1dpf: slightly cns 
necrosis, undeveloped 
trunk, fused tail; 2dpf: 
small and short body, 
abnormal head shape, 
percardial edema, 
dysmorphic axis shape, 
shorten notochord, 
trunk and tail necrosis, 
short and curled tail 
2dpf: 
underdeveloped 
small eyes 
-/- homozygotes are 
embryonic lethal 29 
   
USP 6 ND ND ND ND     
USP 7 
Pharate adult 
death 
 
1dpf: slightly cns 
damage; 2dpf: small 
and short body, small 
head, reduced 
pigment, "bud" on 
head, abnormal 
notochord 
development, fused 
tail, ratty caudal fin, ; 
3dpf: close otoliths, 
slightly percardial 
edema, unconsumed 
yolk in pear shape 
2dpf: small eyes 
-/- homozygotes are 
embryonic 
lethal(Clague). Brain 
specific knockdown 
causes brain 
malformation and 
neonatal lethality, due 
at least in part to p53-
dependent 
mechanisms. 79 
   
USP 8 Larval death  
1dpf: serious cns and 
truck necrosis, fused 
somite; 3dpf: small 
body, slightly cns 
necrosis, percardial 
edema, abnormal 
 
Brain development 
deficiencies in brain 
targeted knockout 
(Hausp fl/fl nes-Cre) 
mice   
   
 notochord 
development, fused 
somite, curled tail with 
ratty caudal fin 
USP 
9X 
  ND ND 
reduction in axonal 
length and 
arborisation, decrease 
in neuronal migration 
82 
 
Involved in 
neuronal fate 
specification and 
NMJ 
function.(Sokol?) 
patients with 
multiple myeloma 
overexpressing 
USP9X have a poor 
prognosis 83 
 
USP 
9Y 
ND ND ND ND     
USP 
10 
  
1dpf: cns necrosis, 
fused somite; 2dpf: 
small and short body, 
reduced pigment, thin 
trunk, body bent 
ventrically, curled tail, 
ratty caudal fin 
     
USP 
11 
ND ND       
USP 
12 
ND ND 
1dpf: cns and tail 
necrosis; 4dpf: slightly 
edema body, 
pericardial edema, 
unconsumed yolk,  
abnormal yolk shape 
with thin yolk 
extension, dysmorphic 
notochord and axis 
shape, curled tail 
     
USP 
13 
ND ND 
1dpf: cns necrosis, 
fused somite; 2dpf:  
     
 small and short body, 
reduced pigment, thin 
trunk, dysmorphic 
notochord shape, 
pericardial edema, 
slightly curled tail 
USP 
14 
(Neuronal)Slower 
adults, early 
death (Sokol) 
   
Mutations in intron 
leads to redyced USP14 
leves. Tremors, 
abnormal brain 
morphology, altered 
synaptic transmission 
and increased 
apoptosis. 29 
   
USP 
15 
ND ND 
1dpf: cns necrosis, 
fused somite; 2dpf: 
underdeveloped head 
and trunk, axis and 
notochord problems, 
pericardial edema, 
fused somite, short and 
slightly curled tail; 
4dpf: unshaped head; 
body edema, round 
shape unconsumed 
yolk, underdeveloped 
liver and gut, tail 
slightly necrosis 
2dpf: small eyes 
4dpf: unshaped 
eyes 
    
USP 
16 
ND ND   
reduces the self-
renewal of 
hematopoietic stem 
cells and the expansion 
of mammary epithelial 
cells, neuroprogenitors, 
and fibroblasts 84 
 
overexpression of 
USP16 reduces the 
expansion of 
normal fibroblasts 
and postnatal 
neural progenitors, 
whereas 
downregulation of 
USP16 partially 
rescues the 
 
 proliferation defects 
of Down syndrome 
84 
USP 
17 
ND ND ND ND     
USP 
18 
ND ND 
1dpf: cns and tail 
necrosis, fused somite; 
2dpf: underdeveloped 
trunk, tail necrosis; 
3dpf: small and short 
body, small head, thin 
trunk, shorten 
notochord length, 
serious pericardial 
edema, unconsumed 
yolk with short yolk 
extensionshorten, short 
and curved tail 
3dpf: small eyes 
Tremors, seizures, 
abnormal nervous 
system, death 29 
   
USP 
19 
ND ND 
1dpf: slightly cns 
necrosis, fused somite; 
2dpf: small and short 
body, reduced 
pigement, small head, 
shorten notochord 
length, pericardial 
edema, short and 
curled tail with slightly 
necrosis (with 
"buds"), 
2dpf: small eyes     
USP 
20 
Earlier adulth 
death  
 
1dpf: cns necrosis, 
fused somite; 2dpf: 
small and short body, 
reduced pigment, 
"buds" on the 
pericardial and yolk 
area,  tail necrosis; 
3dpf: small head, 
precardial edema, 
3dpf: small eyes     
 "buds" (necrosis) on 
the precardical area, 
unconsumed yolk with 
short extension, curled 
tail with slightly 
necrosis at the end   
USP 
21 
ND ND 
1dpf: mild necrosis 
throughout the body; 
3dpf:  underdeveloped 
head, small head, 
abnormal axis and 
notochord 
development, trunk 
necrosis, pericardial 
edema, roundly and 
unconsumed yolk with 
no yolk extension, no 
tail 
3dpf: small eyes     
USP 
22 
 
Axonal 
projection of 
photoreceptor 
cells 79 
 
No early phenotype at 
1dpf; 2dpf: inflated 
brain 
 
-/- homozygotes are 
embryonic lethal 29 
   
USP 
24 
ND ND 
1dpf: body necrosis, 
fused somite; 2dpf: 
small and short body, 
cns necrosis became 
more seriously, 
abnormal notochord 
development, thin 
trunk, fat and short 
yolk extension, curled 
short tail with necrosis 
2dpf: abnormal 
eyes 
  
May be involved in 
PD susceptibility 79 
 
USP 
25 
ND ND 
1dpf: cns and tail 
necrosis; 2dpf: small 
and short body, 
unshaped head, cns 
necrosis, bulging 
2dpf: unshaped 
eyes 
  
Overexpressed in 
Down Syndrome 
brains 79 
 
 forebrain, thin trunk, 
fused somite, tail 
necrosis 
USP 
26 
ND ND ND ND     
USP 
27 
ND ND ND ND     
USP 
28 
ND ND 
ND 
1dpf: head damage, 
fused somite; 2dpf: 
serious cns necrosis, 
reduced pigment, 
notochord and axis 
underdevelopment, 
thin trunk, shorten and 
curved tail 
ND     
USP 
29 
ND ND ND ND     
USP 
30 
Knockdown of 
Usp30 in 
dopaminergic 
neurons protects 
flies against 
paraquat toxicity 
in vivo, 
ameliorating 
defects in 
dopamine levels, 
motor function, 
and organismal 
survival. 85 
       
USP 
31 
ND ND       
USP 
32 
        
USP 
33 
ND ND 
1dpf: cns necrosis; 
3dpf: small and short 
3dpf: small eyes 
in cultured mouse 
embryonic 
 
Regulates axonal 
pathfinding during 
 
 body, small head, 
notochord 
development problem, 
curled tail 
commissural axons and 
was required for 
growth cone collapse 
in response to Slit 
exposure 86  
development 79 
(AQUI??))  
USP 
34 
Pan neuronal 
knockdown is 
developmentaly 
lethal 79 
       
USP 
35 
  ND ND     
USP 
36 
Larval death   
1dpf: slightly cns 
necrosis;  3dpf: small 
and short body, 
reduced pigment, very 
thin trunk, pericardial 
edema, funny yolk 
shape with fat yolk 
extension,  curled tail 
     
USP 
37 
ND ND 
1dpf: cns necrosis; 
3dpf: small and short 
body, small head, 
tectum enlargement, 
pericardial edema, 
round yolk shape, thin 
trunk, notochord 
problem, shorten and 
slightly curled tail 
3dpf: small eyes     
USP 
38 
ND ND       
USP 
39 
Larval death   
1dpf: cns and tail 
necrosis, 2dpf: small 
and short body, small 
head, slightly 
pericardial edema, 
dysmorphic notochord 
development, fused 
2dpf: small eyes     
 somite, curled tail 
USP 
40 
ND ND     
May be involved in 
PD susceptibility 79 
 
USP 
41 
ND ND ND ND     
USP 
42 
ND ND 
1dpf: slightly cns 
necrosis, fused somite; 
3dpf: inflated 
hindbrain, slightly 
pericardial edema and 
body bent 
     
USP 
43 
  
1dpf: slightly cns 
necrosis, fused somite; 
2dpf: small and short 
body, reduced 
pigment, small head, 
bulging forebrain, 
pericardial edema, 
curled tail 
2dpf: small eyes      
USP 
44 
ND ND 
1dpf: abnormal 
development, cns and 
tail necrosis, fused 
somite; 3dpf: very 
small and short body, 
underdeveloped head 
and trunk, shorten 
notochord length, axis 
development problem, 
serious pericardial 
edema, unconsumed 
round yolk with short 
yolk extension, short 
and curled tail 
     
USP 
45 
Pupal, pharate 
adult and young 
adult death 
 
1dpf: cns necrosis; 
2dpf: reduced pigment, 
a bit smaller head, 
close otolith distance, 
2dpf: reduced 
eyes 
    
 slightly pericardial 
edema, thin yolk 
extension 
USP 
46 
    
role in the GABAergic 
neurotransmission 87  
   
USP 
47 
        
USP 
48 
ND ND 
No early phenotype; 
3dpf: small and short 
body, reduced 
pigement, small head, 
pericardial edema, 
body bent, slightly tail 
necrosis 
3dpf: small eyes     
USP 
49 
ND ND ND ND     
USP 
50 
ND ND ND ND     
USP 
51 
ND ND ND ND     
USP 
52 
  ND ND     
USP 
53 
ND ND 
No early phenotype at 
1dpf; 3dpf: small and 
short body, reduced 
pigment, small head, 
inflated brain, 
notochord problem, 
curled tail 
3dpf: small eyes     
USP 
54 
Pharate adult and 
young adult 
death  
       
CYLD   
1dpf: cns necrosis; 
2dpf: small and short 
body,  strange head 
shape, thinner 
mid/hidbrain 
1dpf: small eyes 
(Cyldb) 
    
 boundary, midbrain 
enlargement, round 
yolk shape with thin 
extension, slightly axis 
and notochord 
problem, curled tail 
 
1dpf: cns necrosis, 
trunk necrosis; 2dpf: 
small and short body, 
small head, necrosis 
spread through the 
body, pericardial 
edema, thin trunk, 
notochord problem, 
body bent 
 
 
   
  
 
 
 
 
 
Annex II 
   
255 
 
 
Accession Description 
Pr
ote
ins 
Uniqu
e 
Peptid
es 
Pe
pti
des 
A
A
s 
MW 
[kD
a] 
P09651 Heterogeneous nuclear ribonucleoprotein A1 OS=Homo 
sapiens GN=HNRNPA1 PE=1 SV=5 - [ROA1_HUMAN] 
1 22 26 3
7
2 
38,7 
P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo 
sapiens GN=HNRNPA2B1 PE=1 SV=2 - 
[ROA2_HUMAN] 
1 19 22 3
5
3 
37,4 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens 
GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 
1 33 37 5
8
4 
58,8 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens 
GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 
1 28 37 6
3
9 
65,4 
P04264 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 
PE=1 SV=6 - [K2C1_HUMAN] 
1 32 35 6
4
4 
66,0 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 
PE=1 SV=3 - [K1C9_HUMAN] 
1 27 28 6
2
3 
62,0 
P02769 SWISS-PROT:P02769 (Bos taurus) Bovine serum albumin 
precursor 
1 29 29 6
0
7 
69,2 
P31942 Heterogeneous nuclear ribonucleoprotein H3 OS=Homo 
sapiens GN=HNRNPH3 PE=1 SV=2 - [HNRH3_HUMAN] 
1 13 13 3
4
6 
36,9 
Q15717 ELAV-like protein 1 OS=Homo sapiens GN=ELAVL1 
PE=1 SV=2 - [ELAV1_HUMAN] 
1 12 12 3
2
6 
36,1 
P12004 Proliferating cell nuclear antigen OS=Homo sapiens 
GN=PCNA PE=1 SV=1 - [PCNA_HUMAN] 
1 14 14 2
6
1 
28,8 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 
PE=1 SV=3 - [K2C5_HUMAN] 
1 12 23 5
9
0 
62,3 
P02538 Keratin, type II cytoskeletal 6A OS=Homo sapiens 
GN=KRT6A PE=1 SV=3 - [K2C6A_HUMAN] 
2 11 24 5
6
4 
60,0 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens 
GN=KRT14 PE=1 SV=4 - [K1C14_HUMAN] 
1 8 21 4
7
2 
51,5 
P07195 L-lactate dehydrogenase B chain OS=Homo sapiens 
GN=LDHB PE=1 SV=2 - [LDHB_HUMAN] 
1 14 15 3
3
4 
36,6 
P51991 Heterogeneous nuclear ribonucleoprotein A3 OS=Homo 
sapiens GN=HNRNPA3 PE=1 SV=2 - [ROA3_HUMAN] 
1 16 18 3
7
8 
39,6 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens 
GN=KRT16 PE=1 SV=4 - [K1C16_HUMAN] 
1 8 21 4
7
51,2 
256 
3 
Q99623 Prohibitin-2 OS=Homo sapiens GN=PHB2 PE=1 SV=2 - 
[PHB2_HUMAN] 
1 16 16 2
9
9 
33,3 
P63244 Guanine nucleotide-binding protein subunit beta-2-like 1 
OS=Homo sapiens GN=GNB2L1 PE=1 SV=3 - 
[GBLP_HUMAN] 
1 16 16 3
1
7 
35,1 
P00338 L-lactate dehydrogenase A chain OS=Homo sapiens 
GN=LDHA PE=1 SV=2 - [LDHA_HUMAN] 
1 14 15 3
3
2 
36,7 
Q9P015 39S ribosomal protein L15, mitochondrial OS=Homo sapiens 
GN=MRPL15 PE=1 SV=1 - [RM15_HUMAN] 
1 16 16 2
9
6 
33,4 
P46777 60S ribosomal protein L5 OS=Homo sapiens GN=RPL5 
PE=1 SV=3 - [RL5_HUMAN] 
1 12 12 2
9
7 
34,3 
P07437 Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 
SV=2 - [TBB5_HUMAN] 
1 4 13 4
4
4 
49,6 
P61247 40S ribosomal protein S3a OS=Homo sapiens GN=RPS3A 
PE=1 SV=2 - [RS3A_HUMAN] 
1 16 16 2
6
4 
29,9 
Q13151 Heterogeneous nuclear ribonucleoprotein A0 OS=Homo 
sapiens GN=HNRNPA0 PE=1 SV=1 - [ROA0_HUMAN] 
1 9 10 3
0
5 
30,8 
P61978 Heterogeneous nuclear ribonucleoprotein K OS=Homo 
sapiens GN=HNRNPK PE=1 SV=1 - [HNRPK_HUMAN] 
1 12 12 4
6
3 
50,9 
P06576 ATP synthase subunit beta, mitochondrial OS=Homo sapiens 
GN=ATP5B PE=1 SV=3 - [ATPB_HUMAN] 
1 11 11 5
2
9 
56,5 
P68371 Tubulin beta-4B chain OS=Homo sapiens GN=TUBB4B 
PE=1 SV=1 - [TBB4B_HUMAN] 
1 4 13 4
4
5 
49,8 
P21796 Voltage-dependent anion-selective channel protein 1 
OS=Homo sapiens GN=VDAC1 PE=1 SV=2 - 
[VDAC1_HUMAN] 
1 13 14 2
8
3 
30,8 
O75569 Interferon-inducible double-stranded RNA-dependent protein 
kinase activator A OS=Homo sapiens GN=PRKRA PE=1 
SV=1 - [PRKRA_HUMAN] 
1 12 12 3
1
3 
34,4 
Q9BYD6 39S ribosomal protein L1, mitochondrial OS=Homo sapiens 
GN=MRPL1 PE=1 SV=2 - [RM01_HUMAN] 
1 12 12 3
2
5 
36,9 
P60891 Ribose-phosphate pyrophosphokinase 1 OS=Homo sapiens 
GN=PRPS1 PE=1 SV=2 - [PRPS1_HUMAN] 
1 3 10 3
1
8 
34,8 
P11908 Ribose-phosphate pyrophosphokinase 2 OS=Homo sapiens 
GN=PRPS2 PE=1 SV=2 - [PRPS2_HUMAN] 
1 2 9 3
1
8 
34,7 
P62873 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit 
beta-1 OS=Homo sapiens GN=GNB1 PE=1 SV=3 - 
[GBB1_HUMAN] 
1 5 12 3
4
0 
37,4 
O60506 Heterogeneous nuclear ribonucleoprotein Q OS=Homo 
sapiens GN=SYNCRIP PE=1 SV=2 - [HNRPQ_HUMAN] 
1 13 13 6
2
69,6 
257 
 
3 
P11940 Polyadenylate-binding protein 1 OS=Homo sapiens 
GN=PABPC1 PE=1 SV=2 - [PABP1_HUMAN] 
1 6 11 6
3
6 
70,6 
P19387 DNA-directed RNA polymerase II subunit RPB3 OS=Homo 
sapiens GN=POLR2C PE=1 SV=2 - [RPB3_HUMAN] 
1 8 8 2
7
5 
31,4 
P02662 SWISS-PROT:P02662 Alpha-S1-casein - Bos taurus (Bovine). 1 5 5 1
9
9 
23,0 
P35637 RNA-binding protein FUS OS=Homo sapiens GN=FUS 
PE=1 SV=1 - [FUS_HUMAN] 
1 6 6 5
2
6 
53,4 
P62879 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit 
beta-2 OS=Homo sapiens GN=GNB2 PE=1 SV=3 - 
[GBB2_HUMAN] 
1 3 9 3
4
0 
37,3 
Q01081 Splicing factor U2AF 35 kDa subunit OS=Homo sapiens 
GN=U2AF1 PE=1 SV=3 - [U2AF1_HUMAN] 
1 7 7 2
4
0 
27,9 
P31943 Heterogeneous nuclear ribonucleoprotein H OS=Homo 
sapiens GN=HNRNPH1 PE=1 SV=4 - [HNRH1_HUMAN] 
1 6 8 4
4
9 
49,2 
ENSEMBL:E
NSBTAP0000
0024466 
(Bos taurus) 44 kDa protein 1 8 8 4
0
1 
43,9 
ENSEMBL:E
NSBTAP0000
0016242 
(Bos taurus) similar to alpha-tubulin I isoform 1 2 8 8 4
5
1 
50,1 
Q9UNP9 Peptidyl-prolyl cis-trans isomerase E OS=Homo sapiens 
GN=PPIE PE=1 SV=1 - [PPIE_HUMAN] 
1 9 9 3
0
1 
33,4 
P00761 
SWISS-
PROT:P00761 
Trypsin - Sus scrofa (Pig). - [TRYP_PIG] 1 6 6 2
3
1 
24,4 
O14979 Heterogeneous nuclear ribonucleoprotein D-like OS=Homo 
sapiens GN=HNRNPDL PE=1 SV=3 - 
[HNRDL_HUMAN] 
1 8 10 4
2
0 
46,4 
Q13765 Nascent polypeptide-associated complex subunit alpha 
OS=Homo sapiens GN=NACA PE=1 SV=1 - 
[NACA_HUMAN] 
2 6 6 2
1
5 
23,4 
Q99729 Heterogeneous nuclear ribonucleoprotein A/B OS=Homo 
sapiens GN=HNRNPAB PE=1 SV=2 - [ROAA_HUMAN] 
1 8 9 3
3
2 
36,2 
Q9H9J2 39S ribosomal protein L44, mitochondrial OS=Homo sapiens 
GN=MRPL44 PE=1 SV=1 - [RM44_HUMAN] 
1 11 11 3
3
2 
37,5 
Q15014 Mortality factor 4-like protein 2 OS=Homo sapiens 
GN=MORF4L2 PE=1 SV=1 - [MO4L2_HUMAN] 
1 9 9 2
8
8 
32,3 
Q96AG4 Leucine-rich repeat-containing protein 59 OS=Homo sapiens 
GN=LRRC59 PE=1 SV=1 - [LRC59_HUMAN] 
1 10 10 3
0
7 
34,9 
P07910 Heterogeneous nuclear ribonucleoproteins C1/C2 OS=Homo 
sapiens GN=HNRNPC PE=1 SV=4 - [HNRPC_HUMAN] 
1 8 8 3
0
33,6 
258 
6 
P38159 RNA-binding motif protein, X chromosome OS=Homo 
sapiens GN=RBMX PE=1 SV=3 - [RBMX_HUMAN] 
1 10 10 3
9
1 
42,3 
Q01844 RNA-binding protein EWS OS=Homo sapiens GN=EWSR1 
PE=1 SV=1 - [EWS_HUMAN] 
1 6 6 6
5
6 
68,4 
Q13310 Polyadenylate-binding protein 4 OS=Homo sapiens 
GN=PABPC4 PE=1 SV=1 - [PABP4_HUMAN] 
1 3 8 6
4
4 
70,7 
P14866 Heterogeneous nuclear ribonucleoprotein L OS=Homo 
sapiens GN=HNRNPL PE=1 SV=2 - [HNRPL_HUMAN] 
1 9 9 5
8
9 
64,1 
Q15181 Inorganic pyrophosphatase OS=Homo sapiens GN=PPA1 
PE=1 SV=2 - [IPYR_HUMAN] 
1 5 6 2
8
9 
32,6 
Q14103 Heterogeneous nuclear ribonucleoprotein D0 OS=Homo 
sapiens GN=HNRNPD PE=1 SV=1 - [HNRPD_HUMAN] 
1 6 8 3
5
5 
38,4 
P13804 Electron transfer flavoprotein subunit alpha, mitochondrial 
OS=Homo sapiens GN=ETFA PE=1 SV=1 - 
[ETFA_HUMAN] 
1 7 7 3
3
3 
35,1 
Q07021 Complement component 1 Q subcomponent-binding protein, 
mitochondrial OS=Homo sapiens GN=C1QBP PE=1 SV=1 
- [C1QBP_HUMAN] 
1 5 5 2
8
2 
31,3 
Q9HAV0 Guanine nucleotide-binding protein subunit beta-4 
OS=Homo sapiens GN=GNB4 PE=1 SV=3 - 
[GBB4_HUMAN] 
1 4 8 3
4
0 
37,5 
P09493 Tropomyosin alpha-1 chain OS=Homo sapiens GN=TPM1 
PE=1 SV=2 - [TPM1_HUMAN] 
1 3 7 2
8
4 
32,7 
Q9BRJ2 39S ribosomal protein L45, mitochondrial OS=Homo sapiens 
GN=MRPL45 PE=1 SV=2 - [RM45_HUMAN] 
1 8 8 3
0
6 
35,3 
P43307 Translocon-associated protein subunit alpha OS=Homo 
sapiens GN=SSR1 PE=1 SV=3 - [SSRA_HUMAN] 
1 4 4 2
8
6 
32,2 
P67936 Tropomyosin alpha-4 chain OS=Homo sapiens GN=TPM4 
PE=1 SV=3 - [TPM4_HUMAN] 
1 3 6 2
4
8 
28,5 
P68104 Elongation factor 1-alpha 1 OS=Homo sapiens 
GN=EEF1A1 PE=1 SV=1 - [EF1A1_HUMAN] 
2 8 8 4
6
2 
50,1 
Q9GZS3 WD repeat-containing protein 61 OS=Homo sapiens 
GN=WDR61 PE=1 SV=1 - [WDR61_HUMAN] 
1 6 6 3
0
5 
33,6 
P06753 Tropomyosin alpha-3 chain OS=Homo sapiens GN=TPM3 
PE=1 SV=2 - [TPM3_HUMAN] 
1 2 6 2
8
5 
32,9 
Q9BQ75 Protein CMSS1 OS=Homo sapiens GN=CMSS1 PE=1 
SV=2 - [CMS1_HUMAN] 
1 6 6 2
7
9 
31,9 
P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 
SV=1 - [ACTB_HUMAN] 
2 8 8 3
7
41,7 
259 
 
5 
P62753 40S ribosomal protein S6 OS=Homo sapiens GN=RPS6 
PE=1 SV=1 - [RS6_HUMAN] 
1 5 5 2
4
9 
28,7 
P23396 40S ribosomal protein S3 OS=Homo sapiens GN=RPS3 
PE=1 SV=2 - [RS3_HUMAN] 
1 6 6 2
4
3 
26,7 
Q13243 Serine/arginine-rich splicing factor 5 OS=Homo sapiens 
GN=SRSF5 PE=1 SV=1 - [SRSF5_HUMAN] 
1 6 6 2
7
2 
31,2 
P09001 39S ribosomal protein L3, mitochondrial OS=Homo sapiens 
GN=MRPL3 PE=1 SV=1 - [RM03_HUMAN] 
1 8 8 3
4
8 
38,6 
P45880 Voltage-dependent anion-selective channel protein 2 
OS=Homo sapiens GN=VDAC2 PE=1 SV=2 - 
[VDAC2_HUMAN] 
1 7 8 2
9
4 
31,5 
O95983 Methyl-CpG-binding domain protein 3 OS=Homo sapiens 
GN=MBD3 PE=1 SV=1 - [MBD3_HUMAN] 
1 5 5 2
9
1 
32,8 
P52597 Heterogeneous nuclear ribonucleoprotein F OS=Homo 
sapiens GN=HNRNPF PE=1 SV=3 - [HNRPF_HUMAN] 
1 2 4 4
1
5 
45,6 
P05388 60S acidic ribosomal protein P0 OS=Homo sapiens 
GN=RPLP0 PE=1 SV=1 - [RLA0_HUMAN] 
1 5 5 3
1
7 
34,3 
P15880 40S ribosomal protein S2 OS=Homo sapiens GN=RPS2 
PE=1 SV=2 - [RS2_HUMAN] 
1 5 5 2
9
3 
31,3 
Q01085 Nucleolysin TIAR OS=Homo sapiens GN=TIAL1 PE=1 
SV=1 - [TIAR_HUMAN] 
1 4 6 3
7
5 
41,6 
Q9UNQ2 Probable dimethyladenosine transferase OS=Homo sapiens 
GN=DIMT1 PE=1 SV=1 - [DIM1_HUMAN] 
1 7 7 3
1
3 
35,2 
Q8WXX5 DnaJ homolog subfamily C member 9 OS=Homo sapiens 
GN=DNAJC9 PE=1 SV=1 - [DNJC9_HUMAN] 
1 5 5 2
6
0 
29,9 
O00743 Serine/threonine-protein phosphatase 6 catalytic subunit 
OS=Homo sapiens GN=PPP6C PE=1 SV=1 - 
[PPP6_HUMAN] 
1 5 5 3
0
5 
35,1 
P31483 Nucleolysin TIA-1 isoform p40 OS=Homo sapiens 
GN=TIA1 PE=1 SV=3 - [TIA1_HUMAN] 
1 3 5 3
8
6 
42,9 
O14579 Coatomer subunit epsilon OS=Homo sapiens GN=COPE 
PE=1 SV=3 - [COPE_HUMAN] 
1 3 3 3
0
8 
34,5 
Q00403 Transcription initiation factor IIB OS=Homo sapiens 
GN=GTF2B PE=1 SV=1 - [TF2B_HUMAN] 
1 3 3 3
1
6 
34,8 
Q9Y314 Nitric oxide synthase-interacting protein OS=Homo sapiens 
GN=NOSIP PE=1 SV=1 - [NOSIP_HUMAN] 
1 6 6 3
0
1 
33,2 
P19623 Spermidine synthase OS=Homo sapiens GN=SRM PE=1 
SV=1 - [SPEE_HUMAN] 
1 5 5 3
0
33,8 
260 
2 
Q9H2U2 Inorganic pyrophosphatase 2, mitochondrial OS=Homo 
sapiens GN=PPA2 PE=1 SV=2 - [IPYR2_HUMAN] 
1 3 4 3
3
4 
37,9 
O43186 Cone-rod homeobox protein OS=Homo sapiens GN=CRX 
PE=1 SV=1 - [CRX_HUMAN] 
1 5 5 2
9
9 
32,2 
P50402 Emerin OS=Homo sapiens GN=EMD PE=1 SV=1 - 
[EMD_HUMAN] 
1 5 5 2
5
4 
29,0 
Q6ZN17 Protein lin-28 homolog B OS=Homo sapiens GN=LIN28B 
PE=1 SV=1 - [LN28B_HUMAN] 
1 5 5 2
5
0 
27,1 
Q07955 Serine/arginine-rich splicing factor 1 OS=Homo sapiens 
GN=SRSF1 PE=1 SV=2 - [SRSF1_HUMAN] 
1 4 4 2
4
8 
27,7 
Q6UXN9 WD repeat-containing protein 82 OS=Homo sapiens 
GN=WDR82 PE=1 SV=1 - [WDR82_HUMAN] 
1 7 7 3
1
3 
35,1 
Q7L5D6 Golgi to ER traffic protein 4 homolog OS=Homo sapiens 
GN=GET4 PE=1 SV=1 - [GET4_HUMAN] 
1 2 2 3
2
7 
36,5 
Q16629 Serine/arginine-rich splicing factor 7 OS=Homo sapiens 
GN=SRSF7 PE=1 SV=1 - [SRSF7_HUMAN] 
1 6 6 2
3
8 
27,4 
Q9H9B4 Sideroflexin-1 OS=Homo sapiens GN=SFXN1 PE=1 SV=4 
- [SFXN1_HUMAN] 
1 4 4 3
2
2 
35,6 
Q96C36 Pyrroline-5-carboxylate reductase 2 OS=Homo sapiens 
GN=PYCR2 PE=1 SV=1 - [P5CR2_HUMAN] 
1 3 4 3
2
0 
33,6 
Q15006 ER membrane protein complex subunit 2 OS=Homo sapiens 
GN=EMC2 PE=1 SV=1 - [EMC2_HUMAN] 
1 3 3 2
9
7 
34,8 
Q9H4A6 Golgi phosphoprotein 3 OS=Homo sapiens GN=GOLPH3 
PE=1 SV=1 - [GOLP3_HUMAN] 
1 2 2 2
9
8 
33,8 
O14893 Gem-associated protein 2 OS=Homo sapiens GN=GEMIN2 
PE=1 SV=1 - [GEMI2_HUMAN] 
1 3 3 2
8
0 
31,6 
P16403 Histone H1.2 OS=Homo sapiens GN=HIST1H1C PE=1 
SV=2 - [H12_HUMAN] 
3 5 5 2
1
3 
21,4 
Q96B26 Exosome complex component RRP43 OS=Homo sapiens 
GN=EXOSC8 PE=1 SV=1 - [EXOS8_HUMAN] 
1 4 4 2
7
6 
30,0 
Q9BYD3 39S ribosomal protein L4, mitochondrial OS=Homo sapiens 
GN=MRPL4 PE=1 SV=1 - [RM04_HUMAN] 
1 5 5 3
1
1 
34,9 
P36542 ATP synthase subunit gamma, mitochondrial OS=Homo 
sapiens GN=ATP5C1 PE=1 SV=1 - [ATPG_HUMAN] 
1 5 5 2
9
8 
33,0 
P08758 Annexin A5 OS=Homo sapiens GN=ANXA5 PE=1 SV=2 - 
[ANXA5_HUMAN] 
1 4 4 3
2
35,9 
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0 
P62995 Transformer-2 protein homolog beta OS=Homo sapiens 
GN=TRA2B PE=1 SV=1 - [TRA2B_HUMAN] 
1 3 3 2
8
8 
33,6 
O00165 HCLS1-associated protein X-1 OS=Homo sapiens 
GN=HAX1 PE=1 SV=2 - [HAX1_HUMAN] 
1 4 4 2
7
9 
31,6 
Q13595 Transformer-2 protein homolog alpha OS=Homo sapiens 
GN=TRA2A PE=1 SV=1 - [TRA2A_HUMAN] 
1 4 4 2
8
2 
32,7 
P00387 NADH-cytochrome b5 reductase 3 OS=Homo sapiens 
GN=CYB5R3 PE=1 SV=3 - [NB5R3_HUMAN] 
1 4 4 3
0
1 
34,2 
Q8WXF0 Serine/arginine-rich splicing factor 12 OS=Homo sapiens 
GN=SRSF12 PE=2 SV=1 - [SRS12_HUMAN] 
1 1 3 2
6
1 
30,5 
P02663 SWISS-PROT:P02663 Alpha-S2-casein [Contains: Casocidin-1 
- Bos taurus (Bovine). 
1 4 4 2
0
7 
24,3 
P60510 Serine/threonine-protein phosphatase 4 catalytic subunit 
OS=Homo sapiens GN=PPP4C PE=1 SV=1 - 
[PP4C_HUMAN] 
1 3 3 3
0
7 
35,1 
Q16795 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 9, mitochondrial OS=Homo sapiens GN=NDUFA9 
PE=1 SV=2 - [NDUA9_HUMAN] 
1 2 2 3
7
7 
42,5 
P0CG48 Polyubiquitin-C OS=Homo sapiens GN=UBC PE=1 SV=3 - 
[UBC_HUMAN] 
4 3 3 6
8
5 
77,0 
O75494 Serine/arginine-rich splicing factor 10 OS=Homo sapiens 
GN=SRSF10 PE=1 SV=1 - [SRS10_HUMAN] 
1 2 4 2
6
2 
31,3 
Q92734 Protein TFG OS=Homo sapiens GN=TFG PE=1 SV=2 - 
[TFG_HUMAN] 
1 4 4 4
0
0 
43,4 
P09012 U1 small nuclear ribonucleoprotein A OS=Homo sapiens 
GN=SNRPA PE=1 SV=3 - [SNRPA_HUMAN] 
1 5 5 2
8
2 
31,3 
P05141 ADP/ATP translocase 2 OS=Homo sapiens GN=SLC25A5 
PE=1 SV=7 - [ADT2_HUMAN] 
2 3 3 2
9
8 
32,8 
P62701 40S ribosomal protein S4, X isoform OS=Homo sapiens 
GN=RPS4X PE=1 SV=2 - [RS4X_HUMAN] 
1 2 2 2
6
3 
29,6 
Q9HA64 Ketosamine-3-kinase OS=Homo sapiens GN=FN3KRP 
PE=1 SV=2 - [KT3K_HUMAN] 
1 3 3 3
0
9 
34,4 
Q86V81 THO complex subunit 4 OS=Homo sapiens GN=ALYREF 
PE=1 SV=3 - [THOC4_HUMAN] 
1 3 3 2
5
7 
26,9 
Q9UNE7 E3 ubiquitin-protein ligase CHIP OS=Homo sapiens 
GN=STUB1 PE=1 SV=2 - [CHIP_HUMAN] 
1 4 4 3
0
3 
34,8 
P26599 Polypyrimidine tract-binding protein 1 OS=Homo sapiens 
GN=PTBP1 PE=1 SV=1 - [PTBP1_HUMAN] 
1 2 2 5
3
57,2 
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Q1RMN8 TREMBL:Q1RMN8 (Bos taurus) Similar to Immunoglobulin 
lambda-like polypeptide 1 
1 2 2 2
3
4 
24,5 
P10768 S-formylglutathione hydrolase OS=Homo sapiens GN=ESD 
PE=1 SV=2 - [ESTD_HUMAN] 
1 2 2 2
8
2 
31,4 
Q96DH6 RNA-binding protein Musashi homolog 2 OS=Homo sapiens 
GN=MSI2 PE=1 SV=1 - [MSI2H_HUMAN] 
1 3 3 3
2
8 
35,2 
P08107 Heat shock 70 kDa protein 1A/1B OS=Homo sapiens 
GN=HSPA1A PE=1 SV=5 - [HSP71_HUMAN] 
2 3 3 6
4
1 
70,0 
Q9NUD5 Zinc finger CCHC domain-containing protein 3 OS=Homo 
sapiens GN=ZCCHC3 PE=1 SV=1 - [ZCHC3_HUMAN] 
1 3 3 4
0
4 
43,6 
P67809 Nuclease-sensitive element-binding protein 1 OS=Homo 
sapiens GN=YBX1 PE=1 SV=3 - [YBOX1_HUMAN] 
1 2 2 3
2
4 
35,9 
Q02878 60S ribosomal protein L6 OS=Homo sapiens GN=RPL6 
PE=1 SV=3 - [RL6_HUMAN] 
1 2 2 2
8
8 
32,7 
P19338 Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3 - 
[NUCL_HUMAN] 
1 2 2 7
1
0 
76,6 
O00487 26S proteasome non-ATPase regulatory subunit 14 
OS=Homo sapiens GN=PSMD14 PE=1 SV=1 - 
[PSDE_HUMAN] 
1 2 2 3
1
0 
34,6 
Q01130 Serine/arginine-rich splicing factor 2 OS=Homo sapiens 
GN=SRSF2 PE=1 SV=4 - [SRSF2_HUMAN] 
1 2 2 2
2
1 
25,5 
P48739 Phosphatidylinositol transfer protein beta isoform OS=Homo 
sapiens GN=PITPNB PE=1 SV=2 - [PIPNB_HUMAN] 
1 3 3 2
7
1 
31,5 
P32322 Pyrroline-5-carboxylate reductase 1, mitochondrial 
OS=Homo sapiens GN=PYCR1 PE=1 SV=2 - 
[P5CR1_HUMAN] 
1 2 3 3
1
9 
33,3 
Q96FW1 Ubiquitin thioesterase OTUB1 OS=Homo sapiens 
GN=OTUB1 PE=1 SV=2 - [OTUB1_HUMAN] 
1 3 3 2
7
1 
31,3 
Q9BVG4 Protein PBDC1 OS=Homo sapiens GN=PBDC1 PE=1 
SV=1 - [PBDC1_HUMAN] 
1 2 2 2
3
3 
26,0 
O95926 Pre-mRNA-splicing factor SYF2 OS=Homo sapiens 
GN=SYF2 PE=1 SV=1 - [SYF2_HUMAN] 
1 3 3 2
4
3 
28,7 
A6NDG6 Phosphoglycolate phosphatase OS=Homo sapiens GN=PGP 
PE=1 SV=1 - [PGP_HUMAN] 
1 2 2 3
2
1 
34,0 
Q9UKM9 RNA-binding protein Raly OS=Homo sapiens GN=RALY 
PE=1 SV=1 - [RALY_HUMAN] 
1 2 2 3
0
6 
32,4 
P54920 Alpha-soluble NSF attachment protein OS=Homo sapiens 
GN=NAPA PE=1 SV=3 - [SNAA_HUMAN] 
1 2 2 2
9
33,2 
263 
 
 
 
5 
Q14576 ELAV-like protein 3 OS=Homo sapiens GN=ELAVL3 
PE=1 SV=3 - [ELAV3_HUMAN] 
1 2 2 3
6
7 
39,5 
P48059 LIM and senescent cell antigen-like-containing domain protein 
1 OS=Homo sapiens GN=LIMS1 PE=1 SV=4 - 
[LIMS1_HUMAN] 
1 2 2 3
2
5 
37,2 
Q96HS1 Serine/threonine-protein phosphatase PGAM5, mitochondrial 
OS=Homo sapiens GN=PGAM5 PE=1 SV=2 - 
[PGAM5_HUMAN] 
1 2 2 2
8
9 
32,0 
P26367 Paired box protein Pax-6 OS=Homo sapiens GN=PAX6 
PE=1 SV=2 - [PAX6_HUMAN] 
1 2 2 4
2
2 
46,7 
Q13148 TAR DNA-binding protein 43 OS=Homo sapiens 
GN=TARDBP PE=1 SV=1 - [TADBP_HUMAN] 
1 4 4 4
1
4 
44,7 
P02668 SWISS-PROT:P02668 Kappa-casein [Contains: Casoxin C; 
Casoxin 6; Casoxin A; Casoxin B; Casoplatelin] - Bos taurus 
(Bovine). 
1 2 2 1
6
9 
19,0 
O00425 Insulin-like growth factor 2 mRNA-binding protein 3 
OS=Homo sapiens GN=IGF2BP3 PE=1 SV=2 - 
[IF2B3_HUMAN] 
2 2 2 5
7
9 
63,7 
Q16836 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial 
OS=Homo sapiens GN=HADH PE=1 SV=3 - 
[HCDH_HUMAN] 
1 2 2 3
1
4 
34,3 
P12763 SWISS-PROT:P12763 (Bos taurus) Alpha-2-HS-glycoprotein 
precursor 
1 2 2 3
5
9 
38,4 
P47914 60S ribosomal protein L29 OS=Homo sapiens GN=RPL29 
PE=1 SV=2 - [RL29_HUMAN] 
1 2 2 1
5
9 
17,7 
P35548 Homeobox protein MSX-2 OS=Homo sapiens GN=MSX2 
PE=1 SV=3 - [MSX2_HUMAN] 
1 2 2 2
6
7 
28,9 
P62424 60S ribosomal protein L7a OS=Homo sapiens GN=RPL7A 
PE=1 SV=2 - [RL7A_HUMAN] 
1 2 2 2
6
6 
30,0 
P62258 14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE 
PE=1 SV=1 - [1433E_HUMAN] 
1 2 2 2
5
5 
29,2 
P14923 Junction plakoglobin OS=Homo sapiens GN=JUP PE=1 
SV=3 - [PLAK_HUMAN] 
1 2 2 7
4
5 
81,7 
